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Abstract 
The development of novel protecting group strategies for the 2'-hydroxyl function of 
ribonucleosides has been reviewed and a new design has been formulated. The design 
is based upon a two stage deprotection stategy which is compatible with the final 
steps in RNA synthesis using solid phase methods. Central to this is the intramolecular 
addition to an acetylenic system leading to an acid-labile enol ether system, collapse of 
which results in liberation of the 2'-hydroxyl function. 
A series of propargyl based systems have been synthesised, incorporated and their 
suitability evaluated for the automated chemical synthesis of oligoribonucleotides 
using the phosphoramidite approach. 
Also discussed are the fully automated syntheses of branched oligodeoxynucleotides 
(ODN5), accomplished using a 5' ,2 ' -di(dimethoxytrityl)-protected arabino-uridine 
derivative as the branching monomer. The synthesis and incorporation of the 
branching monomer has been described. The affinities of the branched ODNs towards 
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Introduction 
1. Introduction 
1.1. Biological Importance 
The basic structure and chemical nature of deoxyribonucleic acid (DNA) has been 
known since Watson and Crick's' publication, in Nature of April 1953. The model of 
the double helix created huge interest in the importance of nucleic acids, particularly 
because of the biological implications. It was obvious that within the sequences of 
nucleotide bases in the DNA of the cell lay the information required to specify the 
diversity of biological molecules needed to carry out the functions of that cell. These 
molecules hold the key to life by carrying the genetic code for each organism, through 
which the sequence of DNA could be translated into protein. 
Ribonucleic acid (RNA) which, among other functions, transports the genetic 
information from DNA to the site of protein production, the ribosome. The flow of 
genetic information is called the central dogma of molecular biology 2 in which DNA is 
transcribed into RNA, which is then translated into protein (Figure 1). 
reverse 
transcription 
DNA self-  






Figure 1. The central dogma of molecular biology 
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1.2. DNA and RNA Structures 
Since the discovery of nucleic acids in the latter part of the last century, several 
decades passed before the structures of the constituent purines and pyrimidines, the 
corresponding nucleosides, and the nature of the internucleotide bonds in the 
polynucleotides were clarified. This was followed by elucidation of the structure of 
DNA in 1953, earning Watson, Crick and Wilkins the Nobel prize for chemistry in 
FIi,1 
1.2.1. Primary Structure 
Nucleic acids are very long, thread like polymers made from a linear array of 
monomers called nucleotides. Nucleotides are the phosphate esters of nucleosides and 
these are the components of both DNA and RNA. The primary structures of DNA 
and RNA consist of these phosphodiester linked nucleotides each containing a 2'-
deoxy-D-ribose or D-ribose sugar ring (in DNA and RNA respectively) and an 
Figure 2. Primary structures of DNA and RNA 
2 
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aromatic nucleobase (Figure 2). The nucleobases found in DNA include the purines 
adenine (A) and guanine (G), and the pyrimidines cytosine (C) and thymine (T), while 
RNA incorporates the pyrimidine uradil (U) in place of T. The polynucleotide chain 
has a consistent 5'-+3' polarity with a sequence of relatively hydrophobic nucleobases 
and a negatively charged sugar-phosphate backbone. These attributes play a major 
role in the assembly and maintenance of the secondary and tertiary structures of DNA 
and RNA. 
1.2.2. Secondary Structure 
Complementarity between the individual nucleobases, through hybridization, results in 
an ordered structure that spirals around a central polymer axis. This is known as 
Watson-Crick base pairing, where A and T, or G and C, interact through hydrogen 
bonding (Figure 3). 
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Figure 3. Watson-Crick Base Pairs 
The governing DNA structure found is referred to as the B-form, in which the double 
helix is comprised of two single strands running anti-parallel to each other. In B-DNA 
the C-2' of the deoxyribose ring lies above the plane of the ring in a C-2' endo 
conformation (Figure 4). Two distinct helical grooves are created in B-DNA, called 
the major and minor grooves, which spiral around the surface of the double strand. 
Two other conformations are known: A-DNA, in which the C-3' of the deoxyribose 
ring has a C-3' endo conformation; and Z-DNA has a left handed helical structure 
3 
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compared to right handed configurations for B and A. The phosphates in the backbone 
of Z-DNA are found to be in a zig-zag conformation around the helical structure. 
C-3' endo C-2' endo 
Figure 4. Conformations of A-DNA (C-3' endo) and B-DNA (C-2' endo) 
RNA has the added complexity of a hydroxyl function at the 2'-position which causes 
this nucleic acid to adopt different conformations from those of DNA.' This gives 
RNA a greater structural versatility in the variety of its species, in its chemical 
reactivity and in its diversity of conformations. 
RNA occurs mainly as a single polynucleotide chain but many other forms exist within 
the three main functional classes of RNA found in cells (Section 1.3.). Natural RNA 
can either form long, double stranded structures or contain short double helical 
regions connected by single strands. These double helical regions, known as hairpin 
regions, form when some complementary sequences found in different parts of the 
RNA chain are antiparallel to each other. Other regions in RNA contain loops and 
bulges which are stabilised by both Watson-Crick (G-C and A-U) and the 
energetically less stable non-Watson-Crick hydrogen bonding (G-U). The specific 
three-dimensional structure of RNA is the most important factor in the particular 
activity and biological function of the RNA molecule. 4 
4 
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1.3.0assifications of RNA 
Protein synthesis depends on the collaboration of several classes of RNA molecules. 
In the synthesis of proteins, genes specify the types of proteins that are made in the 
cell. This involves copying certain regions of DNA into RNA, which itself is the direct 
template for protein synthesis. This is known as transcription. Transcription is the 
mechanism by which a template strand of DNA is used by specific RNA polymerases 
to generate one of three different types of RNA. These three RNA classes are: 
Messenger RNA (mRNA): This class of RNA carries the information for 
protein synthesis. It determines the order of amino acids incorporated into 
the growing polypeptide chain. 
Transfer RNA (tRNA): This class of 'small' RNA (most are between 70 
and 90 nucleotides in length) allows the correct insertion of amino acids into 
the growing polypeptide chain by covalent bonds to individual amino acids 
and recognising the encoded sequences of the mRNA. 
Ribosomal RNA (rRNA): This class of RNA is constructed, together with 
numerous ribosomal proteins, to form the ribosomes. Ribosomes take on the 
mRNA and form a catalytic domain into which the tRNA enters with its 
attached amino acid. The proteins of the ribosome catalyse all of the 
functions of polypeptide synthesis. 
RNA polymerase starts its synthesis at a specific DNA sequence, called the promoter, 
which signals where RNA synthesis should begin. It then completes its synthesis at a 
termination point, when the RNA polymerase encounters a second specific sequence 
in the DNA. At this point, both are released and as the DNA-DNA helix rewinds the 
RNA is displaced as a single stranded molecule typically between 70 and 10,000 
nucleotides long. The resultant RNA from transcription is thus complementary to the 
template strand of the DNA duplex and identical to the non-template strand. The non-
template strand is known as the coding strand since its sequences are identical to 
those of the mRNA, except uridine which is substituted for thymine. 
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1.4. Roles of RNA 
Over the last 15 years, discoveries have led to a fuller awareness of the diverse roles 
that RNA plays in biological systems. It has been shown that proteins are not the only 
catalysts of cellular reactions but also that a number of RNA molecules are capable of 
catalysing RNA cleavage and ligation reactions. 4 '5 '6 Cech4 discussed the chemical 
mechanisms of RNA catalysed reactions using the self-splicing ribosomal RNA 
precursor of Tetrahymena and the enzymatic activities of its intervening RNA 
sequence. It has also been suggested that RNA takes a more active catalytic role 
during protein synthesis.' RNA has been found to act as an enzyme, termed a 
ribozyme, either by itself or when complexed to a protein. This has led to an 
increased interest and research in these and other areas.' 
1.5. Applications of Synthetic Oligonucleotides 
The way of thinking of scientists has been transformed by the increased availability of 
synthetic oligonucleotides, hence, new ideas and approaches to problems have arisen. 
The development over the last 40 years of rapid and efficient syntheses, and 
simultaneously the advent of molecular cloning techniques, has widened the 
availability of synthetic oligonucleotides. They have found their way into many areas 
of biology and biochemistry. For example in the cloning and synthesis of man-made 
genes,' ° as primers for various polymerase chain reaction (PCR) applications" and for 
the sequencing of DNA. 12  They have also found applications as probes for examining 
how proteins interact with polynucleotides,' 3 for studies on nucleic acid structure 14 
and in the antisense approach for the treatment of viral diseases and cancer.' 5 They 
have been used in recombinant DNA technology, which was developed in the late 
seventies to synthesise proteins. Genes for a specific protein are chemically 
synthesised before being expressed in micro-organisms to produce the protein. 
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Probably the major application for synthetic oligodeoxynucleotides (ODNs) is in the 
area of DNA based diagnostic and antisense based therapeutic approaches. In this, 
analogues are now slowly beginning to reach the stage of clinical trials for the 
treatment of infections and some cancers. The antisense approach to rational drug 
design has created huge interest in this area of research, and has been proposed as an 
important class of new pharmaceuticals. Antisense refers to the use of small synthetic 
oligonucleotides which inhibit gene expression through hybridization to coding 
(sense) sequences by Watson-Crick base pairing. This is discussed in the appendix. 
The important roles tRNA, mRNA and rRNA play in biological systems have been 
recognised, and major advances in the understanding of these have been made. There 
is the potential of ribozymes being used for therapeutic purposes, using them in the 
cleavage of mRNA in harmful genes. As a fuller understanding of the diverse roles 
RNAs play in biological systems is gained, new applications for the use of synthetic 
RNAs will occur. 
1.6. Synthesis of Oligonucleotides 
1.6.1. Introduction 
As previously described, an oligonucleotide is a single stranded chain consisting of a 
certain number of nucleoside units linked together by phosphodiester bridges. The 
phosphodiester bridges are usually between the 3'-hydroxyl of one nucleoside and the 
5'-hydroxyl of another forming the backbone of the oligonucleotide. Oligonucleotides 
are very sensitive molecules which possess wide ranging functionalities so only the 
mildest of reaction conditions can be employed in their synthesis. In order to achieve 
the specific and sequential formation of internucleoside 3'-5' phosphodiester linkages, 
selective blocking and deblocking strategies must be employed. These strategies are 
used in the protection and deprotection of the primary and secondary hydroxyl 
groups, primary amino groups and often two of the three oxygens of the phosphate 
7 
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group. The bonds between the sugar and the purine or pyrimidine bases are also 
sensitive, especially the C"-N glycosylic bond which is labile to acids. Protecting 
groups must therefore be removed under mild conditions without causing any side 
reactions or alterations to the oligonucleotide. 
1.6.2. Phosphodiester Chemistry 
The most convenient way to assemble an oligonucleotide is by the use of nucleoside 
phosphates as the building blocks, coupling them together to form a single strand. In 
1958 Khorana et al  16  were the first to use the phosphodiester approach for the 
synthesis of dinucleotides (3) with a C 5 '-C3 ' linkage, and then went on to successfully 
synthesise larger oligonucleotides. The phosphodiester method involves the 
condensation of a nucleoside (1), having a free 3'-hydroxyl group and a 5'-hydroxyl 
group protected by the acid sensitive trityl group, with a nucleoside (2) containing a 
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Figure 5. Phosphodiester approach to oligonucleotides 
Condensing agents such as 1,3-dicyclohexylcarbodiimide (DCCI) or 2,4,6-
triispropylbenzenesulfonyl chloride (TPSC1) were used in the coupling reaction of the 
two nucleosides. The exocydic amino groups of the nucleobases were also suitably 
protected during coupling using benzoyl or isobutyryl groups, both of which are still 
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approach was the time consuming nature of separating various condensation products 
using ion-exchange chromatography. 
1.6.3. Phosphotriester Chemistry 
In 1955 that Michelson and Todd 7 reported the first chemical synthesis of a 
dinucleotide containing a C 5 '-C3 ' linkage. Figure 6 shows the activation of 5'-0-
acetylthymidine-3'-O-benzyl hydrogen phosphonate (4) as the corresponding 
phosphorochioridate (5) using N-chlorosuccinimide (NCS). The reaction of 5 with 3'-
0-acetyithymidine (6) produced the dinucleotidephosphate triester (7) which could 
then be deprotected. 
Figure 6. Michelson and Todd's phosphotriester approach 
It was a decade later when Letsinger et al 18,19 introduced the 3-cyanoethyl phosphate 
protecting group using the solid phase synthesis principle. They used an insoluble 
polymeric support for the stepwise synthesis of di-, tn-, and tetranucleotides, for small 
scale synthesis. They continued the use of this method in solution phase synthesis, as 
shown in Figure 7. The condensation of the 5'-O-protected deoxyribonucleoside (8) 
with phosphate monoester, activated with 2,4,6-trimethylbenzenesulfonyl chloride 
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Figure 7. Letsinger's Phophotriester approach 
Addition of thymidine, with its 5'-hydroxy function unprotected, in the presence of 
2,4,6-triisopropylbenzenesulfonyl chloride (TPS-Cl) produced the protected 
dinucleoside phosphate triester (10). The monomethoxytrityl (MMTr) and the - 
cyanoethyl protecting groups were removed by treatment with acetic acid and 
aqueous ammonia respectively to give the fully deprotected dimer (12). 
To prevent undesired 3'-3' and 5'-5' coupled products, Letsinger et a!2° developed 
the -benzoylpropionyl 3'-hydroxy protecting group. This could be removed using 
hydrazine hydrate in pyridine-acetic acid, without disruption of the phosphotriester 
function. These developments led to a strategy for the stepwise synthesis of 
oligodeoxyribonucleotides containing other nucleosides as well as thymidine. 2 ' It was 
found that the 2-cyanoethyl phosphate protecting group was too labile to withstand 
the conditions used in work-up and purification of large ODNs. It was therefore 
10 
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necessary to find a stable phosphate protecting group which was capable of being 
removed efficiently. Reese et a122 developed the use of aryl groups containing electron 
withdrawing groups (13a, 13b), which were removed by either (E)-2-
nitrobenzaldehyde oxime (14) or syn-pyridine-2-carboxaldehyde oxime (15), instead 








13a R'=CI, R=H 





Figure 8. Reese Is phosphate protecting group and deprotection reagents 
Investigations into cleavage conditions" showed that the 2-chiorophenyl group was 
the most effective aryl group for phosphate protection in the phosphotriester 
approach to ODN synthesis. It was found to be stable during synthesis, and was 
removed with the minimum of cleavage to the intemucleotide linkages. 
The development and synthesis of nucleoside building blocks were designed so as to 
eliminate the formation of 3'-3' and 5'-5' internucleotide linkages. Therefore, 
monofunctional phosphorylating agents became the reagents of choice, with 




 1 d- I 
OCH2CH2CN OCH2CCI3 
16 	 17 
Figure 9. Phosphorochloridates 
Introduction 
Activation of the phosphodiester building blocks is a crucial step in the 
phosphotriester approach to ODN synthesis. Sterically hindered arylsulfonyls (18, 
19)2526 became the preferred activators of phosphodiesters due to their ability to 
minimise the sulfonylation of the free 5'-hydroxyl function of the incoming 
nucleosides. 
CH(CH3)2 	 CH3 





CH(CH3)2 	 CH3 
18 	 19 
Figure 10. Coupling reagents 
The rate of reaction can be enhanced by addition of a nucleophilic catalyst, such as N-
methyliniidazole (Figure 11). Figure 11 shows the formation of the mesitylenesulfonic 
acid-phosphate mixed anhydride (21) and the symmetrical pyrophosphate tetraester 
(22). Without the presence of a catalyst, the reaction of 21 and 22 with 3'-0-
acetyithymidine to produce the dinucleoside phosphate triester (24) proceeds slowly. 
However, when N-methylimidazole is introduced the reaction proceeds rapidly (10 
mm, 220C). The N-methylimidazole is a better leaving group and participates in the 
reaction by forming a more activated phophorylating intermediate (23). 1H-Tetrazole 
and 3-nitro-methylimidazole have also been used as catalysts in this reaction. 
The yield of the phosphotriester coupling is an improvement to that of the 
phosphodiester approach, since the phosphotriester is protected from further reaction 
with phosphorylating agents. With the development of phosphate protecting groups 
and efficient condensing reagents, coupling steps could be reduced from several hours 
in solution to less than 5 minutes on solid phase 
.27  The synthesis of a 20-residue ODN 






















Figure 11. Formation of a dinucleoside phosphate triester 
Two side -reactions give rise to limitations with the phosphotriester approach. During 
coupling, there is a competitive reaction of suiphonylation of the 5'-hydroxyl group 
with the coupling reagent of about 1 %. This therefore reduces the coupling efficiency 
of the phosphotriester couplings to 97-99 %, and thus limits the length of the ODN 
attainable to about 40 residues. 29  Secondly, and more seriously, deoxyguanosine 
residues can be phosphorylated and substituted with nitrotriazole at the 0 6-position 
unless another protecting group is used. 
For large scale (multi-gram) synthesis of short ODNs, the phosphotriester method, 
usually solution phase, is especially useful. However, the phosphotriester approach 
does not have the speed and efficiency of the phosphite-triester method described in 




R = phenoxyacetyl 




1.6.4. Phosphite Triester Chemistry 
The development of the phosphite triester method by Caruthers et a130 , is often 
referred to as phosphoramidite chemistry, revolutionised oligonucleotide synthesis 
from a manual or semi-manual operation into a commercialised process using 
automated instrumentation. The coupling of two nucleotide units could be achieved in 
minutes rather than hours and were easily oxidised to the required phosphotriester by 
aqueous iodine. Originally introduced in 1975 by Letsinger et a!3 ' the phosphite-
triester method was based on the great reactivity of phosphorochloridite reagents 
upon alcohols giving phosphite-triesters. Figure 12 illustrates the reaction between a 
5 '-0-protected thymidine (25) and 2,2,2,-trichioroethyiphosphorodichiorodite, 
generating the deoxyribonucleoside-3 '-O-phosphorochioridite intermediate (26) 























Figure 12. Letsinger's phosphite triester approach 
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3'-O-protected thymidine was added followed by aqueous iodine oxidation to give the 
rapid formation of the dinucleoside phosphate triester (28), and also the symmetrical 
3'-3' (29) and 5'-5' (30) dinucleoside phosphate triesters. 32  The 2,2,2-trichioroethyl 
group was shown to be suitable for the synthesis of a thymidine tetranucleotide. 
Several other phosphate protecting groups were investigated by Ogilvie et al.33 such 
as 2,2,2-tribromoethyl, p-chlorophenyl, 2-phenylethyl, 2-p-nitrophenylethyl, benzyl, 
methyl and -cyanoethy1. The methyl and f3-cyanoethyl groups were found to be the 
most useful and remain the most widely used today. Matteucci et al34 ' 35 demonstrated 
the solid phase synthesis of a dodecanucleotide using the methyl group for phosphate 
protection and IH-tetrazole as the catalyst for coupling. Several serious problems 
accompanied the use of nucleoside chiorophosphites or tetrazolides in the solid-phase 
synthesis of ODNs. Low temperatures (-70 °C) and dry, inert conditions were required 
for the preparation of these reagents immediately prior to use. During preparation 
amounts of 3'-3' dinucleoside phosphite triesters were formed which created 
purification problems and lower yields. These problems were overcome, by Beaucage 
et a136  in 1981, with the development of deoxyribonucleo side phosphoramidites. 
These have the advantage of being more stable to hydrolysis and room temperature 
but are still readily activated to form an internucleotide linkage in essentially 
quantitative yield with few side products. Therefore, two of the most important 
criteria for solid-phase ODN synthesis, high yields and few side products, are covered 
by the use of deoxyribonucleoside phosphoramidites. 
Figure 13 is an example of this approach consists of reacting the 5'-O-dimethoxy-
trityl protected deoxyribonucleoside (31) with chloro-N, N-dimethylaminomethoxy-
phosphine and NN-diisopropylethylamine, to afford 32 which can be isolated by 
conventional methods and stored as a dry powder. 32 is activated with 1H-tetrazole 
and the reaction with 3'-O-levulinylthymidine gives the corresponding phosphite 
triester (34) in quantitative yields in a few minutes. This is then oxidised using 
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Figure 13. Caruthers phosphite triester approach 
Due to the varied instability of 32 in acetonitrile, they were unreliable for automated 
systems. This brought about the study of other possible N,N-
dialkylaminomethoxyphophines 37 including the diisopropylamino (a), morpholino (b), 











(b) 	 (c) 
	
(d) 
Figure 14. NN-dialkylaminomethoxyphosphines. 
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It was found that the diisopropylamino (a) and morpholino (b) phosphoramidites 
could be purified by silica gel chromatography and were stable to acetonitrile for at 
least a month without significant decomposition. However, it was seen as a 
disadvantage having the deprotection step for the removal of the methyl phosphate 
protecting groups. In order to eliminate this step, the -cyanoethyl group was 
















Figure 15. Diisopropyl and morpholino phosphoramidites 
The phosporamidites (37, 38) were prepared from the protected deoxyribonucleosides 
using the monofunctional phosphitylating reagent 39 (Figure 15). This allowed the 
elimination of thiophenol from the deprotection procedures since the -cyanoethy1 
group could be cleaved under the basic conditions required for the deprotection of 
nucleobase protecting groups. 
Among the other reported phosphate protecting groups such as 2,2,2-trichloro-1,1-
dimethylethyl, 39 p-nitrophenylethyl, 40 and allyl,4 ' only the -cyanoethy1 group meets 
most of the demands and remains the most widely used today. It is capable of 
protecting the phosphorus group during automated synthesis, allowing fast and 
efficient synthesis, and is removed under conditions which eliminate the possibility of 
chain cleavage. However, it is still thought that the -cyanoethyl protected 
deoxyribonucleoside phosphoramidites are expensive to produce even on kilogram 
scale .42  Ravikumar et a142 reported the use of cyanobutenyl group for the protection 
of internucleotide linkages (Figure 16). 
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where B = I or protected A , C or (3. 
40 
	 41 
Figure 16. Cyanobutenyl as a phosphate protecting group. 
The bis[N,N-diisopropylamino]-4-cyano-2-butenyloxy-PhOSPhifle is easily accessible, 
has excellent phosphitylating properties and the cyanobutenyl group can be removed 
under mild conditions using aqueous ammonium hydroxide. The calculated cost of 
manufacturing the cyanobutenyl phosphoramidites on kilogram scale was found to be 
approximately 60% cheaper than the cost of cyanoethyl phosphoramidites. 
1.6.5. H-Phosphonate Chemistry 
The H-phosphonate method, which was first described be Todd et a143 in 1957, has 
recently been re-examined in the last few years for both DNA 44 and RNA45 synthesis, 
and has emerged with high potential. The renewed interest is due to the increased 
stability of nucleotides and the speed of reaction, avoiding the need for a phosphorous 
protecting group. An example of this approach is shown in Figure IT 
Treatment of the nucleoside H-phosphonate (42) with pivaloyl chloride rapidly 
generates the mixed anhydride 43. This intermediate is then coupled to a 5'-
unprotected nucleoside (44) which is attached to a solid support. The resulting 
phosphite diester (45) can then be capped, detritylated with acid and condensed with 
the next 5'-dimethoxytrityldeoxynucleoside 3'-H-phosphonate. The oxidation of all 
the internucleotide linkages is carried out after the assembly of the oligonucleotide by 
treatment with aqueous iodine to give the natural oligomer (46). 
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Figure 17. H-phosphonate approach 
Alternatively, by choosing appropriate oxidants, other analogs are possible. For 
example, the use of a primary or secondary amine produces the corresponding 
phosphoramidites 47 and the oxidation with elemental sulphur in carbon disulphide 
and triethylaniine generates phosphorothioates (48) .46 Although the H-phosphonate 
approach is not as efficient as the phosphoramidite approach, it is still effective in the 
synthesis of selected analogues. 
1.7. Solid-Phase Synthesis 
Solid-phase synthesis is fundamentally a heterogenous coupling reaction between a 
nucleotide derivative and another residue attached to an insoluble support. Originally 
developed by Merrifield 47  for the synthesis of proteins, Letsinger' 8 was the first to 
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apply this principle for the synthesis of di- and trinucleotides in 1965. The solid-phase 
approach to the synthesis of oligonucleotides has become the accepted and standard 
technique worldwide. 
The chemical synthesis of oligonucleotides is generally carried out using 
phosphoramidite chemistry in the 3' to 5' direction. This takes advantage of the high 
chemical reactivity of the primary 5'-hydroxyl function. Generally, solid-phase 
synthesis has several advantages over the solution phase method. The first residue is 
attached via a linker to an insoluble support giving the advantage of being able to use 
a large excess of the soluble nucleotide derivative, forcing the coupling reaction to 
high yield. The excess reactant nucleotide and reagents can then be simply removed 
by filtration and washing, without loss of the desired support bound dinucleotide. 
Other coupling reactions can be carried out and the reagents similarly removed, aiding 
purification. All the reactions occur in one vessel, allowing for automation of the 
reaction processes resulting, in reduction of labour and synthesis times. 
1.7.1 Solid Support 
The two main solid supports used in oligonucleotide synthesis are the controlled pore 
glass (CPG) and polystyrene supports. 48  The supports have to be inert towards, and 
insoluble in all the solvents and reagents that are used in synthesis. The CPG support 
was found to be ideal due to its rigidity and inability to swell. The supports are 
manufactured with different particle sizes, generally between 500 and 1000A in pore 
size, with the latter favoured for syntheses over 45 residues. Automated syntheses 
using these supports is limited to scales of between 10 and 50 i.tmol g', below which 
the reactions become irreproducible, and above which are subject to steric crowding 
between growing chains. 
The initial residue is loaded onto the support at a functionalised reaction site (Figure 
18). In order to extend these sites away from the surface of the support and to ensure 
accessibility of the reagents, the growing oligonucleotide is attached to a spacer arm. 
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Figure 18. Attachment of a nucleoside to controlled pore glass (CPG) 
In the synthesis of DNA, the first deoxynucleotide is attached at its 3'-position via a 
3'-succinate derivative (49) to an amino group on the spacer arm using 
dicyclohexyldicarboidiimide (DHC) and DMAP. The spacer arm shown in Figure 18 
is a long chain alkylamine attached, to the CPG. 
1.7.2. Assembly of an Oligonucleotide Chain 
A small column is packed with the deoxynucleoside loaded support which can be used 
with a DNA synthesiser. These are commercially available along with the solvents and 
reagents needed for the synthesis of oligonucleotides. The synthesiser allows the 
solvents and reagents to flow through the column in a predetermined order allowing 
the assembly of the chain. 
Figure 19 shows the basic steps involved in one cycle of solid-phase synthesis using 
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Figure 19. Solid-phase synthesis cycle using the phosphoramidite approach. 
STEP 1. The initial step is the removal of the dimethoxytrityl group from the polymer 
attached nucleoside (52) with dichioroacetic or trichioroacetic acid (TCA), to give the 
free 5'-hydoxyl (53). 
STEP 2. The phosphoramidite nucleotide (54) is activated with 1H-tetrazole and 
added to the polymer bound nucleoside (53) to form the phosphite-triester dimer (55). 
This is followed by the capping of all of the unreacted free 5'-hydroxyl functions 
using acetic anhydride. This also has the benefit of reversing any phosphitylation of 
the 0-6 position of guanine. 
22 
Introduction 
STEP 3. The intermediate phospite-triester dimer (55) is then oxidised to the 
phosphotriester dimer (56) with aqueous iodine with the hydrogen iodide released 
during oxidation being neutralised with pyridine or 2,6-lutidine. 
STEP 4. The cycle is then repeated by detritylation of the dimer and the addition of a 
further nucleotide to the chain. This is then repeated until the desired length and 
sequence of 3'—*5' oligonucleotide is obtained. 
STEP 5. Once the synthesis is complete, the oligonucleotide is cleaved form the solid 
support and deprotected with ammonium hydroxide. 
In the use of the phosphoramidite approach, either 2-cyanoethyl (shown) or methyl 
groups are used as the phosphate protecting groups. The 2-cyanoethyl group is 
removed by f-elimination using ammonium hydroxide as the oligonucleotide is 
cleaved from the solid support, whereas the methyl group is removed by treatment 
with thiophenate ion generated by thiophenol and triethylaniine. 
In the phosphotriester approach, aryl groups are used as the phosphate protecting 
groups, which are selectively displaced using .syn-pyridine-2-carboxaldehyde or (E)-2-
nitrobenzaldehyde oxime (Figure 8). 
The average coupling efficiency in the phosphoramidite approach to DNA synthesis, 
when carried out on a machine, is approx. 99 %. The coupling efficiencies are 
calculated by spectroscopic measurement of the intensity of orange colour 
(dimethoxytrityl cation) liberated during detritylation. 
All of the above steps can be performed on a commercially available automated DNA 
synthesiser. The purification of the crude oligonucleotides is the only remaining step 
which requires manual manipulation. Due to the large number of reactions that take 
place during oligonucleotide synthesis, a number of impurities are formed on the 
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support. These are cleaved as the desired oligonucleotide is cleaved from the support, 
therefore purification is necessary. 
1.7.3. Purification of Oligonucleotides 
The phosphoramidite approach to oligonucleotide synthesis employs a capping step 
that acetylates the 5'-hydroxyl functions that have failed to undergo coupling. This 
prevents the build-up of large amounts of incorrectly sequenced and shortened chains. 
The truncated sequences that have been capped remain so until the end of the 
synthesis when they are uncapped during the ammonia deprotection procedure. 
Two powerful separation methods have become popular for the purification of 
oligonucleotides. Polyacrylamide gel electrophoresis uses the charge difference of a 
oligonucleotide, with it capable of separating fragments with only one charge 
difference. The other is high performance liquid chromatography (I{PLC), in 
particular reverse phase chromatography, which uses the hydophobic nature of the 
product to aid purification. The DMTr group, in the final nucleotide in the sequence, 
can either be removed or retained. Retaining the group aids purification through its 
highly lipophilic character, allowing the oligonucleotide to be well resolved from the 
shorter, non-DMTr protected impurities. After purification, the terminal 5'-O-DMTr 
group can then be simply removed by treatment with aqueous 80% acetic acid. 
However, the change in the total polarity, introduced by the addition of a single 
DMTr group, is greatly reduced when synthesising longer oligonucleotides (> 30-
mer). Consequently when a long oligonucleotide is purified by reverse-phase HPLC, 
the retention times of the failure sequences and the desired product are similar. This 
creates separation and purification difficulties. In an attempt to increase the 
hydrophobic character of the 5'-hydroxyl protecting group, several researchers 
modified the DMTr group (Figure 20). Seliger and Gort2 49 introduced para-alkoxy 
groups on triphenylmethylcarbinol (57). Fourrey et a!5° introduced the fluorescent 
1,1 -bis-(4-methoxyphenyl)- 1' -phenylmethyl chloride (58). However, in both cases, 
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Figure 20. Hydrophobic 5 '-hydroxyl protecting groups 
Ramage and Wahl" introduced 4-( 1 7-tetrabenzo [a, c,g, i]Fluoromethyl)-4' ,4"-
dimethoxytrityl chloride (Thf-DMTr-Cl) (59) as a new hydrophobic protecting group. 
Raniage et a152 previously demonstrated the advantages of using peptidic derivatives 
of Tbf for the purification of peptides by reverse phase HPLC. The Tbf moiety 
possessed strong hydrophobic and fluorescent properties, ideal for purification 
purposes. The DMTr group was modified by substituting position 4 of one of the 
phenyl ring with Thf. This preserved the regio selectivity of the trityl group to primary 
hydroxyls, while forming a new hydrophobic 5'-protecting group. In comparison with 
DMTr-on purification, Thf-DMTr showed increased separation from truncated 
sequences and demonstrated the usefulness of Thf-DMTr in the purification of short 
(12-mer) and longer (>100-mer) sequences. 53  The Thf-DMTr group was then 
removed by treatment with 2% TFA. 
1.8. Synthesis of Oligoribonucleotides 
Discoveries during the last 15 years have transformed the understanding of the diverse 
roles that RNA plays in biological systems (Sections 1.4. and 1.5.). Therefore, there 
has been an increasing interest in the synthesis, especially chemical synthesis, of 
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biologically active RNA for biomedical, biochemical and physical studies. The 
developments made in the methodology of the chemical synthesis of DNA sequences 
has had an enormous effect on biological research. Methodologies for the chemical 
synthesis of oligoribonucleotides on solid phase supports have not kept pace with 
advances in DNA synthesis. The lack of efficiency in chemical RNA synthesis 
compared to DNA synthesis is due to the additional hydroxyl group at the 2' position 
and the necessity for its protection during synthesis. There is a lack of wholly 
satisfactory protecting group strategies. However, improved techniques have been 
developed for solid-phase oligoribonucletide synthesis, as well effective enzymatic 
synthesis procedures. 
1.8.1. Enzymatic Synthesis of Oligoribonucleotides 
As described in Section 1. 1, the flow of genetic information in living systems is from 
DNA being transcribed to RNA and then translated to protein. The cell uses enzymes 
called RNA polymerases to make RNA from a DNA template. Milligram quantities of 
RNA can be produced by a researcher using RNA polymerase from bacteriophage T7, 
template DNA and nucleoside triphosphates. 54 The template used consists of two 
chemically synthesised oligodeoxynucleotides annealed together. 
The T7 polymerase system has proved useful as a simple means of producing specific 
RNA sequences. However, it is highly dependent on length and sequence. Shorter 
oligoribonucleotides of 12 bases or less give poor yields and are difficult to purify to 
homogeneity. It has been observed that the T7 polymerase undergoes abortive 
initiations, and may add an undesired base, thus complicating purification. 14 
Sequences which do not begin with a guanosine at the 5'-end have proven extremely 
troublesome to make. For each particular sequence, conditions have to be customised 
to optimise yields. Finally, T7 polymerase incorporates only the four natural RNA 
bases into an oligoribonucleotide, and therefore does not allow for the incorporation 
of modified or non-standard nucleoside bases or even deoxyribonucleosides. 55 
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1.8.2. Chemical Synthesis of Oligoribonucleotides 
An alternative to the T7 method is the chemical synthesis of RNA, which has, to a 
certain degree, paralleled the methodology of DNA synthesis previously described in 
this chapter. The development of practical methods to synthesise RNA has been 
hindered by the requirement to protect the additional 2'-hydroxyl group. Although the 
assembly of oligoribonucleotides is analogous to that of oligodeoxyribonucleotides, 
the rate of the coupling reactions are slower. This is due to the use of bulky 2'-
hydroxyl protecting groups. The choice of protecting group is extremely important, as 
it must remain stable during chain assembly, and be removed only at the very end of 
the deprotection cycle. This applies in particular to the phosphate protecting groups, 
since triester phosphates are highly unstable in the presence of a neighbouring 
hydroxyl group. It must also be removed quantitatively under conditions that will not 




































Figure 21. Acid -catalysed cleavage and migration of inter -ribonucleotide linkages 
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It has long been realised that the internucleotide linkages of RNA sequences can both 
migrate (as in 60-*61-->62) and undergo cleavage (as in 60-*61-+63 + 64) under 
acidic or basic conditions. 55  The mechanism of acid-catalysed migration and cleavage 
is believed to be that suggested in Figure 21.56,56  The cleavage and migration of RNA 
takes place via a cyclic pentacoordinate trigonal bipyrimidal oxyphosphorane 
intermediate/transition state 1).17  
In 1956, Brown et a!58  described an experiment showing the partial hydrolysis of 
cytidine 3'-0-benzy1phosphate under basic and acidic conditions. This experiment 
indicated that the conversion of a 3'-->5' to a 2'-+5' intemucleotide linkage can occur 
with phosphodiester and protected phosphotriester RNA oligomers under these 
conditions. 59  This is a major problem, since it is impossible, with current technologies, 
to separate oligoribonucleotides containing one or multiple 2'-+5' internucleotide 
linkages from correctly connected oligoribonucleotides. It is, therefore, important to 
avoid phosphoryl migration or chain cleavage during deprotection of the 2'-hydroxyl 
function. 
The development of the 2'-hydroxyl protecting group began when Griffin et al60 ' 6 ' 
tested the acid labile tetrahydropyran-2-yl group (Thp) (65) for this purpose in 1964 
(Figure 21). 
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Figure 22. 2 '-Hydroxyl Protecting Groups 
Complete removal of the Thp group was achieved in 3 - 4 hours using 0.01M HC1 at 
20 °C. These relatively mild conditions did not induce significant phosphoryl 
migration. The Thp group has been successfully used in the phosphotriester approach 
to oligoribonucleotide synthesis. 62 However, only relatively short sequences of 20 
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units or less were capable of being made using this method due to the protecting 
group strategies involved for the 5'-hydroxyl function. Current strategies use 9-
phenylxanthen-9-yl (pixyl) (68) or 4,4'-dimethoxytrityl (67) groups for the protection 
of the 5'-hydroxyl function (Figure 23). 
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Figure 23. 5 '-Hydroxyl Protecting Groups 
These groups are removed under acidic conditions prior to chain elongation during 
oligoribonucleotide synthesis. During the acid deprotection step, the 2'-Thp group 
undergoes partial hydrolysis. 63  Following partial deprotection, acid-catalysed 
internucleotide bond cleavage and gives rise to the accumulation of various side 
products which limits this approach. Another disadvantage of the Thp is its inherent 
chirality. This complicates the purification of the ribonucleoside building blocks, due 
to the formation of diastereo isomers. This led to its replacement with an achiral 
alternative, 4-methoxytetrahydropyran-4-yl (Mthp) (66), for protection of the 2'-
hydroxyl function during oligoribonucleotide synthesis in solution 
.64  This solved the 
problem of chirality, but, due to its acid lability, the 2'-O-Mthp group is also 
incompatible with the pixyl and dimethoxytrityl groups used for the protection of the 
5'-hydroxyl functions. 
Interest in developing methods for the rapid synthesis of oligoribonucleotides on solid 
supports using the 5'-O-pixyl and dimethoxytrityl group strategies, led Reese et a! 65 
to introduce the 1- [(2-chloro-4-methyl)phenyl]4-methoxypiperidin-4-yl (Ctmp) (69) 
group for protection of the 2'-hydroxyl function. 
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The Ctmp group was designed to be unaffected by the acid conditions required for 
removal of the 5'-terminal protecting group, yet it is easily removed under mildly 
acidic conditions (eg. pH 2.0-2.5. R.T.) in the final deprotection step. This is achieved 
by the tertiary anilino function of the acetal, which is protonated at pH < 2 (70), thus 
producing a strong inductive effect and enhanced stability under the conditions used 
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Figure 24. 1-[(2-chloro-4-melhyl)phenyl]4-methoXYPiPeridifl-4Y1 (Ctmp) 
Typically, the rate of hydrolysis of the 2'-O-Mthp uridine was 140 times faster at pH 
1.0 than at pH 3.0. This was found to be considerably quicker than the rate of 
hydrolysis of 2'-O-Ctmp uridine which was only approximately 2.25 times faster at 
pH 1.0 than at pH 3.0. Furthermore, the Ctmp and Mthp protecting groups both 
undergo hydrolysis at pH 2 - 2.5 and at room temperature, and are predicted to be 
completely removed under conditions which RNA is completely stable. It was soon 
established that the Ctmp group was suitable for the protection of the 2'-hydroxyl 
functions in the solid phase synthesis of oligoribonucleotides, using either the H-
phosphonate66  or the phosphoramidite approach. 67 
Although the Ctmp group proved satisfactory for the protection of the 2'-hydroxyl 
functions in oligoribonucleotide synthesis, the preparation of the 1-[(2-chloro-4- 
methyl)phenyl]4-methoxypiperidin-4-yl reagent (71) is rather long and inefficient. This 
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led to the development of a new synthetic route, thus making a number of similar 
halogenated enol ethers available. 68  It was found that 1-(2-fluorophenyl)-4-methoxy-
1 ,2,5,6-tetra-hydropyridine (72) was easier to prepare than the Ctmp reagent and that 
the 1 -(2-fluorophenyl)-4-methoxypiperidin-4-yl (Fpmp) protecting group had 
enhanced properties compared to those of the Ctmp protecting group. 
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Figure 25. Enol Ether reagents for the introduction of the Ctmp and Fpmp 
The Fpmp group was found to be approximately 1.3 times more stable to hydrolysis 
than the Ctmp group in the pH range 0.5 - 1.5.69 Therefore, the removal of the 5'-0-
DMTr or pixyl protecting group during oligoribonucleotide synthesis would be more 
selective when Fpmp rather than Ctmp groups are used to protect the 2'-hydroxyl 
function. The 5'-O-DMTr-2'-O-Fpmp protected phosphoramidite building blocks are 
now commercially available and have been widely used in oligoribonucleotide 
synthesis. 7° 
The introduction of Fpmp, and other similar acetals, has been simplified by use of a 
bifunctional silylating reagent, I ,3-dichloro- 1,1,3,3 -tetraisopropyldisioxane, which 
was introduced by Markiewicz70 in 1978. Markiewiczs' reagent is used to 
simultaneously protect both the 5'- and 3'-hydroxyl functions (74), thus leaving the 
2'-hydroxyl free for introduction of the Fpmp group (75). Removal of the cyclic silyl 
group is achieved with fluoride ions to give a 2'-O-Fpmp nucleoside (76), which can 
be then be converted to its 5'-O-DMTr-2'-O-Fpmp protected ribonucleoside 3'-0-
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Figure 26. Synthesis of 2 '-O-Fpmp protected ribonucleoside 3 '-0- 
phosphoramidite 
Recent observations have indicated that certain RNA sequences can undergo 
internucleotide cleavage and migration under the conditions suggested for the removal 
of the Fpmp groups (pH 2.0 - 2.5).' Improvements to the RNA synthetic cycle 
protocol has shown that a solution of sodium acetate (pH 3.25, 30°C, 36 hours) is 
suitable for the removal of all the 2'-O-Fpmp protecting groups without any 
disruption to the internucleotide bonds. 72 
Another group which has been successfully used in the protection of the 2'-hydroxyl 
function is the t-butyldimethylsilyl (TBDMS) (79) group. First developed in 1973 by 
Ogilvie, 73  the group is reasonably stable to either basic or acidic conditions, and is 
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cleaved rapidly by fluoride ion within 30 minutes at 20 °C. 74 The usefulness of the 
TBDMS group as a 2'-O-hydroxyl protecting group for ribonucleosides in the 
synthesis of oligoribonucleotides was questioned by Jones and Reese. 75 They reported 
the migration of the 2' and 3'-O-TBDMS group (80 and 82) of the ribonucleosides 
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Figure 27. 2 '-O-tert-B utyldimethylsilyl protecting group 
Under these conditions, the interconversion half-life is approximately 1 hour. In 
anhydrous pyridine, the T 112 conversion of 80 to 82 was 1140 minutes at 36 °C, 
considerably slower than that of the methanolic conditions. However, under identical 
conditions, conversion of 82 to 80 was seen to have a half-life of 380 minutes. Under 
the conditions of 80% acetic acid, 0.1 M methanolic hydrochloric acid or in pure 
solvents such as chloroform and anhydrous DMF, no detectable isomerisation 
occurred within 25 hours at 20 O(7ó  Further investigations have been carried out into 
the possibility of interconversion during the synthesis of 2'-O-TBDMS 
phosphoramidites (Figure 28).76  Generally, the introduction of TBDMS on to the 2'-
0-hydroxyl function of a 5'-O-DMTr protected nucleoside is achieved by use of 
TBDMS chloride in the presence of imida.zole (83-M and 85). This produces a 
mixture of 2'-0 and 3'-O-silyl isomers (84 and 85 respectively), which require 
seperation by careful silica gel chromatography. Phosphitylation of the 2'-O-silyl 
isomer is usually carried out by use of (2-cyanoethoxy)-N,N-


























Figure 28. Synthesis of 2 '-O-TBDMS protected ribonucleoside 3 '-0- 
phosphoramidite 
Usman et a177 carried out the automated chemical synthesis and purification of an 
oligoribonucleotide similar to the 3'-half molecule of an E.coli formylmethionine 
tRNA. The oligoribonucleotide, 43 nucleotides in length, was successfully prepared 
using 2'-O-TBDMS protected phosphoramidites with a 15 minute coupling time. 
Stawinski et a178 found that treatment with concentrated ammonium hydroxide at 
55°C, used for the deprotection of nucleobase and removal from the solid support, led 
to the partial removal of the 2'-O-TBDMS group (27%, 8h) and cleavage of the 
internucleotide linkages (3% after 8h). The 2'-O-TBDMS cleavage rate could be 
greatly reduced by the addition of ethanol to the conc. ammonium hydroxide in a 1:3 
mixture and performing the cleavage at room temperature for 2 to 3 days . 79 The final 
deprotection step involves the removal of the 2'-O-TBDMS group from the 
oligoribonucleotide. This is generally achieved using tetra-n-butylammonium fluoride 
(TBAF) within 4 hours, without cleavage or migration of the phosphodiester function. 
However, removal of the TBDMS groups from larger oligoribonucleotides requires 




The commercially available 2'-O-TBDMS protected phosphoramidites have been 
extremely popular in the chemical synthesis of oligoribonucleotides. 78 ' 79ThiS is due to 
the ease of preparation of 2'-O-TBDMS ribonucleoside derivatives and facile removal 
by the action of fluoride ion sources such as TBAF and (Et 3N)3.31{F. 80  However, 
some serious inconveniences have been described' using the TBDMS group, due to 
the hindrance of the internucleotide coupling reaction and incomplete elimination of 
fluoride ions. 
Steric hindrance has resulted in the synthesis of oligoribonucleotides being slow. 
Coupling times of up to 15 minutes were required in each nucleotide addition cycle, 
compared with the two minute reactions commonly required for oligo-
deoxynucleo sides. The relatively long coupling times were thought to be a 
consequence of steric interfering by the bulky, lipophilic TBDMS group. 82 Thus, the 
steric bulk of the 2'-hydroxyl protecting group became an additional factor which 
needed to be considered in the design of a suitable protecting group. 
Schwartz et a!83  developed a novel 2'-hydroxyl protecting group, o-
nitrobenzyloxymethyl, that was designed to be compatible with oligo-
deoxyribonucleotide synthesis (Figure 29). The 2'-O-(o-nitrobenzyloxymethYl) 
ribonucleoside phosphoraniidites (87) gave average coupling yields greater than 98%, 
.ising condensation times of 2 minutes, in the synthesis of two 16-mers and a 31-
mer. 83  The o-nitrobenzyloxymethyl group is then photochemically cleaved by 
exposure to long-wave UV light for 4.5 hours at pH 3.7.The improved efficiency was 
thought to be due to the relief of steric crowding in the vicinity of the 
phosphoraniidite function. However, care was needed during synthesis to prevent the 
loss of o-nitrobenzyloxymethyl protection due to UV emission from overhead 
lighting. 
In the course of studies aimed at developing less hindered systems, Gough et a183 
discovered the p-nitrobenzyloxymethyl group (88) for the protection of the 2'-
hydroxyl function. As in the case of o-nitrobenzyloxymethyl, it led to 2 minute 
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Figure 29. Ortho and para nitrobenzy1oxymethy1 protecting groups 
coupling times with high efficiencies, thus allowing RNA to be synthesised as rapidly 
as DNA. Similar to TBDMS, the p-nitrobenzyloxymethyl group is cleaved by 
treatment with 1 .OM tetrabutylanimomum fluoride in THF for 24 hours. 
In the search for the ideal 2'-hydroxyl protecting group, other systems have been 
studied for their suitability in oligoribonucleotide synthesis. The 
(trimethylsilyl)ethoxymethyl ether (SEM) (89) was reported 
 14  to possess many of the 










Figure 30. 2 '-O-(SEM) and 2 '-O-(HIFA) ribonucleoside phosphoramidites 
The SEM group is stable to base and all but the harshest acidic conditions. It can be 
readily introduced and the oxygen-carbon bond rather than the oxygen-silicon bond, 
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as in the TBDMS system, renders it unable to migrate. Finally, this group can be 
readily removed by treatment with BF 3 .OEt2 in acetonitrile for 15-30 minutes. 
Rastogi and Usher" have proposed a new 2'-hydroxyl protecting group, the 2-
hydroxyisophthalate formaldehyde (HIFA) (90). This group had the unique feature of 
requiring a two stage deprotection. As the bis-ester, it was relatively stable to acidic 
conditions and was found to be 112 times more stable than the Fpmp group at pH 1. 
During the basic conditions required for the removal of the base and phosphate 
protecting groups and cleavage from the solid support, the his-ester was converted to 
the bis-carboxylate. It was reported that the conversion increases the rate of acid-
catalysed hydrolysis of the acetal by 42-fold at pH 1, and possibly, by 1320-fold at pH 
3. It was found to be within a factor of 2.35 of the rate of hydrolysis of Fpmp at pH 3. 
However, long coupling times of 5 minutes and lengthy deprotection conditions were 
required for the synthesis. 
In a recent publication, KJosel et a186  described the potential of the 1,1 -dianisyl-2,2,2-
trichioroethyl group (DATE) (91) for the protection of the 2'-hydroxyl function. 
Although DATE was found to be compatible with established protection techniques 
for oligoribonucleotide synthesis, its obvious bulk required longer coupling times (5 
minutes) and produced poorer yields. 
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Figure 31. 1,1-Dianisyl-2,2,2-trichloroethy1 group. 
As an alternative to the phosphoramidite approach to oligoribonucleotide synthesis, 
interest in the H-phosphonate approach has increased (see Section 1.6.5.). The first 
report of oligoribonucleotide synthesis using H-phosphonates, used the TBDMS 
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group as protection for the 2'-hydroxyl function. 87 Later reports have included the use 
of the photolabile o-nitrobenzyl group 88 and the acid sensitive Thp89 and Ctmp90  
groups. Evaluation of 2'-hydroxyl protection using the H-phosphonate approach was 
undertaken by Rozners et af ° , using a variety of 2'-hydroxyl protecting groups 
(TBDMS, o-chlorobenzoyl, Thp, Ctmp, Fpmp and the 1-(2-chloroethoxy)ethyl 
groups). Out of those compared, the most successful syntheses were clearly those 
where the TBDMS group was used for the protection of the 2'-hydroxyl function. 
They also concluded that the use of 2'-acetal protection in combination with H-
phosphonates was of limited value in oligoribonucleotide synthesis. 
1.9. Project Aims 
Due to the progress made in the understanding of the diverse roles RNA molecules 
play in biological systems, an increased demand for synthetic RNA has evolved. 
However, methodologies for the chemical synthesis of RNA has not kept pace with 
advances in DNA synthesis. As previously discussed, the difficulty arises mainly from 
the presence of the additional 2'-hydroxyl function. Suitable selective protection and 
deprotection of the 2'-hydroxyl function is the key to successful RNA synthesis. 
Thus, the main aim of this project was to develop a novel 2'-hydroxyl protecting 
group for the automated synthesis of oligoribonucleotides. An effective synthesis and 
introduction of the proposed group was to be obtained, and its potential examined. 
This will be discussed in the following chapters. 
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2.0. Results and Discussion 
2.1. Proposed 2'-Hydroxyl Protecting Group for RNA Synthesis 
The selection of a suitable protecting group for the 2'-hydroxyl function for RNA 
synthesis is a non-trivial matter and must satisfy several requirements: 
. It must be stable to the acidic conditions employed for the repeated removal of the 
dimethoxytrityl group (the most common 5'-hydroxyl protecting group used in 
DNA and RNA synthesis). 
• It should be stable to the alkaline conditions that are used in the concerted removal 
of the heterocyclic base and phosphate protecting groups and cleavage of the chain 
from the solid support. 
• It should be removable after completion of the synthesis, under sufficiently mild 
conditions such that there is no modification of the bases, or cleavage or migration 
of the internucleotide linkages. 
• Steric bulk should be minimised so that extended coupling times are not required. 
• The reagent employed in the removal of the 2'-hydroxyl protecting group should 
not make purification and isolation of the fully deprotected RNA too cumbersome 
or time consuming. 
The removal of the 2'-hydroxyl protecting group should involve as little manipulation 
as possible, as RNA readily undergoes digestion in the presence of contaminating 
traces of endonucleases, such as ribonuclease. It would therefore be advantageous if 
the 2'-hydroxyl protecting group remained intact during purification. This would 
facilitate prolonged storage until the RNA was required, at which point the 2'-
hydroxyl functions could be deprotected. 
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A variety of protecting group strategies have been studied. These were discussed in 
the previous chapter, along with the difficulties and problems which arose in their 
application. The complexity of the protecting group strategy can best be seen from the 
fact that only two types of ribonucleoside-3'-phosphoramidites, namely the 5'-0-
(DMTr)-2'-O-(Fpmp) and the 5'-O-(DMTr)-2'-O-(TBDMS) combinations, are 
commercially available and have been applied with some success (Section 1.8.2.). 
However, coupling times of ~! 10 minutes are required for both the Fpmp and 
TBDMS group strategies, compared with 2 minute reactions commonly used for 
DNA synthesis. The relatively long coupling times are thought to be a consequence of 
steric interference by the 2'-hydroxyl protecting group. Such steric crowding in the 
vicinity of the phosphoramidite function could be relieved by incorporation of a 
flexible arm into the structure of the 2'-hydroxyl protecting group. 
Kierzek et a19 ' discussed the coupling efficiency of the condensation reactions 
between the ribonucleoside phosphoramidites 92 (a-d) and deoxythymidine bound to 
a solid support. Analysis and quantitation of the dimers after treatment with 
ammonium hydroxide observed the coupling efficiencies of 93 (a-d) decrease in order 
of 93a > 93b > 93c > 93d. 





OCH2CH2CN 	 I 
OTh 
whereRH 	92 (a) 	 OH 
R=OCH3 (b) 
R'GFhp 	(c) 	 93(a-d) 
R=OTBDMS (d) 
Figure 32. Steric hindrance of 2 '-0-protecting group 
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Therefore, in the design of a least hindered system, it would be advantageous if it 
contained sterically undemanding groups, a and 3 to the 2'-O-position, thus reducing 
the steric interference around the activated phosphoramidite moiety. In order to 
satisfy these requirements, a functionalised propargyl system was proposed (Figure 
33). 
Ls  
= 	 OH 
R  
' OHCHCN 
Figure 33. Functionalisedpropargyl based system 
Baldwin92  proposed a set of 'rules' for ring forming reactions which gave guidelines 
on the prediction of intramolecular cydisation processes. He proposed 5 to 7-Exo-
Dig favoured cycisations (Figure 34)93.94 According to the guidelines that Baldwin 
suggested, the proposed functionalised propargyl system, hex-4-yne-l-ol, can 
undergo a 5-Exo-Dig ring formation. 
5-Exo-Dig 	 6-Exo-Dig 	 7-Exo-Dig 
Figure 34. Baldwin's 'rules'for ring closure 
The cycisation of acetylenic amines and alcohols have been well documented. 
95,96  It 
has been shown that a hydroxy group can undergo intramolecular addition to a triple 
bond in the transformation of internal enynols to furans. 97 '98 '99 Figure 35 shows the 
cycloisomerisation of (Z)-2-en-4-yn-1-ol to its corresponding furan.' °°" ° ' 
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Similar intramolecular cyclisations of acetylenic carbonyl compounds, via their silyl 
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R1 )R3 
Figure 35. Synthesis offurans via enynols 
OSiMe3 	 HgCl2 
H 	 H 	 os 3  1 0 LHMDS HgQ 
Me 	
SMe3 Nal, HC I 
4EZj 
CH7 
Figure 36. Intramolecular cyclisations via silyl enol ether derivatives 
The proposed functionalised propargyl system is required to be stable during 
synthesis; therefore, the hydroxyl function of the ring system precursor is protected 
with a benzoyl group (Figure 37, 94). The benzoyl group is commonly used in the 
protection of the heterocyclic bases, and can be removed under the alkaline conditions 
required for the removal of the phosphate protecting groups and cleavage of the 
completed chain from the solid support. This ensures complete stability during 
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synthesis and should generate the proposed 5-Exo-Dig ring system precursor during 














Figure 37 Alkaline deprotection conditions 
The partially deprotected 2'-hydroxyl protecting group could then be cleaved under 
mild acidic conditions, without interference to the internucleotide linkages or 
modification to the bases,, by the proposed mechanism (Figure 38). Similar 
mechanistic pathways have been proposed in the synthesis of furans using deuterium 
labelled species 96 
Base 	 Base 	 Base 
:>: 	
-0 0 OH 
0 0 
,,.\ 
H 	 S 
Figure 38. Mechanism of cleavage of 2 '-hydroxyl protecting group 
Standard protocols for the introduction of a 2'-hydroxyl protecting group involves the 
protection of the exocycic amino functions and simultaneous protection of the 5'-
and 3'-hydroxyls thus, leaving the 2'-hydroxyl function free for manipulation. 
Incorporation of an alkyl group onto the 2'-hydroxyl position is generally achieved 
using standard Williamson type procedures. This employs the use of sodium 
hydride' 15  or silver(1) oxide 106,107,108  with an excess of alkyl halide to form the ether. 
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To allow incorporation of the protecting group onto the 2'-hydroxyl function. 6-
bromo-hex-4-ynyl benzoate (104) was synthesised (Figure 39).. 
2.2. Synthesis of proposed 2'-hydroxyl protecting group 
Figure 39 describes the initial synthetic route considered for the synthesis of 1-bromo-
2-hexynbenzoate, commencing from the commercially available 1 -pentyne-4-ol (96). 
Route 1: 	 0 
OH 
Pyridine 	
0-10 - 	 BenzDylchloride 
96 	 97 
0 	 0 
I) Butyl lithium 	 PPh3,lnlida2nle 
2) (O T4  
HO 	 Br 
98 
Figure 39. Route 1: Synthesis of 6-Bromo-hex-4-ynyl benzoate 
Formation of pent-i -ynyl benzoate (97) was achieved in 87% yield by nucleophilic 
displacement of chlorine from benzoyl chloride in the presence of pyridine. This was 
then treated with one equivalent n-butyllithium in THF at -78 °C followed by 
paraformaldehyde, and allowed to stir overnight at room temperature. After aqueous 
work up and purification by wet flash chromatography, 6-hydroxy-hex-4-ynyl 
benzoate was obtained in 10% yield. After several attempts, the yield could not be 
enhanced and, therefore, a second route was proposed (Figure 40). 
The initial step in this second route involved alkylation of propargyl tetrahydropyranyl 
ether (100). This was achieved by treatment of the ether with one equivalent of n-
butyllithium in THF at -78°C, followed by 3-bromo- i -chloropropane. After heating at 
reflux overnight, 6-(tetrahydropyranyloxy)-hex-4-ynyl chloride (101) was obtained in 
84% yield after purification by distillation. The benzoate ester, 6- 
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(tetrahydopyranyloxy)-hex-4-ynyl benzoate (102), was obtained in 81% yield by 
heating 101 in DMIF at reflux in the presence of sodium benzoate. The 
tetrahydropyranyl ether was simply cleaved by treatment with 10% aqueous oxalic 
acid in MeOH (48 hours, room temperature) to give 6-hydroxy-hex-4-ynyl benzoate 
(103) in 86% yield (48% overall). 
Route 2: 
II1 	= 	
1) Butyl lithium 
H 










0 	 0 
10% Oxalic acid 	 PPh3, Pyndine 10 
'0
— 
 "--= ~'O MeOH 	 CBr4 HO Br 
	
103 	 104 
Figure 40. Route 2: Synthesis of 6-Bromo-her-4-ynyl benzoate 
Conversion of 103 to 6-Bromo-hex-4-ynyl benzoate (104) was achieved by treatment 
with triphenyiphosphine, carbon tetrabromide and pyridine to give a yield of 82%. 
2.3. Incorporation of the 2' -hydroxyl protecting group 
As previously discussed, the alkylation of the 2'-hydroxyl function is generally 
achieved via simultaneous protection of the 5'- and 3'-hydroxyl functions, thus 
leaving the 2'-hydroxyl free for manipulation. Using the Markiewicz 7° reagent, 1,3-
dichioro- 1,1 ,3,3-tetraisopropyldisioxane, with pyridine, the 5'- and 3 '-hydroxyl 
functions of uridine (105) were simultaneously protected, giving 3',5'-O- 
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(tetraisopropyl-disioxane-1,3-diYl)Uridifle (106) in a yield of 72% (Figure 41). 
Previously, Wagner et al °5 discussed the necessity to protect the N 3 position of 
uridine to prevent alkylation. This was achieved through the use of three different 
groups. Introduction of the benzoyl group to the N 3 -position of uridine was 
performed by the addition of benzoyl chloride to a mixture of 106, Na 2CO3 and 5% 
tetrabutylammonium bromide in DCM:H20 (1:1), producing the N 3 -benzoyl protected 
















Figure 41. 3 ',S 'O(Tetraisopropy1disiloxane-1,3-diyI)-N 3-(PrOteCted) uridine 
The N3 -pivaloyl protected uridine (108) was obtained in 79% yield by treatment of 
106 with chiormethyl pivalate in the presence of base. '° The 2'-hydroxyl function of 
106 was transiently protected by reaction with chiorotrimethylsilane before 
isobutyrylation at the N 3 -position. After treatment with 4-toluenesuiphonic acid to 
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remove the trimethylsilyl group, 3' ,5 '-O-(tetraisopropyl-disioxane- 1,3 -diyl)-N 3 -(4-
tert-butylbenzoyl) uridine (109) was obtained in 49% yield." 
Various forms of N 3  protection were required due to the different procedures required 
for the. incorporation of alkyl groups to the 2'-hydroxyl function. Attempts to 
incorporate the proposed protecting group failed using excess 1-bromo-2-
hexynbenzoate with sodium hydride or silver(1)oxide. The leaving group was then 
improved by replacement of bromide with iodine to give 6-iodo-hex-4-yn'l benzoate 
(110). Synthesis of 110 was achieved similarly to the bromide, by the addition of 
iodine in one portion to a solution of 103, triphenyiphosphine and imid.azoie to give 




















Figure 42. Synthesis offunctionalised systems 
In order to further improve the leaving group for ether formation, 6-mesyl (111) and 
6-trichloroacetimidate-hex-4-ynyl benzoate (112) were synthesised (Figure 42).' ' 
Although ether formation had been achieved on a variety of other systems,' 3 ' 4 
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application of these leaving groups to the proposed system with fully protected 
uridine did not yield any of the desired product. 
Sproat et al"' used the strong and sterically hindered base, 2-tert.-butylimino-2-
diethyl-amino- 1,3 -dimethylperhydro- 1,3 ,2-diazaphosphorin (BDDDP), in the 
synthesis of 2'-0-methyl and 2'-O-allyl
16,117,111  However, use of this 
procedure, substituting methyl iodide with 6-iodo-hex-4-ynyl benzoate, failed to 
incorporate the proposed 2'-hydroxyl protecting group. Difficulty in the formation of 
2'-O-(hex-4-ynyl benzoate) was thought to be due to steric effects created by the bulk 
of the uridine protecting group strategies. 
The activation of hydroxyl groups using organotin derivatives in the field of 
carbohydrates, nucleosides, polyols and selected natural products has been 
In 1974, Moffatt et al 120  described the synthesis and isolation of some 
organotin derivatives of nucleosides. The preparation of 2',3'-O-(dibutylstannylene) 
nucleosides (113) was achieved by heating a methanolic suspension of the nucleoside 
with dibutyltin oxide (Figure 43). Upon treatment of 2',3'-O-(dibutylstannylene) 
nucleosides, Moffatt was able to acylate the 2'- and 3'-hydroxyls using various 
acylating agents, producing mixtures of 2'-0- and 3'-O-acyl nucleosides (114a and 
114b respectively) in approximately 1:3 ratios. 
HO---  4ase 	
HO ase 






R&i 	 + 
(R=AcorPh) OHO 	
OOH
O LR R LO 
113 
	
114(a) 	 (b) 
Figure 43. 2'.3 '-O-(dibutylstannylene) nucleosides 
Schwartz et a182 incorporated the o-nitrobenzyloxyethyl group onto the 2'- and 3'- 
hydroxyls of uridine using 2',3'-O-(dibutylstaimylene) uridine and tetra-n- 
butylammonium bromide in DMF. A slight modification of this procedure was 
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employed for the incorporation of the proposed protecting group, 2'-O-(hex-4-ynyl 
benzoate). 6-Iodo-hex-4-ynyl benzoate was added to a solution of uridine, dibutyltin 
oxide and tetra-n-butylammonium bromide in DMF. After heating for 24 hours at 
60°C, a mixture of the 2'- and 3'-O-(hex-4-ynyl benzoate) uridine isomers (115a and 
llSb respectively) were obtained in an approximate ratio of 3:1 (Figure 44). _L4 	 H u 	HO  . 4 
 
	




OH OH 	 OH OR 	 OR OH 
115(a) 	 (b)
04 
R= 	 Ph 
Figure 44. Synthesis of 2'- and.3 '-O-(hex-4-ynyl benzoate) uridine 
Chromatographic separation of the two isomers at this stage was not possible; 
however, two separation procedures were developed. 
In the first, treatment with Markiewicz reagent, followed by deprotection using 
potassium fluoride dihydrate, produced solely the 2'-O-(hex-4-ynyl benzoate) uridine 
isomer in an overall yield of 31%. 
Route 1: 
Markiewicz 	 Si 	0 	
.2H2O 	
U 
Mixture of 	Reagent 
Si 115(a) and (b) ° 	 OH OR Pyridine 	
1116 117 
R= 	 Ph 
Figure 45. Route 1: Isolation of 2'-0-(hex-4-ynyl benzoate) uridine 
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The second, and preferred method, was achieved by dimethoxytritylation of the 
mixture (115), which enabled the chromatographic separation of the two isomers 
(Figure 46). The mixture of isomers were dried by coevaporation with pyridine, then 
treated with dimethoxytrityl chloride, producing the 2'-O-(hex-4-ynyl benzoate) 




DMTrO 	 DMTrO 	u 
Mixture of 	DMTrC1 
115(a) and (b) 
Pyridine 
OR OH 	 OH OR 
1.18 	 119 
DM TrO- 	u 
2-cyanothyl N,Ndiisopmpyl- 
-phosphaminochioridite 
119 	 N. 	 o 
N,N diisopropylethylaniine 
120 
Figure 46. Synthesis of 5 '-O-(dimethoxytrityl)-2 '-O-(hex-4-ynyl benzoate)-uridine - 
3 '-0-(2-cyanoethyl-N,N-diisopropylphosphorwnidite) 
The 2'-O-(hex-4-ynyl benzoate) isomer was then phosphitylated using standard 
phosphoramidite synthesis procedures. 121  Purification by both chromatography and 
precipitation were required to-give the desired phosphoramidite (120) in a yield of 
72%. Before evaluating the coupling efficiency of the phosporaniidite derivative (120) 
in solid phase synthesis, a solution synthesis of a dinucleoside was performed. 
Preparation of the 3'-terminal uridine unit was carried out by a simple three step 
synthesis (Figure 47). Dimethoxytritylation of the 5'-hydroxyl of uridine (121), 
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followed by benzoylation of the N3 position and 2'- and 3'-hydroxyls gave the fully 
protected uridine (122). Removal of the dimethoxytrityl group by treatment with 
trifluoroacetic acid in DCM gave the desired 3',2',N 3 -tri(benzoyl)-uridine (123). 
DMTrO 	UBZ 	Ho __I
I 
lJBz H 	u DMTrG DMTIO 	u 
°1 	
AgNO3 	 TI TFA 
30 
pyridine 	 pyridine 	
° ° 	
DCM 
Bz BO °Bz OH OH 	 OH OH 	 Bz 
121 	 122 	 123 
Figure 47. Synthesis of 3 ',2 ',N-tri(benzoy)-uridine 
Condensation of 5' -O-(dimethoxytrityl)-2 '-O-(hex-4-ynyl benzoate)-uridine-3 '-O-(2-
cyanoethyl-N,N-diisopropylphosphoraniidite) (120) with the 3'-terminal uridine unit 
was carried out in acetonitrile in the presence of 1H-tetrazole, to give the fully 




+ 	 so NCCH2CH20—P=O 
120 	CH3CN  
U~V40 
UBz 
Bz0 0 B 
124 
Figure 48. Solution synthesis of diribonucleotide derivative 
2.4. Solid Phase Synthesis of PolyUridine 
The intemucleotide linkages of oligouridylic acids [such as (U'p)9U1 have been shown 
to be considerably more susceptible to acid-promoted hydrolysis, and presumably also 
to migration, than other oligoribonucleotides of similar or greater length containing 
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different base sequences. Capaldi et a17 ' has proposed that the increased acid lability 
of r[(U'p)9U] compared with that of uridylyl-(3'—*5')-uridine is due to distant 
nucleotide, or even uradil residues in r[(U'p) 9U], promoting the interaction between 
specific 2'-hydroxyl functions and intemucleotide linkages. 
It was, therefore, decided to synthesise oligouridylic acids using the 2'-0-(2-
hexynbenzoate) group. If the protecting group strategy for the 2'-hydroxyl function 
proved successful for the syntheses of oligouridylic acids, it should then be possible to 
transfer the protocols to the syntheses of other sequences. 
Solid phase synthesis using the phosphoramidite derivative (120) was carried out. 
First it was necessary to attach the terminally protected ribonucleoside to the 
commercially available long-chain alkylamine silica support. This was achieved by 
conversion of 3'-O-(hex-4-ynyl benzoate) uridine to the corresponding 2'-O-succinate 
derivative which was subsequently reacted with the amino group of the support. The 
3'-0-protected nucleoside was used, since it is produced during the protection of the 
2'-O-hydroxyl and is not required for the synthesis of RNA containing normal 3'-5' 
phosphodiester linkages. The support was dried overnight and the loading of the 
bound ribonucleoside was determined by detritylation of 2 mg portions of the support 
with perchioric acid and measurement of the absorbance at 498nm (16 tmol g').' 22 
DMTrO 	u 
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Figure 49. Derivatization of LCAA solid support 
52 
Results and Discussion 
The derivatized silica support was then used for the synthesis of polyuridine. 10 
nucleotides in length [DMTr-(U'p) 9U]. The phosphoramidite derivative (120) was 
dissolved in acetonitrile to a concentration of 0.1 M, and was used in the synthesis of 
oligouridylic acid [DMTr-(U'p)9U] using three different conditions. Coupling times of 
2, 5 and 10 minutes were employed for the condensation reactions, hence enabling the 
evaluation of the coupling efficiency and, if any, the steric interference of the 
phosporamidite derivative (120). No other variables were altered during the 
syntheses, as shown in the synthetic cycle protocols below (Figure 50). 
Synthetic Cycle Reagent and/or Duration (t/sec) Duration (t/sec) Duration (t/sec) 
Steps Solvent Synthesis A Synthesis B Synthesis C 
0.5M Tetrazole in 
Coupling reaction 
CH3CN 




60 60 60 
0.1M 12 in THF, 
Oxidation 
Pyridine, Water 
30 30 30 
Detritylation 3% TCA in DCM 30 30 30 
Overall Coupling 
Efficiency 81% 83% 84% 
Figure 50. Synthetic cycle protocols for DMTr-(U'p) 9 U 
The coupling efficiencies obtained from the three syntheses showed little variation 
from the 2 minute (81%) to 10 minute (84%) coupling times, thus supporting the idea 
that the 2'-O-(hex-4-ynyl benzoate) group did not introduce steric interference in the 
vicinity of the phosphoramidite moiety. 
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2.5. Deprotection and Stability Studies 
Before subjecting the synthesised oligonucleotide to deprotection conditions, the 2'-
0-(hex-4ynyl benzoate) deprotection was first tested at the nucleoside level (Figure 
51). The 2'-protected nucleoside (119) was detritylated, as before, to produce 2'-0- 
(hex-4-ynyL benzoate)uridine (127) in a yield of 98%. The 2'-0-(hex-4-ynyl benzoate) 
group was found to be stable to the acidic conditions employed in the removal of the 
5'-DMTr group. To further test its stability to acidic conditions, (127) in 0.1 mol dm 3 
hydrochloric acid (pH 1.1) at 25°C was monitored using reverse-phase HPLC over 7 
days. At the end of this period,, it was found to be completely intact: therefore, due to 
its stability to acidic conditions it would remain intact during the repeated detritylation 
steps employed- in solid-phase synthesis. 
DMTrO 
	
W0 	 0 
OH 	 Ph 
119 
HO, 
TFA  __ 	 0 
DCM ( 	 O—( 




IN 	 H 
3:1 OH 0  
128 
Figure 51. Synthesis of 2'-0-(hex-4-yn-1-oI) uridine 
The conditions required for the removal of the phosphate protecting groups, and 
cleavage of the, completed chain from the solid support, were used in the removal of 
the benzoyl group. Complete removal of the group required treatment for 4 days with 
33% aqueous ammonia solution and ethanol (3 : 1) at room temperature, yielding 2 7 .-
0-(hex-4-yn-1-ol) uridine (128) quantitatively. Analysis of the product by reverse-
phase JJPLC firmly established that complete deprotection of the 2'-hydroxyl funtion, 
to give uridine, did not occur. This indicates that the 2'-O-(hex-4-yn-1-ol) group is 
completely stable to the alkaline deprotection conditions, thus preventing the 
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formation of a free 2'-hydroxyl group, which would of led to either hydrolytic 
cleavage or migration of the internucleotide linkages of RNA. It would also allow the 
synthetic oligoriboncleotides to be purified, without any risk of degradation, before 
the 2'-O-protecting groups are required to be removed. 
Capaldi and Reese" studied the stability of internucleotide linkages of 
oligoribonucleotides in the aqueous acid conditions required during cleavage of Ctmp 
and Fpmp acetal protecting, groups. From their studies, it was concluded that the ideal 
final deblocking process of the 2'-hydroxyl function should be carried out above pH 3 
within 24 hours, if hydrolytic cleavage and migration were to be avoided. 
Deprotection of the 2'-O-(hex-4-yn- 1 -ol) group was studied over the pH range 1 to 3 
using Q. 1 dm' (pH L 1, 0.01 dm' (pH 10) hydrochloric acid, and a buffer solution of 
50mM ammonium formate (pH 3.1). The 2'-O-(hex-4-yn- 1 -o1) uridine monomer (1 
mg) was dissolved in appropriate aqueous acid or buffer solution, and monitored by 
reverse-phase HPLC. 
Deprotection 
Conditions (room temp.) 
2'-O-(hex-4-yn-1-oI) uridine 
- 	 Uridine (hours) 
pH 1.1 9.5h 
pH 2.0 24.3h 
pH 3.1 96.5h 
Figure 52. Deprotection Studies of 2'-0-(hex-4-yn-1-ol) uridine 
The tabulated data of the time taken for the deprotection of 2'-O-(hex-4-yn- I -ol) to 
the fully deprotected uridine is shown in Figure 52. It can be seen from the results that 
complete deprotection was obtained, however, the conditions required for the 
cleavage were harsh and would therefore cause cleavage and migration of the 
55 
Results and Discussion 
internucleotide linkages of RNA. Addition of an equimolar quantity of HgC1 2 to the 
deprotection conditions was found to increase the rate of removal; however, 
reproducibility of results proved extremely difficult. 
In conclusion, it was found that the two cleavage steps, in the deprotection of 2'-0-
(hex-4-ynyl benzoate.) uridine to uridine, required extended reaction times and harsher 
conditions than those which are suitable for the handling of RNA. Therefore, 
modification of the original 2'-O-(hex-4-ynyl benzoate) system was required to 
improve the efficiency of both cleavage steps. 
2.6. Modification of 2 1 -Hydroxyl Protecting Group 
The conditions required for the clevage of the 2'-hydroxyl protecting group from the 
completed RNkmolecule, is by fat the most important factor tu be now considered in 
the design a protecting group. Increase in the rate of base hydrolysis of the benzoyl 
group can be achieved by the incorporation of a para or ortho electron withdrawing 
group, such as a nitro substituent, onto the phenyl ring. However, on base hydrolysis, 
the alcohol 2.'-O-(hex-4.'yn-1-Ql) is still formed, yieldingthe acid cleavage system that 
has already been studied. Therefore, by replacement of the 0-benzoate by S-benzoate 
would create 2'-O-(hex-4-yn-l-thiol) system (138) for the final cleavage step (Figure 
52). The interaction of the thiol with the acetylene may be favoured due to the 
'softness' of the nucleapbile. 
2.6.1. Synthesis of 2 '-O-(Hex-4-ynyl thiobenzoate) uridine 
To study the feasibility of a thiol-based system for the final deprotection step, it was 
necessary to synthesise 2'-O-(hex-4-ynyl thiobenzoate) uridine (137). (Figure 52). 
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Figure 52. 2 '-O-(hex-4-ynyl thiobenzoate) uridine 
The synthetic procedures used in the synthesis and incorporation of the 2'-O-(hex-4-
ynyl benzoate) group were applied to the synthesis of 137. The ester, 6-
(tetrahydopyranyloxy)-hex-4-ynyl tbiobenzoate (131), was obtained in 71% yield by 
heating 101 in DMF at reflux, in the presence of sodium tbiobenzoate. The 
tetrahydropyranyl ether was cleaved by treatment with 10% oxalic acid .to give 6-
hydroxyhex-4-ynyl thiobenzoate (132) in 50% yield. Formation of 6-Iodo-hex-4-ynyl 
thiobenzoate by the addition of iodine in one portion to a solution of 132, 
triphenyiphosphine and imidazole gave 133 in a yield of 76%.I12 
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Figure. 53.. Synthesis of 646do-hex-4-ynyl. thiobenzoate 
Incorporation of the hex-4-ynyl .thiobenzoate group to the 2'-hydroxyl function of 
uridine was achieved using identical protocols to those used in the synthesis of 2'-0-
(hex-4-ynyl benzoate) uridine (Figure 51). 133 was added to a solution of uridine, 
dibutyltin oxide and tetra-n-butylammonium bromide in DMF. After heating for 24 
hours at 60°C, a mixture of the 2'- and 3'-O-(hex-4-ynyl thiobenzoate) uridine 
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isomers (134a and 134b respectively) were obtained in an approximate ratio of 3:2 
(Figure 54). Chromatographic separation of the two isomers was achieved by 
dimethoxytritylation of the mixture (134), producing 2'-O-(hex-4-ynyl thiobenzoate) 
uridine (136) and 3'-O-(hex-4-ynyl thiobenzoate) uridine (135) in yields of 30% and 
20%, respectively. Dimethoxytritylation of 2' -O-(hex-4-ynyl thiobenzoate)-5 '-0-
(dimethoxtrityl) .uridine in DCM with TFA gave 137 in a yield of 76%. 
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Figure 54. Synthesis 012  '-O-(hex-4-yn-1-thiol) uridine 
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2.6.2. Deprotection and Stability Studies of 2'-O-(Hex-4-ynyl thiobenzoate) 
uridine 
The 2'-O-(hex-4-ynyl thiobenzoate) group showed similar characteristics to 2'-0-
(hex-4-ynyl benzoate) uridine. Using reverse-phase HPLC, 2'-O-(hex-4-ynyl 
thiobenzoate) uridine (137) was monitored over a 7 day period under acidic 
conditions (pH 1. 1).  It was found to be still intact at the end of this period, thereby 
indicating its potential stability during repeated acid cleavage of the trityl group in the 
synthesis cycle. 
Cleavage of the benzoyi group (137—*138) was achieved using the standard 
conditions required. for the. removal of the phosphate proiecting groups, along with 
cleavage of the completed chain from the solid support. Complete removal of the 
group required treatment for 72 hours with 33% aqueous ammonia solution and 
ethanol (3: 1) at room temperature. Analysis of the product by HPLC established that 
the complete deprotection of the 27-hydroxyl function to. give uridine did not occur. 
As with the 2'-O-(hex-4-yn-1-ol) group, 2'-O-(hex-4-yn-1-thiol) uridine was found to 
be stable to alkaline conditions, thus preventing formation of the free 2'-hydroxyl 
group which would have led to either hydrolytic cleavage and/or migration of the 
internucleotide linkages of RNA. It would also allow the synthetic oligoriboucleotides 
to be purified, without any risk of degradation, before the 2'-O-protecting groups are 
required to be removed. 
The conditions used in the study of the deprotection of 2'-O-(hex-4-yn- I -ol) uridine 
were employed in the study of 2'-O-(hex-4-yn- 1 -thkil) uridine (138). Treatment of 
138 with acidic solutions in the range pH 1 to pH 3 were monitored using HPLC. 
However, formation of the unprotected uridirie monomer was not observed under any 
of the conditions empinyed. It was found that it was necessary for the thiol based 
system to be stored and studied under argon, due to susceptibility of the system to 
oxidation. 
59 
Results and Discussion 
It was, therefore, necessary to further investigate alternative systems based on the 
proposed propargyl system. 
2.7. Acetylenecarboxylic acids as potential 2'-Hydroxyl Protecting 
Groups 
As well as intramolecular additions of alcohols to acetylenes, cyclisation of 
acetylenecarboxylic acids (139) to lactones (140) has also been observed. 
123,124,125 
Yamamoto reported the synthesis of y-methylenebuyrolactones using this procedure 
(Figure 55). 126 
R 	 R 
40H HgO 
R' 
139 	 140 
Figure 55. Cyclisalion of Acetylenecarboxylic .  acids 
Therefore, the study of a propargyl based system incorporating a carboxylic acid 
based system was proposed (Figure 56). 
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Figure 56. Carlioxylic acid based system 
Protection of the carboxylic acid functionality would be required during RNA 
synthesis, hence protection as the methyl or ethyl esters were suggested (142). On 
treatment with the standard alkaline cleavage conditions formation of the carboxylic 
6O 
Reszdts and l)jsc1is1011 
acid based system, would be achieved. To offer an indication of the products formed 
during base hydrolysis of the methyl or ethyl ester, the methyl and ethyl esters of 
phenyl acetic acid (143 and 145) were treated with 33% ammonia solution and 
ethanol (3 : 1). Formation of the phenyl acetamide (144) and phenyl acetic acid (146) 
were observed, respectively (Figure 57). 
In order to determine the feasibility of both groups in the final deprotection step of the 
2'-hydroxyl function, the methyl and ethyl esters of 2'-O-(hept-5-ynoic acid) uridine 
were synthesised. 
0- r No 3:11 
143 




O OH  
146 
Figure 57. Base hydrolysis of methyl and ethyl esters 
2.7.1. Synthesis of Methyl and Ethyl-7-iodo-hept-5-ynoate 
The synthetic procedures used in the incorporation of the two previous systems were 
applied to the synthesis of 2'-O-(methyl-hept-5-ynoate) uridine and 2'-O-(ethyl-
hept-5-ynoate) uridine. 
Synthesis of methyl and ethyl- 7- iodo-hept- 5 -ynoate were achieved, each in a 5 step 
synthesis from 6-(tetrahydropyranyloxy)-hex-4-yne chloride (101) in overall yields of 
27% and 41%, respectively (Figure 58). 101 in the presence of sodium cyanide gave 
the formation, of 6-(tetrahydropyranyloxy)-hex-4-yne cyanide (147), in a yield of 
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96%. 127  Heating 147 to reflux in 25% NaOH solution and methanol gave 7-
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Figure. 51 Synthesis of Methyl and Ethyl- 7-iodo-hepl-5-ynoate 
The formation of the methyl ester (149) was achieved in a quantitative yield by 
treatment of 148 with diazomethane. 148 in the presence of DMAP, NEt 3 and 
ethyichioroformate gave the ethyl ester. (152) in a yield of 85%.129  This was followed 
by the removal of the tetrahydropyranyl ether (149—*150 and 152-153), and the 
formation of the iodide (150—*151 and 153-A54). 
2.7.2. Synthesis of 2 1 -0-(Methyl- and 2 1 -0-(Ethyl-hept-5-ynoate) uridine 
Incorporation of both groups was accomplished by the treatment of uridine, in the 
presence of DBTO, TBAB in DMF, with the previously prepared methyl and ethyl-7-
iodo-hept-5-ynoate (151 and 154), in yields of 81% and 80% respectively (Figure 59). 
Dimethoxytritylation enabled the chromatographic separation of both sets of isomers, 
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of which the 2'-O-protected isomers were detritylated to give 2'-O-(methyl-hept-5-
ynoate) uridine (158) and 2'-O-(ethyl-hept-5-ynoate) uridine (162) both in overall 
yields of 17%. 
HOTh 	
H 	u 	HO 	U Bu2 SnO, TBAB
4
+ 1.151  
OH OH 	2.154 	
OH OR 	 OR OH 
155(a) 	 (b) 
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156 	 157 
160 161 
DMTrO 	u 	 H 	U 
TFA 
DCM 
OH OR 	 OH 0 
156 	 R'= Me, 158 
160 	 R'= Et, 162 
Figure 59. Synthesis of 2 '-O-(Methyl- and 2 '-O-(Ethyl-hept-5-ynoate) uridine 
The alkaline cleavage conditions required for the removal of the phosphate protecting 
groups, and cleavage of the completed chain from the solid support, were employed in 
the base hydrolysis of the methyl and ethyl esters. Treatment with 33% aqueous 
ammonia solution and ethanol (3 : 1) at room temperature over 3 days gave complete 
hydrolysis of the methyl and ethyl esters. However, on analysis of the products by 
reverse-phase HPLC, it was established that deprotection of the 2'-hydroxyl function, 
to give uridine had also occurred. Therefore, the instability of the proposed propargyl 
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systems to the required ammonia deprotection conditions would lead to cleavage and 
migration of the internucleotide linkages of a completed RNA chain. Thus, the methyl 
and ethyl-hept-5-ynoate systems are not suitable for the protection of the 2'-hydroxyl 
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Figure 60. Base hydrolysis 
2.8. Conclusions 
An original series of 2'-hydroxyl protecting groups for the synthesis of 
oligoribonucleotides have been designed and synthesised. The design of these groups 
was based on a functionalised propargyl system, that involved cleavage via a ring 
system precursor. The precursor was protected during synthesis, using compatible 
protecting group strategies, and was activated during the conditions required for 
removal of the phosphate protecting groups and cleavage from the solid support. 
Three functionalised propargyl based systems were proposed; 2'-O-(Hex-4-yn-1-ol) 
(128), 2'-O-(hex-4yn-1-thiol) (137) and 2'-O-(hept-5-ynoic acid) (142) groups were 
studied for their cleavage conditions and their stability to the parameters required 
during the synthesis of RNA. Efficient syntheses and incorporation procedures of the 
proposed protecting groups were found. 
The 2'-O-(hex-4-ynyl benzoate) group (127) satisfied most characteristics of an ideal 
2'-hydroxyl protecting group. Synthesis of three lOmers of polyuridine were achieved 
using the phosphoraniidite approach to solid-phase synthesis. The coupling 
efficiencies from the three syntheses showed little variation for the 2, 5 and 10 minute 
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coupling times employed for the condensation reactions of the phosphoramidite 
monomers (120) (81%, 83% and 84%, respectively). This indicated minimal steric 
interference in the vicinity of the phosphoramidite moiety, which is a major drawback 
in the commercial systems presently available. 
The 2'-O-(hex-4-ynylbenzoate) group was found to be completely stable to the 
parameters required during synthesis, and was hydrolysed to the hydroxyl bearing ring 
system precursor (128) under basic ammonia conditions (Figure 51). Cleavage of the 
group was achieved at pH 3.1 in 96.5 hours (Figure 52). 
In an attempt to improve the rate of cleavage, thiol (137) and carboxylic acid (142) 
based systems were studied. Once hydrolysed to the thiol based system (138), 
cleavage of the group from the 2'-hydroxyl function was not obtained. This may be 
ascribed to the thiols susceptibility to oxidation. The carboxylic acid based system was 
found to be unstable to the aqueous ammonia conditions. This caused partial full 
deprotection of the 2'-hydroxyl function to give uridine, which would have led to the 
cleavage and migration of the internucletide linkages. Thus, the thiol and carboxylic 
acid systems were observed to be unsuitable for the protection of the 2'-hydroxyl 
function during RNA synthesis. 
The immense difficulty in finding suitable protection for the 2'-hydroxyl function for 
RNA synthesis has been highlighted through the study of the three proposed systems 
described in this chapter. This is due to the stringent criteria that have to be fulfilled. 
The 2'-hydroxyl protecting group has to be stable to the repeated acid conditions 
applied during synthesis, but is required to be stable to the basic ammonia conditions 
used in the cleavage of the completed chain from the solid support. Therefore, it 
would be advantageous to design a system that is stable to the acid conditions 
employed during synthesis, but is activated to an acid labile system during the 
ammonia cleavage step. The results obtained will be extremely useful when designing 
other propargyl based systems. 
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2.9. Future Work 
2.9.1. 2'-Hydroxyl Protecting Groups 
Due to time constraints it has not been possible to fully investigate the potential of 
other propargyl based systems. Ideally, the system would maintain all the 
characteristics of the 2'-O-(hex-4-ynyl benzoate) group, but have an improved rate of 
cleavage in the final deprotection step, within the conditions required for the stability 
of RNA. Work is still required in finding a group that fulfils all the required criteria 
for a 2'-hydroxyl protecting group. Modifications to the alkyl chain of the 2'-O-(hex-
4-ynyl benzoate) group, by addition of various substituents, would be of interest. In 
particular, the addition of two methyl groups at the C-3 position of hex-4-ynyl 
benzoate. 
2.9.2. Phosphate Protecting Group 
The 3-cyanoethyl group is currently the most widely used phosphate protecting group 
for the intemucleotidic bonds in the synthesis of oligonucleotides by the 
phosphoramidite approach (Section 1.6.4.). The feasibility of combining the 2'-
hydroxyl protecting group for the protection of the phosphate group has been 
considered. Preliminary studies have highlighted the possibility of incorporating the 
propargyl based system, 6-hydroxy-hex-4-ynyl benzoate, into a deoxynucleoside iV,iV-
dialkylamino phosphoramidite, via the chloro-NN-dialkylaminoalkoxyphosphine 165 
(Figure 61). Preparation of N, N-diisopropyl-(hex-4-ynyl benzoate)- I -phosphonamidyl 
chloride (165) was achieved by addition of NN-diisopropylamine to a freshly 
prepared solution of (hex-4-ynyl benzoate)-1-phosphodichloridite (164). The 
phosphoramidite, 5' -0-4,4' -dimethoxytrityl-(N 4-Benzoyl)-cytidine-3 '-0- [N.N - 
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addition to 165 in the presence of diisopropylethylamine. The phosphoramidite was 

























Figure 61. Synthesis of 5 '-0-4,4 '-dimethoxytrityl-(N'-Benzoyl)-cytidine-3 '-0- 
IN,N-diisopropyl-(hex-4-ynyl benzoate)-1-phosphoramiditeJ 
The applicability of the phosphoramidite (167) was not demonstrated; however 
improvements to the propargyl based system would lead to evaluation of this type of 
phosphate protection. 
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2.9.3. Hydrophobic 5'-O-Protecting Group 
The purification of oligonucleotides using modified DMTr groups has previously been 
discussed (Section 1.7.3.). Ramage and Wahl" demonstrated the potential of 4-(17-
tetrabenzo [a,c,g,i]fluoromethyl)-4' ,4' '-dimethoxytrityl chloride (Thf-DMTr-Cl) (59) 
as a new hydrophobic 5'-hydroxyl protecting group. The Tbf moiety has been proven 
to be ideal for purification purposes due to its strong hydrophobic and fluorescent 
properties. It was, thus, desirable to sufficiently separate the Thf moiety from the 
synthesised chain, to avoid steric bulk from the bulky Thf moiety. Hay' 3° and Hager ' 3 ' 
achieved this through connection of the Tbf moiety via a linker to a trityl compound. 
The linker consisted of a ten carbon alkyl chain with one alkoxy group to allow acid 
cleavage following purification of the oligomer (Figure 62). 
I 
168 
Figure 62. Bis-(4-methylphenyl)-4-(1O-(1 7-tetrabenzo[a,c,g,iJfluorenyl)decyloxy) 
phenyl methyl chloride 
2.9.3.1. Synthesis of 5'-O-Hydrophobic Protecting Group 
Work by Hay 130  and Hager 131,  within the group, discussed the synthesis of ethyl-4-
[1 O-( 1 7-tetrabenzo [a,c,g,I] fluorenyl)-decyloxy] benzoate (171) from the terabutyl-
arnmonium salt of 8bH-Tbf ( 170) and the bromo ester, ethyl-4-(10-bromodecyloxy)-











Results and Discussion 
decyloxy) phenyl methanol (173) was formed via a Grignard reaction of 4-










Figure 63. Synthesis of Bis-(4-methylphenyl)-4-(10-(1 7- 
tetrabenzofa,c,g,IJfluorenyl)decyloxy) phenyl methanol 
Study of the chlorination of 173 to 168, and incorporation to the 5'-hydroxyl function 





Chemicals were purchased from commercial sources such as Aldrich, Lancaster, and 
Fluka, checked and used without further purification. Melting points were determined 
in open capillaries using a Buchi 510 melting point apparatus and are uncorrected. 
Thin layer chromatography (tic) was performed on aluminium sheets precoated with 
silica gel (Kieselgel 60 F254) in the solvent system indicated. Wet flash 
chromatography was performed using silica gel 60 (230-400 mesh). Compounds were 
visualised using suitable combinations of ultra violet absorption at 254 and 365nm,, 
iodine vapour and methanolic sulphuric acid. Infrared spectra were recorded on a 
Perkin Elmer Lamda 11 single beam spectrophotometer. Fast atom bombardment 
mass spectra (FAB MS) were recorded on a Kratos MS50TC and electron impact 
mass spectra (El MS) on a 4/500 Finnigan. Electospray and APCI on a VG Platform. 
Elemental analyses were carried out on a Perkin Elmer 2400 instrument. Proton NIMR 
were recorded on a Varian Gemini 200 and a Bruker AC250 (250MHz) in the solvent 
indicated relative to tetramethylsilane (TMS) as the external standard. Carbon-13 
NMR spectra were recorded on a AC250 (60MHz) instrument in the solvents 
indicated relative to TMS. Phosphorus-31 NIvIIR spectra were recorded on a AC 250 
(60MHz) instrument in the solvents indicated relative to phosphoric acid as the 
internal standard. A Bruker WH360 was used to record NMR spectra at 300MHz. 
The chemical shifts () were reported in parts per million. All solvents were of 
analytical grade or were distilled before use. The following were dried when required 
using the regents indicated; dichloromethane (calcium hydride), diethyl ether (sodium 
wire), tetrahydofuran (sodium/benzophenone indicator), pyridine (calcium hydride), 
acetonitrile (calcium hydride). 
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3.1.1. Oligoribonucleotide Synthesis 
The synthesis of oligoribonucleotides was performed on an Applied Biosystems 381A 
DNA synthesiser courtesy of Link Technologies. Tetrazole coupling catalyst, acetic 
anhydride and lutidine capping reagents, trichioroacetic acid deprotection solution, 
iodine oxidation mixture, acetonitrile and solid support were supplied by Link 
Technologies. Syntheses were carried out using the protocols as described in Section 
2.4. 
3.1.2. HPLC 
Deprotection and stability studies were monitored using reverse-phase high 
performance chromatography (RP-HPLC). This was performed using a Gilson system 
comprising of two 306 solvent delivery systems, an 811C dynamic mixer, an 805 
manmetric module, a 119 UVfVIS detector and a Gilson software-driven gradient 
controller. Gradients were eluted from a Vydac reverse phase silica column (5iJ 
particle size) C 18, 250 x 2.6mm using a linear grade of acetonitrile (A) in Milhi-Q 




Anhydrous pyridine (1.88g, 22.4mmol) and benzoyl chloride (3.35g, 23.8mmol) were 
added dropwise to a solution of l-pentyne-4-ol (96) (2.0g, 23.8mmol) in anhydrous 
CH202  (15m1) at room temperature. The reaction mixture was heated at reflux for 6 
hours, cooled to room temperature and the pyridine hydrochloride filtered off. The 
filtrate was washed with 2M NaOH solution (2x25ml), separated, dried (MgSO 4), 
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filtered and reduced in vacuo. The residue was purified by wet flash chromatography 
(DCM) to give the title compound as a clear oil (3.91g, 87%). tic R (30% 
Hexane/DCM) 0.68; v... - 3297 (C-H alkyne), 2117 (carbon-carbon alkyne), 1718 
(C=O stretch); SH (200MIHz, CDC1 3) 1.95-2.04 (m., 3H, H-C, CH2), 2.33-2.42 (m, 
2H, C112), 4.42 (t, 2H, CH2 , J = 6.2), 7.38-7.70 (m, 5H, aromatic)ppm; 8C (63MHz, 
CDC13) 15.14 (CH2), 27.45 (CH2), 63.25 (CH2), 68.95 (alkyne), 82.82 (C-H alkyne), 
128.16, 128.69, 129.34, 130.35, 132.77 (aromatic), 166.31 (CO) ppm; m/z (FAB) 
189 (MiH); HRMS (FAB) Found 189.09197, C 12H 1302 Requires 189.08977. 
6-Hydroxy-hex-4-ynyl benzoate (98). 
Compound (97) (1.0g, 5.3mmol) in anhydrous THY (20m1) was cooled to -30 °C 
under an atmosphere of argon. 1.6M nButyl lithium (3.36m1, 5.3mmol) was added 
dropwise and the reaction allowed to stir for 30 minutes, at -30 °C. Previously dried 
paraformaldehyde (0.48g, l6mmol) was added and the reaction allowed to warm to 
room temperature and stirred overnight. Diethyl ether (30m1) and water (30m1) were 
added to the reaction mixture and K 2CO3 was added until the aqueous layer became 
pasty. The organic layer was then separated, dried (MgSO4) and reduced in vacuo. 
The residue was purified by wet flash chromatography (DCM) to give the title 
compound as a clear oil (0.12g. 10%). tic R (5% MeOHIDCM) 0.63; vr 3425 
(OH), 2959 (CH, aromatic), 2226 and 2286 (carbon-carbon alkyne), 1719 (C0 
stretch); oH (200M11z, CDC1 3) 1.78 (s, 1H, OH) 1.90-2.03 (ni, 214, C11 2), 2.36-2.45 
(m, 211, CH2), 4.22 (t, 2H, ThpO-CH2, J = 2.1H4, 4.41 (t, 2H, C11 2-benzoate, J = 
6.214z), 7.25-8.16 (m, 5H, aromatic)ppm; OC (63MHz, CDC13) 15.56 (CH2), 27.60 
(CH2), 51.18 (CH2), 63.46 (CH2), 79.13 (ailcyne), 84.74 (alkyne), 128.26, 129.44, 
130.08, 132.86 (aromatic), 166.46 (C=O) ppm; m/z (FAB) 219 (MIFf); HRMS 
(FAB) Found 219.10284, C 13H1503 Requires 219.09954. 
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6-(tetrahydropyranyloxy)-hex-4-yne chloride (101). 
Propargyl tetrahydropyranol (100) (1.0g. 7.1mmol) was dissolved in anhydrous THY 
(lOml) and cooled to -78 °C under an atmosphere of nitrogen. 2.5M nButyllithium 
(2.85ml, 7.1mmol) was added dropwise to the reaction mixture. After 30 minutes 3-
bromo- 1 -chloropropane (1.1 2g, 7.1 mmol) in TI{F was added dropwise over a 10 mm. 
period. The reaction mixture was allowed to warm to room temperature and heated at 
reflux for 20 hours. After cooling diethyl ether (15m1) and water (15m1) were added 
and extracted (2x1 5m1). The combined organic layers were dried (MgSO4), filtered 
and reduced in vacuo. The residue was taken up in ether and passed through neutral 
grade alumina. The alumina was washed with ether and run dry. The ether was 
reduced in vacuo and the residue was purified by Kugelrohr distillation under vacuum 
(94°CI0.04mmHg) to give the title compound as a clear oil (1.30g, 84%). tic R 
(DCM) 0.57; C.H.N. Found C: 60.22%, H: 7.73, C 11 H1702C1 Requires C: 60.97%, 
H: 7.91, v. 2959 (CH), 2222 and 2286 (carbon-carbon alkyne); EiH (360MI11z, 
CDCI3) 1.42-1.85 (m, 6H, C11 2), 1.87-2.00 (m, 2H, CH2), 2.35-2.42 (m, 211, CH2), 
3.64 (t, 211, C112-Cl, J= 6.2Hz), 3.48-3.56 and 3.77-3.88 (m, 2H, C11 2-0), 4.12-4.32 
(m, 2H, O-CH2-alkyne), 4.79 (t, 1H, CH, J = 2.5Hz) ppm; 8C (360MHz, CDC1 3 ) 
16.01 (alkyne-C142), 18.85 (CH2), 25.23 (CH2), 30.03 (CH2), 31.01 (CH 2), 43.39 
(CH2-CI), 54.24 (0-CH 2 -alkyne), 61.73 (C}{2-0), 77.42 (alkyne), 84.25 (alkyne), 
96.46 (CH) ppm; m/z (FAB) 217 (Md); HRMS (FAB) Found 217.1002 1, C 11 H 1702 C1 
Requires 217.09601. 
6-(Tetrahydropyranyloxy)-hex-4-ynyl benzoate (102). 
Compound (101) (0.31g, 1 .43mmol) was suspended in DMF (15m1) to which dried 
sodium benzoate (0.34g, 2.36mmol) was added. The reaction mixture was heated at 
reflux for 6 hours under an atmosphere of nitrogen and then left to cool. Ether (30m1) 
was added before filtering and washing with ether. The ether and DMF were removed 
in vacuo. The residue was purified by wet flash chromatography (DCM) to give the 
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title compound as a clear oil (0.35g, 8 1%). tic Rf (5% MeOHIDCM) 0.63; v 2959 
(CH, aromatic), 2222 and 2286 (carbon-carbon alkyne), 1718 (C0 stretch); 5H 
(200MHz, CDCI3) 1.48-1.84 (m, 611, C11 2), 1.92-2.2.02 (mt, 211, CH2), 2.37-2.45 (m, 
2H, C112), 3.46-3.54 and 3.77-3.86 (m, 2H, CH 2-0), 4.12-4.31 (m, 2H, O-CH2-
alkyne), 4.39 (t, 211, C112-benzoate, J = 6.211z), 4.77 (t, 111, CH, J = 3.1Hz)), 7.24-
8.03 (mt, 5H, aromatic) ppm; 8C (63MHz, CDCI 3) 15.43 (alkyne-CH2), 18.76 (CH2), 
25.02 (CH2), 27.44 (CH2), 29.92 (Cl2), 54.15 (0-CH2-alkyne), 61.59 (CH2-O), 
63.56 (CH2-benzoate) 76.38 (alkyne), 84.65 (alkyne), 96.33 (CH), 128.00, 129.19, 
129.88, 132.58 (aromatic), 166.06 (C0) ppm; mlz (FAB) 302 (Mn); HRMS (FAB) 
(MW) Found 303.16015, C 18H2204 Requires 303.15844. 
6-Hyd roxy-hex-4-ynyl benzoate (103). 
Compound (102) (1.4g. 4.64mmol) was dissolved in MeOH (45m1) to which 5% 
Oxalic acid (15m1) was added. This was allowed to stir at room temperature for 48 
hours before the MeOH was removed in vacuo. Water (1 OOml) and EtOAc (1 OOml) 
were added and the layers separated, extracting with EtOAc (2x50m1). The combined 
extracts were dried (MgSO 4), filtered and reduced in vacuo. The residue was purified 
by wet flash chromatography (Dclvi) to give the title compound as a clear oil (0.87g, 
86%). tic R (5% MeOHIDCM) 0.63; 3425 (OH), 2959 (CH, aromatic), 2226 
and 2286 (carbon-carbon alkyne), 1719 (C=O stretch); 8H (200MHz, CDCI3) 1.78 
(s,lH, OH) 1.91-2.02 (m, 2H, CH 2), 2.36-2.43 (m, 2H, alkyne-CH2), 4.22 (t, 2H, 
HO-CH2, J = 2.1Hz), 4.41 (t, 2H, CH 2-Benzoate, J = 6.2Hz), 7.25-8.05 (m. 5H, 
aromatic) ppm; SC (63MIHz, CDC1 3) 15.54 (alkyne-CH2), 27.57 (CH2), 51.15 (HO-
C112), 63.44 (CH2-Benzoate), 79.13 (alkyne), 84.71 (alkyne), 128.24, 129.43, 130.04, 
132.87 (aromatic), 166.46 (C0) ppm; m/z (FAB) 219 (MW); HRMS (FAB) Found 
2 19.10016, CI3H!503 Requires 219.09954. 
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6-Bromo-hex4ynyl benzoate (104). 
A solution of triphenyiphosphine (0.48g, 1 .84mmol) in anhydrous ether was added 
dropwise to a solution of 103 (0.20g. 0.92mmol), CBr 4 (0.61g, 1.84mmol) and 
pyridine (0.075m1, 9.1 7mmol) under an atmosphere of nitrogen at 0 °C. The reaction 
was stirred at 0 °C for 2 hours and then at room temperature overnight. The ether was 
removed in vacuo at 0°C and the residue dissolved in n-pentane. This was filtered and 
reduced in vacuo. The residue was purified by wet flash chromatography (DCM) to 
give the title compound as an oil (0.21, 82%). tic R (DCM) 0.45; VlL 2957 (CH, 
aromatic), 2233 (carbon-carbon alkyne), 1717 (C=O stretch); SH (200MHz, CDC13) 
1.92-2.02 (mt, 2H, CH2), 2.39-2.47 (m, 211, alkyne-CH2), 3.88 (t, 2H, Br-CH 2, J 
2.3Hz), 4.39 (t, 2H, CH 2 -Benzoate, J = 6.2Hz), 7.25-8.05 (m, 5H, aromatic) ppm; öC 
(63MiHz, CDC13 ) 15.17 (alkyne-CH 2), 15.81 (Br-CH2), 27.44 (CH2), 63.39 (CH2-
Benzoate), 75.97 (alkyne), 86.34 (alkyne), 128.22, 129.42, 130.04, 132.84 
(aromatic), 166.33 (C=O) ppm; m/z (FAB) 281 (M'); HRMS (FAB) Found 
280.0 1002, C 13H 13 O2Br Requires 280.00989. 
3', 5'-O-(Tetraisopropyldisiloxane-1,3-diyl)-u rid ine (106). ° 
1 ,3-Dichloro- 1,1 ,3,3-tetraisopropyldisioxane (0.75m1, 2.2mmol) was added dropwise 
over 5 minutes to a suspension of uridine (105) (0.5g, 2. immol) in anhydrous pyridine 
cooled to 0°C under an atmosphere of argon.. The reaction was allowed to warm to 
room temperature and stirred for 3 hours. The reaction was quenched with MeOH 
(5m1) and reduced in vacuo. The residue was taken up in DCM and washed with 5% 
NaHCO3 solution and extracted with DCM (2x50m1). The combined extracts were 
dried (Na2 SO4), filtered and reduced in vacuo. The residue was purified by wet flash 
chromatography (1-5% MeOH/DCM) to give the title compound as a white foam 
(0.72g. 72%). m.p. 77-78°C; tic R (5% MeOH/DCM) 0.34; C.H.N. Found C: 
52.11%, H: 7.67%, N: 5.40, C 21 H38N207Si2 Requires C: 51.82%, H: 7.87%, N: 
5.76%; 5H (200MHz, DMSO) 0.93-1.04 (m, 28H, CH(CH3)2), 3.85-4.17 (m, 5H, 
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2',3',4',5'-H), 5.49-5.54 (m, 1H, 5-H), 5.62 (d, 1H, 1'-H, J = 4.0Hz), 7.68 (d, 11-1, 
6-H, J = 8.1Hz), 11.38 (s, 1H, 3-11) ppm; iC (63MHz, DMSO) 12.06, 12.44, 12.84 
(4xCH), 16.87-17.46 (8xCH3 ), 60.33 (C-5'), 68.90 (C-3'), 73.65 (C-2'), 81.01 (C-
4'), 90.64 (C-l'), 101.07 (C-5), 139.93 (C-6), 150.24 (C-2), 163.33 (C-4) ppm; m/z 
(FAB) 487 (MH); HRMS (FAB) Found 487.23117, C 21 H39N207Si2 Requires 
487.22958. 
3', 5'-O-(Tetraisopropyldisiloxane-1,3-diyl)-N 3-(benzoyl)urjdjne (107). 109 
Benzoyl chloride (0.08g. 0.47mmol) was added to a vigorously stirred suspension of 
106 (0.21g, 0.42mmol), Na2CO3 (0.36g. 3.4mmol) and 5% tetrabutyl ammonium 
bromide (0.007g) in DCM:H 20 (20m1, 1:1). After 72 hours the organic phase was 
separated and the aqueous phase extracted with DCM (2x30m1). The combined 
extracts were dried (Na2 SO4), filtered and reduced in vacuo. The residue was purified 
by wet flash chromatography (1-5% MeOHIDCM) to give the title compound as a 
white foam (0.15g, 62%). tIc R1 (5% MeOHIDCM) 0.71; C.H.N. Found C: 56.66%, 
H: 7.31%, N: 4.65%, C28H42N208 Si2 Requires C: 56.92%, H: 7.17%, N: 4.74%; 8H 
(200MHz, CDC13) 0.98-1.08 (m, 28H, CH(CH3)2), 2.95 (s, br, 1H, OH), 3.96-4.37 
(m, SH, 2',3',4',5'-H), 5.73 (s, 1H, 1'-H), 5.79 (d, 1H, 5-11, J = 8.211z), 7.25-7.94 
(m, 6H, 6-H, aromatic) ppm; 8C (63MHz, CDCI 3) 12.32, 12.76, 12.85, 13.23 
(4xCH), 16.66-17.29 (8xCH3), 60.02 (C-5'), 68.75 (C-3'), 75.06 (C-2'), 81.95 (C-
4'), 90.66 (C-l'), 101.67 (C-5), 129.03, 130.35, 131.24, 135.03 (aromatic), 139.45 
(C-6), 148.24 (C-2), 161.99 (C-4), 168.44 (C=O) ppm; m/z (FAB) 591 (MEV); 
HRMS (FAB) Found 591.25685, C 2 81-L 3N208 Si2 Requires 591.25503. 
3', 5'-O-(Tetraisopropyldisiloxane-1,3-diyl)-N 3-(pivaloyl)urjd inc (108).' 10 
Compound (106) (0.10g. 0.21 mmol) was dissolved in anhydrous DMF (1 OmI). 
Anhydrous potassium carbonate (0.1 4g, 1.1 mmol) and chloromethyl pivalate (0.03g, 
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0.08m1, 0.2mmol) were added and the mixture stirred overnight under an atmosphere 
of argon. The reaction mixture was filtered and the filtrate reduced in vacuo. The 
residue was purified by wet flash chromatography (1-5% MeOHJDCM) to give the 
title compound as an off white foam (0.099g. 79%). tic Rf (5% MeOHIDCM) 0.69; 
C.H.N. Found C: 54.32%, H: 8.37%, N: 4.99%, C27H48N2O9Si2 Requires C: 53.97%, 
H: 8.05%, N: 4.66%; oH (200MiHz, CDC13) 0.97-1.07 (m, 28H, CH(CH 3)2), 1.14-
1.18 (m, 9H, C(CH3)3), 3.95-4.39 (m, 5H, 2',3',4',5'-H), 5.70 (m, 2H, 1'-H, 5-H), 
5.71-5.73 (rn, 211, CH2 pivalate), 7.66 (d, 1H, 6-H, J = 8.2Hz) ppm; 8C (63MIHz, 
CDC13) 12.36-13.21 (isopropyl CH), 16.67-17.29 (isopropyl CH 3), 26.86 (tert-butyl 
CH3s), 38.69 (quaternary C of tert-butyl) 60.15 (C-5'), 64.44 (CH2 of 
pivaloyloxymethyl), 68.75 (C-3'), 75.06 (C-2'), 81.95 (C-4'), 90.66 (C-l'), 101.24 
(C-5), 138.70 (C-6), 149.84 (C-2), 162.43 (C-4), 177.34 (pivaloyl CO) ppm; mlz 
(FAB) 601 (NH); HRMS (FAB) Found 600.29 122, C27IL8N209Si2 Requires 
600.28984 
3' ,5' -O-(Tetraisopropyidisiloxane- 1,3-diyl)-N 3-(4-tert-butylbenzoyl) uridine 
(109)." 
Triethylamine (0.42m1, 3mmol) and chlorotrimethylsilane (0.24m1, 1 .8Smmol) were 
added to a suspension of 106 (0.30g. 0.62mmol) in anhydrous DCM, cooled to 0 °C in 
an ice bath temperature under an atmosphere of argon. The mixture stirred overnight 
at room before being poured into vigorously stirred 1 M aqueous sodium bicarbonate. 
The separated organic phase was dried (Na 2SO4), filtered and reduced in vacuo to 
give a pink foam. The residue was dried by coevaporation with anhydrous pyridine 
(2x5ml), dissolved in anhydrous pyridine (4m1) and cooled to 0 °C in an ice bath. 4-
tert-Butylbenzoyl chloride (0.36m1, 1 .84mmol) and NN-diisopropylethylaniine 
(0.34m1, 1 .9mmol) were added and the reaction stirred overnight at room 
temperature. The reaction was quenched with MeOH (4m1) and the solvent removed 
in vacuo. The 2'-O-trimethylsilyl group was removed by treatment with 4-toluene 
suiphonic acid. The residue was taken up in DCM (lOmi) and stirred vigorously with 
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0.5M 4-toluene suiphonic acid monitoring the reaction by TLC. After lOminutes the 
layers were separated and the organic layer washed with water (lOmi), dried 
(Na2 SO4), filtered and reduced in vacuo. The residue was purified by wet flash 
chromatography (1-5% MeOH/DCM) to give the title compound as a white foam 
(195mg, 49%). m.p. 66-77°C; tic Rf (5% MeOHIDCM) 0.70; C.H.N. Found C: 
59.56%, H: 7.42%, N: 4.79%, C32H47N208 Si2 Requires C: 59.78%, H: 7.21%, N: 
4.36%; SH (200MHz, CDCI3) 0.98-1.10 (mt, 28H, CH(CH3)2), 1.31-1.35 (m, 911, 
C(CH3)3), 3.95-4.30 (m, 511, 2',3',4',5'-H), 5.61 (s, 1H, I'-H), 5.76 (d, 1H, 5-11, J = 
8.211z), 7.25-7.87 (m, 4H, aromatic), 8.07 (d, 111, 6-H, J = 8.211z) ppm; 8C (63MHz, 
CDC13) 12.35-13.29 (isopropyl CHs), 16.72-17.44 (isopropyl C11 3 s), 30.81 (tert-butyl 
C113 s), 35.25 (quaternary C of tert-butyl) 59.36 (C-5'), 68.00 (C-3'), 76.31 (C-2'), 
81.49 (C-4'), 91.19 (C-l'), 101.05 (C-5), 126.17, 128.44, 130.49 (aromatic), 139.25 
(C-6), 148.82 (C-2), 162.31 (C-4), 168.36 (benzoyl C0) ppm; m/z (FAB) 642 (M); 
HRMS (FAB) Found 643.2846 1, C 32H47N208 Si2 Requires 643.28710. 
6-Iodo-hex-4-ynyl benzoate (110). 
Iodine (3.03g, 11.9mmol) was added in one portion to a cooled (0 °C) solution of 
compound (103) (2.0g, 9.2mmol), triphenyiphosphine (0.29g. 1.lmmol), and 
imidazole (0.09g. 1 .3mmol) in anhydrous ether! acetonitrile (3:1) (1 OOml) under an 
atmosphere of nitrogen. Temperature was maintained at 0 °C for 1.5 hours with 
stirring. The reaction mixture was poured into water (1 OOml) and extracted with ether 
(3x50m1). The combined extracts were washed with saturated aqueous Na 2 S203 
(lOOmi) and water (iOOml) and dried (Na2SO4), filtered and reduced in vacuo. The 
residue was purified by wet flash chromatography (DCM) to give the title compound 
as a clear oil (2.94g, 98%). tic R1 (DCM) 0.51; C.H.N. Found C: 47.86%, H: 3.98% 
C 13H13021 Requires C: 47.58%, H: 3.99%; v 2957 (CH, aromatic), 2229 (carbon-
carbon alkyne), 1714 (C=O stretch); 5H (200MHz, CDC13) 1.91-2.02 (m, 211, CH 2), 
2.35-2.43 (m, 2H, alkyne-CH2), 3.66 (t, 211, I-CH 2 , J = 2.4Hz), 4.40 (t, 211, CH2 -
Benzoate, J = 6.2Hz), 7.25-8.06 (m, 5H, aromatic) ppm; öC (63M}Iz, CDCI3) 15.68 
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(alkyne-CH2), 27.57 (CH2), 30.87 (I-CH2), 63.40 (CH2-Benzoate), 75.63 (alkyne). 
85.86 (alkyne), 128.24, 129.43, 130.02, 132.85 (aromatic), 166.35 (C0) ppm; m/z 
(FAB) 328 (M'); HRMS (FAB) Found 327.99 177, C 13H13 021 Requires 327.99603. 
6-Mesyl-hex-4-ynyl benzoate (111). 
Compound (103) (0.20g, 0.92mmol) was dissolved in anhydrous DCM (20m1) to 
which pyridine (1.44g, 0.90nmiol) was added and cooled to 0 °C. Methane 
sulphonylchloride (0.22m1, 2.8mmol) was added dropwise and the reaction stirred for 
2 hours, allowing to warm to room temperature. Water (25m1) and ether (25m1) were 
added and the organic phase extracted (2x25m1). The extracts were dried (MgSO 4)), 
filtered and reduced in vacuo. The residue was purified by wet flash chromatography 
(DCM) to give the title compound as a clear oil (0.26, 94%). tic R1 (DCM) 0.46; vm 
2939 (CH, aromatic), 2307 and 2237 (carbon-carbon alkyne), 1716 (CO stretch), 
1367 and 1174 (-S020-); 8H (200MHz, CDC1 3) 1.97-2.05 (m, 2H, C112), 2.41-2.48 
(m, 2H, alkyne-C112 ), 3.08 (s, 311, S-CH 3), 4.40 (t, 211, C112-benzoate, J = 6.2Hz), 
4.81 (t, 2H, O-CH2 , J = 2.211z), 7.25-8.04 (m t, 511, aromatic) ppm; SC (63MHz, 
CDC13) 15.62 (alkyne-CH 2), 27.28 (CH2), 38.77 (CH3), 58.05 (0-CH2), 63.21 (CH2-
Benzoate), 72.99 (alkyne), 89.20 (alkyne), 128.29, 129.42, 129.92, 132.95 
(aromatic), 166.32 (C=O) ppm; m/z (FAB) 297 (MW); HRMS (FAB) Found 
297.08027, C 14H 1 705 S Requires 297.07967. 
6-Trichloroacetimidate-hex-4-ynyl benzoate (112). 
Dried potassium carbonate (0.30g. 2.2mmol) and trichloroacetonitrile (0.22m1, 
2.2mmol) were added to a solution of compound (103) (0.46g, 2.1mmo!) in 
anhydrous DCM (5m1) under an atmosphere of argon. The mixture was stirred for 5 
hours before being filtered and concentrated in vacuo. The residue was purified by 
wet flash chromatography (DCM) to give the title compound as a clear oil (0.53, 
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70%). tIc R (DCM) 0.62; C.H.N. Found C: 49.94%, H: 3.87%, N: 3.88% 
C15H1 4NO3 C13 Requires C: 49.68%, H: 3.89%, N: 3.86%; v 3338 (N-H), 2955 
(CH, aromatic), 2312 and 2238 (carbon-carbon alkyne), 1718 (CO stretch), 1666 
(C=N); 6H (200MHz, CDC13) 1.97-2.04 (m, 2H, CH2), 2.40-2.48 (m,, 2H, alkyne-
CH2), 4.40 (t, 2H, CH2-Benzoate, J = 6.2Hz), 4.88 (t, 211, CH 2, J = 2.1Hz), 7.25-8.05 
(mt, 5H, aromatic), 8.42 (s, 1H, NH) ppm; 1C (63MHz, CDC1 3) 15.70 (alkyne-CH 2), 
27.45 (CH2), 57.26 (0-CH2), 63.40 (CH2 -Benzoate), 74.16 (alkyne), 86.72 (ailcyne), 
128.26, 129.45, 130.08, 132.85 (aromatic), 161.84 (C=N}f), 166.38 (C=O) ppm; m/z 
(FAB) 363 (M); HRMS (FAB) Found 361.00323, C 15H14N0303 Requires 
361.00393. 
Mixture of 2'-0 and 3'-O-(Hex-4-ynyl benzoate)uridine (115). 
Uridine (1.30g, 5 .3mmol), dibutyltin oxide (1.59g, 6.4mmol) and tetrabutyl 
ammonium bromide (1.88g, 5.8mmol) were suspended in anhydrous DMF (lOmi) 
under an atmosphere of nitrogen. Compound (110) (3.97g, 12.1mmol) was added 
with vigorous stirring and the reaction mixture heated to 60 °C. After 22 hours the 
reaction was filtered, washed with DMF (20m1) and the filtrate reduced in vacuo. The 
residue was purified by wet flash chromatography (1-5% MeOH!DCM) to give the 
title compound as a off white sticky foam (1.92g, 8 1%). tIc Rr (15% MeOHIDCM) 
0.45; m/z (FAB) 446 (M- 4); HRMS (FAB) Found 445.16455, C 22H2508N2 Requires 
445. 16109. 
3',5'-0-(Tetraisopropyldisiloxane- 1,3-diyl)-2 9 -0-(hex-4-ynyl benzoate) uridine 
(116). 
Compound (115) (132mg, 0.30mmol) was dried by coevaporation in anhydrous 
pyridine (2x2m1) then suspended in anhydrous pyridine (1.5m1) and cooled to 0°C 
under an atmosphere of argon. 1 ,3-dichloro- 1,1,3,3 -tetraisopropyldisioxane (0.1 OmI, 
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0.30mmol) was added dropwise over 5 minutes. The reaction was allowed to warm to 
room temperature and stirred overnight. The reaction was quenched with MeOH 
(5m1) and allowed to stir for 5 minutes before being reduced in vacuo. The residue 
was taken up in DCM and washed with 5% NaHCO3 solution (20m1) and extracted 
with DCM (2x50m1). The combined extracts were dried (Na 2 SO4), filtered and 
reduced in vacuo. The residue was purified by wet flash chromatography (0-2% 
MeOH!DCM) to give the title compound as an off white foam (93mg, 46%). tic R 
(5% MeOH/DCM) 0.34; C.H.N. Found C: 59.52%, H: 7.55%, N: 4.56%, 
C34H50N209 Si2 Requires C: 59.45%, H: 7.34%, N: 4.08%; SH (200MHz, CDC13 ) 
0.95-1.08 (m, 28H, CH(CH3 )2), 1.93-2.00 (CH 2), 2.35-2.39 (iii,, 2H, CH2), 3.97-4.53 
(m, 9H, 2xCH2 , 2',3',4',5'-H), 5.66 (d, 1H, 5-H, J = 7.8Hz), 5.74 (d, 1H, 1'-J4), 
7.38-8.04 (m, 6H, 6-H, aromatic), 9.34 (s, 1H, 3-H) ppm; öC (63MHz, CDC13) 
12.06, 12.44, 12.84 (4xCH), 15.34 (CH2), 16.87-17.46 (8xCH 3), 27.66 (CH2), 58.40 
(CH2), 60.11 (C-5'), 63.32 (CH2), 68.90 (C-3'), 73.65 (C-2'), 81.01 (C-4'), 90.64 
(C-l'), 101.07 (C-5), 127.78-132.55 (aromatic), 139.93 (C-6), 150.24 (C-2), 163.33 
(C-4) ppm; mlz (FAB) 687 (MW); HRMS (FAB) Found, C34H50N2O9 Si2 Requires 
686.30549. 
2'-O-(Hex-4-ynyl benzoate) uridine (117). 
Compound (116) (62mg, 0.09mmol) was dissolved in THF (4m1). Potassium fluoride 
dihydrate (5 1mg, 0.54mmol) and a catalytic amount of 18-crown-6-ether were added 
and the reaction allowed to stir at room temperature for 5 hours. The reaction was 
filtered, washed and reduced in vacuo. The residue was purified by wet flash 
chromatography (1-5% MeOH in DCM) to give the title compound as an off white 
foam (27mg, 67%). tic R1 (10% MeOHJDCM) 0.32; C.H.N. Found C: 59.10%, H: 
5.60%, N: 4.07%, C 22H24N208 Requires C: 59.45%, H: 5.44%, N: 6.30%; 8H 
(200MHz, CDCI3) 1.88-2.01 (m, 2H, CH2 ), 2.34-2.41 (m, 211, CH 2 ), 3.78-4.41 (m, 
9H, 2xCH 2, 2',3',4',5'-H), 5.70 (d, 1H, 5-H, J = 8.014z), 5.82 (d, 111, 1'-H, J = 
MHz), 7.25-8.04 (m, 6H, H-6, aromatic) ppm; 8C (63MHz, CDC1 3) 15.46 (CH2 ), 
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27.28 (CH2), 58.72 (Cl2), 61.46 (C-5'), 63.45 (CH2), 69.12 (C-3'), 75.92 (alkyne), 
80.18 (C-2'), 85.13 (C-4'), 86.82 (alkyne), 89.26 (C-l'), 102.32 (C-5), 128.32-
133.03 (aromatic), 141.44 (C-6), 150.27 (C-2), 163.35 (C-4), 166.75 (benzoate 
C=O) ppm; mlz (FAB) 445 (MIFf); HRMS (FAB) Found 445.16078, C22H25N208 
Requires 445.16 109. 
2'-0 and 3'-O-(Hex-4-ynyl benzoate)-5'-O-(dimethoxytrityl) uridine (119 and 
118). 
Compound (115) (0.60g. 1 .3Smmol) was coevaporated with anhydrous pyridine 
(2x5m1) then dissolved in anhydrous pyridine (2m1) and cooled in an ice bath to 0 °C 
under an atmosphere of argon. 4,4'-Dimethoxytrityl chloride (0.50g, 1 .48mmol) was 
added over a 1 hour period portionwise. The reaction was allowed to warm to room 
temperature and left to stir overnight. MeOH (5m1) was added and the solvent 
removed in vacuo. The residue was taken up in DCM (30ml) and washed with 5% 
NaHCO3 solution, dried (Na2 SO4), filtered and reduced in vacuo to give a foam. The 
residue was purified by wet flash chromatography (1-5% MeOH in DCM containing 
1% pyridine, v/v/v) to give the title compounds as a white foam. 
3'-O-(Hex-4-ynyl benzoate)-5'-O-(dimethoxytrityl) uridine (118). 
(0.18g. 18%). tIc R(10% MeOH/DCM) 0.38; C.H.N. Found C: 69.10%, H: 5.60%, 
N: 4.07%, C431L2N2010 Requires C: 69.16%, H: 5.67%, N: 3.75%; oH (200MIHz, 
CDC13 ) 1.84-1.97 (m, 2H, Cl2), 2.24-2.38 (m., 211, CH2), 3.41-3.52 (m, 21, 5 1 -H) 
3.78 (s, 6H, OMe), 4.01-4.48 (m, 7H, 2xCH2 , 2',3',4'-H), 5.27 (d, 1H, 5-11, J = 
8.1Hz), 5.93 (d, 1H, 1'-H, J = 1.8Hz), 6.81-8.04 (m, 19H, H-6, aromatic) ppm; OC 
(63MHz, CDC13) 15.41 (CH2), 27.29 (CH2), 55.05 (OMe), 58.38 (CH2), 61.41 (C-
5'), 63.32 (CH2), 73.31 (C-2'), 75.79 (C-3'), 82.96 (C-4'), 86.43 (CAr 3 ), 89.77 (C-
1'), 102.33 (C-5), 113.09-136.38 (aromatic), 139.96 (C-6), 150.51 (C-2), 162.30 (C- 
82 
Experimental 
4), 166.60 (benzoate C=O) ppm; m/z (FAB) 746 (M); HRMS (FAB) Found 
746.28431, C431142N20 10 Requires 746.28395. 
2'-O-(Hex-4-ynyl benzoate)-5'-O-(dimethoxytrityl) uridine (119). 
(0.53g, 53%).tic Rf (10% MeOFUDCM) 0.58; C.N.N. Found C: 69.10%, H: 5.60%, 
N: 4.07%, C43H42N2010 Requires C: 69.16%, H: 5.67%, N: 3.75%; oH (200MIHz, 
CDC13) 1.93-2.02 (m,, 2H, CH 2), 2.36-2.40 (m 2H, C112), 3.53 (d, 211, 5'-H), 3.78 (s, 
6H, OMe), 3.80-4.40 (m, 7H, 2xCH2 , 2',3',4'), 5.70 (d, iN, 5-11, J = MHz), 5.80 (d, 
1H, 1'-H, J = 4.0Hz), 6.78-8.06 (m, 19H, H-6, aromatic) ppm; SC (63MHz, CDC13) 
15.45 (CH2), 27.22 (CH2), 55.13 (OMe), 58.72 (CH2), 61.64 (C-5'), 63.42 (CH2), 
69.28 (C-3'), 80.07 (C-2'), 85.24 (C-4'), 86.86 (CAr3), 89.36 (C-l'), 102.39 (C-5), 
113.44-136.25 (aromatic), 140.18 (C-6), 150.08 (C-2), 162.75 (C-4), 166.77 
(benzoate C=O) ppm; mlz (FAB) 746 (M); HRMS (FAB) Found 746.28431, 
C43 17 42N2010 Requires 746.28395. 
5 1 -0-(Dimethoxytrityl)-2'-O-(hex-4-ynyt benzoate)-u ridine-3'-O-(2-cyanoethyl 
N,N-diisopropylphosphoramidite) (120). 
Compound (119) (0.50g, 0.67mmol) was coevaporated in anhydrous CH 3CN (3x5m1) 
and dissolved in anhydrous DCM (2.5m1) under an atmosphere of argon. N,N-
Diisopropylethylamine (0.28m1, 1 .27mmol) was added dropwise followed by 2-
cyanoethoxy N,N-diisopropylaminochlorophosphine (0.35m1, 1 .6Smmol) with 
vigorous stirring and left overnight. MeOH (imi) then EtOAc (iOml) were added and 
then washed with saturated aqueous NaHCO 3 and saturated NaC1 solutions. The 
organic layer was extracted, dried (Na2SO4), filtered and reduced in vacuo. The 
residue was purified by wet flash chromatography (0-2% MeOHIDCM containing 1% 
pyridine) and then taken up in 1 ml of dry toluene and precipitated in petroleum ether 
under vigorous stirring (1 50m1, cooled to -65°C) to give the title compound as a white 
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foam (0.46g. 72%). tic R (5% MeOHIDCM) 0.61; 5H (200MBz, CDC1 3) 0.98-1.28 
(mt, 12H, CH3), 1.93-1.96 (mt, 2H, C112), 2.31-2.42 (m.. 211, C11 2), 2.60-2.67 (ni. 2H, 
CH2 CN), 3.38-3.68 (m, 6H, OCH2 , CH, 5'-H), 3.77 (s, 6H, OMe), 3.80-4.42 (in. 
711, 2xCH2, 2',3',4'), 5.25 (d, 1H, 5-11, J = MHz), 5.98 (d, 1H, 1'-H, J = 2.9Hz), 
6.79-8.03 (m, 19H, H-6, aromatic) ppm; öC (63MHz, CDC13) 15.57 (CH2), 20.12 
(CH2CN), 24.26-24.49 (4xMe), 27.22 (CH 2), 42.66-43.24 (2xCH), 55.13 (OMe), 
58.72 (CH2), 61.64 (C-5'), 63.42 (CH2), 69.28 (C-3'), 80.07 (C-2'), 85.24 (C-4'), 
86.82 (CAr3), 87.32 (C-l'), 101.79 (C-5), 113.04-135.08 (aromatic), 117.50 (CN), 
139.93 (C-6), 149.82 (C-2), 162.65 (C-4), 166.31 (benzoate C=O) ppm; 8P (63MHz, 
CDC13) 151.15, 151.27; m/z (FAB) 948 (NH'); HRMS (FAB) Found 947.39716, 
C52H59N40 1 1 P Requires 946.39180. 
5'-O-Dimethoxytrityl-uridine (121). 23 
Uridine (1.00g, 4. immol) was suspended in anhydrous pyridine under an atmosphere 
of argon. AgNO3 (0.76g, 4.5mmol) and 4,4'-Dimethoxytrityl chloride (1.45g, 
4.5mmol) were added. Afler 1.5 hours the reaction mixture was filtered and washed 
with DCM (20m1). The filtrate was washed with 5% NaHCO3 sol. and extracted with 
DCM (2x50m1). The extracts were dried (Na 2 SO4), filtered and reduced in vacuo. 
The residue was purified by wet flash chromatography (1-5% MeOH in DCM 
containing 1% pyridine, v/v/v) to give the title compound as a white foam (1.15g, 
51%). tic Rf (10% MeOHIDCM) 0.25; C.H.N. Found C: 65.68%, H: 6.04%, N: 
5.55%, C oH oN08 Requires C: 65.92%, H: 5.53%, N: 5.13%; 8H (200MHz, 
CDC13 ) 3.48-3.49 (s, 2H, 5'-H), 3.75 (s, 611, OMe), 4.16-4.46 (m, 3H, 2',3',4'-H), 
5.32 (d, III, 5-H, J = 8.1Hz), 5.93 (d, IH, 1'-H, J = 2.7Hz), 6.78-7.71 (m t, 13H, 
aromatic), 7.99 (d, 1H, 6-H, J = 8.1Hz) ppm; 5C (63MIHz, CDC1 3) 55.06 (OMe), 
61.75 (C-5'), 69.46 (C-3'), 75.19 (C-2'), 83.48 (C-4'), 86.79 (CAr 3), 90.12 (C-l'), 
102.07 (C-5), 113.09-136.05 (aromatic), 144.20 (C-6), 150.95 (C-2), 163.73 (C-4) 
ppm m/z (FAB) 546 (M); HRMS (FAB) Found 546.19995, C 30H30N208 Requires 
546.20022. 
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5'-O-Dimethoxytrityi-13 9 ,2',N3-tri(benzoyl)]_urjdine (122). '0'  
Compound (121) (77mg, 0.14mmol) was dissolved in anhydrous pyridine (0.5m1) and 
cooled to 0°C under an atmosphere of nitrogen. Benzoyl chloride (0.066m1, 
0.56mmol) was added to and the reaction stirred overnight at room temperature. 
MeOH (2m1) and water (20m1) were added and then extracted with DCM (2x20m1). 
The combined extracts were dried (Na2 SO4), filtered and reduced in vacuo. The 
residue was purified by wet flash chromatography (DCM containing 1% pyridine, 
v/v/v) to give the title compound as a white foam (62mg, 51%). tic Rf (DCM) 0.22; 
C.H.N. Found C: 70.95%, H: 5.07%, N: 2.77%, C 51 H42N20 11 Requires C: 71.32%, 
H: 4.93%, N: 3.26%; 6H (200MHz, CDC13) 3.53-3.68 (m, 4H, 3', 4', 5'-H), 3.78 (s, 
6H, OMe), 4.47 (d, 111, 2'-H, J = 2.411z), 5.37 (d, 1H, 5-H, J = 8.2Hz), 5.92 (d, 1H, 
1 '-H, J = 2.8Hz), 6.83-7.98 (m, 29H, aromatic, 6-H) ppm; 8C (63MHz, CDC1 3 ) 
55.14 (OMe), 62.33 (C-5'), 72.03 (C-3'), 73.57 (C-2'), 82.47 (C-4'), 85.75 (CAr3), 
87.56 (C-l'), 102.97 (C-5), 113.31-139.79 (aromatic), 143.80 (C-6), 150.09 (C-2), 
162.33 (C-4), 165.07, 165.31, 168.10 (C=O) ppm; m/z (FAB) (M4); HRMS (FAB) 
Found 858.27873, C 51 1-142N20 11 Requires 858.27886. 
39,29,N 3  -tri(benzoyl)-u rid ine (123). 105 
Compound (122) (40mg, 0.47mmol) was dissolved in DCM (2m1). Trifiuoroacetic 
acid (23jxL) was added and the reaction stirred for 30 minutes at room temperature. 
This was diluted with DCM (20m1) and washed with saturated NaHCO 3 (20m1) and 
water (20mJ). The organic layer was separated, dried (Na 2 SO4), filtered and reduced 
in vacuo. The residue was purified by wet flash chromatography (1% MeOH/DCM) 
to give the title compound as a white foam (25mg, 96%). m.p. 102-5°C; tic Rf (10% 
MeOHIDCIvI) 0.59; oH (200MHz, DMSO) 3.77 (s, 2H, 5'-H), 4.46 (d, 1H, 2'-H, J = 
2.6Hz), 5.53 (s, br, 1H), 5.69-5.80 (m,, 3H), 5.37 (d, 1H, 5-H, J = 8.2Hz), 5.92 (d, 
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111, 1'-H, J = MHz), 7.37-8.01 (m, 16H, aromatic, 6-H) ppm; SC (63MHz, CDC1 3 ) 
61.03 (C-5'), 72.19 (C-3'), 73.64 (C-2'), 83.33 (C-4'), 86.23 (C-l'), 102.75 (C-5). 
128.46-134.02 (aromatic), 150.70 (C-2), 163.16 (C-4), 158.68, 164.63, 164.95. 
167.25 (C=O) ppm; m/z (FAB) 557 (MW); HRMS (FAB) Found 557.15555, 
C30H25N209 Requires 557.15600. 
Fully Protected Diribonucleotide Derivative (124) 
A mixture of compound (123) (25mg, 0.045mmol) and 1H-tetrazole (10mg, 
0.21 3mmoi) was rendered anhydrous by coevaporations three times each with 
anhydrous toluene and anhydrous pyridine and with anhydrous acetonitrile. The 
mixture was then taken up in acetonitrile and mixed with (120) (63mg, 0.067mmol) 
under an atmosphere of argon. After stirring at room temperature for 2.5 hours, the 
mixture was treated with a solution of iodine (55mg, 0.21mmol) in pyridine-water 
(imi, 98:2, v/v). The resulting mixture was stirred at room temperature for 40 
minutes, and the asturated Na 2 S03 was added to reduce the excess iodine. The 
mixture was diluted with DCM and washed two times with saturated NaHCO 3 and 
water. The organic phase was separated, dried (Na 2 SO4), filtered and reduced in 
vacuo. The residue was purified by wet flash chromatography (DCM containing 1% 
pyridine, v/v/v) to give the title compound as a foam (42mg, 66%). tIc R (DCM) 
0.25; SH (200MHz, CDC13) 1.87-1.96 (m, 211, CH 2 ), 2.32-2.36 (m, 211, CR2). 2.75-
2.85 (m., 214, CH2 CN), 3.78 (s, 611, OMe), 3.90 (m, 211, CR2), 4.30-4.58 (mt, 12H, 2', 
3', 4', 5'-H, CH2), 5.16 (m, 111), 5.64-6.02 (m, 3H), 6.83-7.98 (m, 35H, aromatic. 6-
H) ppm; 8C (63MiHz, CDCI 3) 15.43 (CR2), 27.20, (CR2), 55.11 (OMe), 58.65 (CH,), 
62.69, 62.84 (C-5'), 63.58 (CH2), 70.72, 72.42 (C-3'), 73.38 (C-2'), 81.27 (C-2'), 
84.07 (C-4'), 87.08, 87.62 (C-l'), 102.56, 102.66 (C-5), 113.01-139.79 (aromatic), 
149.33, 150.33 (C-2), 158.71, 158.46, 162.93 (C-4), 165.27, 165.41, 166.84 168.26 
(C0) ppm; m/z (FAB) 1418 (M'); HRMS (FAB) Found 1418.42279, C 76H69N5021 P 
Requires 1418.42242. 
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3'-O-(Hex-4-ynyl benzoate)-2 '-O-(succinate)-5'-O-(dimethoxytrityl) uridine 
(125). 
Compound (118) (0.30g. 0.40mmol) was coevaporated in anhydrous pyridine (2x2m1) 
and then dissolved up in anhydrous pyridine (2m1) under an atmosphere of argon. 
Succinic anhydride (0.12g, 1.21 mmol) and dimethylaminopyridine (25mg, 0.2mmol) 
were added. After 3 days the pyridine was removed in vacuo and the residue 
coevaporated with toluene (3x5m1). The residue was taken up in DCM and washed 
with saturated brine, dried (Na 2 SO4), filtered and reduced in vacuo to give the title 
compound as a light brown foam (0.3 ig, 91%).; tic Rf (10% MeOHJDCM) 0.35; oH 
(200MIHz, CDC13) 1.84-1.90 (m, 2H, CH2), 2.26-2.35 (m,, 211, Cl2), 2.71 (br, 4H, 
CH2CH2), 3.51 (m, 211, 5'-H) 3.77 (s, 6H, We), 4.18-4.56 (m, 711, 2xCH2, 2',3',4'-
H), 5.32 (d, 111, 5-11, J = 8.811z), 6.06 (11-1, 1'-H), 6.81-7.98 (m,, 19H, H-6, aromatic) 
ppm; OC (63M1{z, CDC1 3) 15.62 (CH2), 27.50 (CH2), 28.91 (CH2), 55.08 (OMe), 
58.65 (CH2), 61.21 (C-5'), 63.44 (CH2), 73.91, 74.01 (C-2', C-3'), 81.68 (C-4'), 
86.58 (CAr3), 87.37 (C-l'), 102.39 (C-5), 113.01-136.75 (aromatic), 139.95 (C-6), 
150.36 (C-2), 163.68 (C-4), 166.36 (benzoate C=O), 170.95, 175.22 (C=O) ppm; 
m/z (FAB) 846 (M'); HRMS (FAB) Found 846.29678, C471146N2013 Requires 
846.29999. 
Derivatization of Long Chain Aminoalkyl Silica. 
A mixture of compound (125) (0.10g, 0.12mmol), 50mg of long chain aminoalkyl 
silica (500A °  pore size, 1 lOt particle size), DHC (0.10g. 0.49mmol), DMAP (7mg, 
0.06mmol) were mixed thoroughly in anhydrous pyridine (4m1) and triethylamine 
(0.1 ml). After stirring overnight under an atmosphere of argon, a small sample of the 
support was washed with MeOH followed by DCM and then dried. The dried support 
(1.9mg) was treated with perchloric acid solution (4ml) (70% HC10 4 , 51 .4mJ + 
MeOH 46m1) and the absorbance measured at 498nm. The loading was calculated to 
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be 26tmoI g'. The bulk support was washed with pyridine and the residual amino 
groups capped by treatment with pyridine (5m1), acetic anhydride (0.5m1) and DMAP 
(50mg) for 30 minutes. The support was then washed with MeOH, DCM and ether 
before being dried and the final loading determined. Final loading, 1 6.tmol g' 
2'-O-(Hex-4-ynyl benzoate) uridine (127). 
Compound (119) (67mg, 0.90mmol) was dissolved in DCM (5m1) to which 
trifluoroacetic acid (45p1, 0.045m1) was added. After stirring at room temperature for 
20 minutes the reaction was diluted with DCM (25m1) and washed with saturated 
aqueous NaHCO 3 then water. The extracts were dried (Na 2 SO4), filtered and reduced 
in vacuo to give a foam. The residue was purified by wet flash chromatography (1-5% 
MeOH in DCM) to give the title compound as a white foam (39mg, 98%). Analysis 
by HPLC (Vydac reverse phase C 18 , 250 x 2.6mm, 5j.i, A = CH3 CN, B = H20,0-1% 
TFA; imi/min. 0-2mm. 0%A, 2-32mm. 0-90%; R 20.1 minutes; tic Rf (10% 
MeOHJDCM) 0.32; C.H.N. Found C: 59.10%, H: 5.60%, N: 4.07%, C 22H24N208 
Requires C: 59.45%, H: 5.44%, N: 4.30%; 6H (200411z, CDC1 3) 1.88-2.01 (m, 2H, 
CH2), 2.34-2.41 (m, 211, C11 2), 3.78-4.41 (m, 9H, 2xCH2 , 2',3',4',5'-H), 5.70 (d, 
1H, 5-H, J = 8.0Hz), 5.82 (d, 1H, 1 '-H, J = MHz), 7.25-8.04 (m, 6H, H-6, aromatic) 
ppm; SC (63MHz, CDC1 3 ) 15.46 (CH2), 27.28 (CH2), 58.72 (CH2), 61.46 (C-5'), 
63.45 (CH2), 69.12 (C-3'), 75.92 (alkyne), 80.18 (C-2'), 85.13 (C-4'), 86.82 
(alkyne), 89.26 (C-l'), 102.32 (C-5), 128.32-133.03 (aromatic), 141.44 (C-6), 
150.27 (C-2), 163.35 (C-4), 166.75 (benzoate C=O) ppm; m/z (FAB) 444 (M'); 
HRMS (FAB) Found 445.16012, C 22H25N208 Requires 445.15876. 
2'-O-(Hex-4-yn-1-oI)u rid ine (128). 
Compound (127) (115mg, 0.26mmol) was suspended in ammonia/ethanol (3 : 1) 
solution (24m1) and sealed in a vial. After 95 hours no starting material remained. The 
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reaction mixture was cooled to -20 °C and the solvent removed in vacuo. The residue 
was washed with DCM to give the title compound as a solid. Analysis by HPLC 
(Vydac reverse phase C18, 250 x 2.6mm, 5.t, A = CH3CN, B = H20, 0.1% TFA; 
imi/min. 0-2mm. 0%A, 2-32mm. 0-90%; R = 12.7 minutes; tic R (15% 
MeOHIDCIvI) 0.26; SH (200MHz, DMSO) 1.49-1.70 (m, 2H, CH 2), 2.18-2.24 (m, 
2H, CH2), 3.39-3.44 (m, 2H, CH2 , 5'-H), 3.53-3.66 (m, 2H, CH2), 3.86-4.31 (m, 511, 
2',3',4'-FI, C112), 5.67 (d, 1H, 5-H, J = 8.1Hz), 5.88 (d, 1H, 1'-H, J = 5.3Hz), 8.04 
(d, 111, H-6, J = 8.1Hz) ppm; öC (63IvIIHz, DMSO) 14.79 (CH2), 31.47 (CH2), 57.43 
(CH2), 59.45 (CH), 60.76 (C-5'), 68.49 (C-3'), 76.15 (alkyne), 79.64 (C-2'), 85.61 
(C-4'), 85.87 (C-l'), 87.09 (alkyne), 102.01 (C-5), 140.61 (C-6), 150.71 (C-2), 
163.23 (C-4) ppm; m/z (FAB) 341 (MW); HRMS (FAB) Found 341.13528, 
C15F12 1 N207  Requires 341.13488. 
6-(Tetrahydropyranyloxy)-hex-4-ynyi thiobenzoate (131) 
Compound (101) (11.40g, 52.6mmol) and dried sodium tbiobenzoate (11.13g, 
70mmol) in DMF were heated at reflux for 16 hours under an atmosphere of argon. 
The reaction was cooled, filtered and the solvent removed in vacuo. The residue was 
dissolved in DCM, filtered and then reduced in vacuo before being passed through a 
silica plug (DCM:Hexane, 2:1) to give the title compound as an oil (11.90g, 7 1%). tic 
Rf (5% MeOHIDCM) 0.76; v.. - 2941 (CH, aromatic), 2221 (carbon-carbon alkyne), 
1664 (C=O stretch); m/z (FAB) 319 (MW); HRMS (FAB) Found 319.13668, 
C18H2303 S Requires 319.13679. 
6-Hydroxy-hex-4-ynyl thiobenzoate (132). 
Compound (131) (11.90g, 37.4mmol) was dissolved in MeOH (500mi) to which 10% 
oxalic acid (21 Omi) was added. This was allowed to stir at room temperature for 24 
hours before the MeOH was removed in vacuo. Water (200mi) and EtOAc (lOOmi) 
89 
were added and the organic layer separated with EtOAc (2xlOOml). The combined 
extracts were dried (MgSO 4), filtered and reduced in vacuo. The residue was purified 
by wet flash chromatography (DCM) to give the title compound as a clear oil (4.35g, 
50%). tic Rf (5% MeOHJDCJvJ) 0.54; v 3408 (OH), 2929 (CH, aromatic), 2224 
(carbon-carbon alkyne), 1661 (C=O stretch); 6H (200MHz, CDC1 3 ) 1.81-1.92 (m, 
214, CH2), 2.05 (br, 1H, OH), 2.32-2.39 (mt, 211, allcyne-CH2), 3.16 (t, 2H, CH2 -S, J = 
7.2Hz), 4.24 (t, 211, CH2 -OH, J = 2.2Hz), 7.25-7.97 (m, 511, aromatic) ppm; 8C 
(63MHz, CDC13 ) 17.79 (alkyne-CH2), 27.70 (CH2), 28.27 (C112), 51.06 (HO-CH 2), 
79.36 (alkyne), 84.64 (alkyne), 127.03, 128.44, 133.24, 135.64 (aromatic), 191.81 
(C=O) ppm; m/z (FAB) 235 (MH'); HRMS (FAB) Found 234.07097, C 13 H 1402 S 
Requires 234.07302. 
6-Iodo-hex-4-ynyl thiobenzoate (133) 
Iodine (0.65g, 2.56mmol) was added in one portion to a cooled (0 °C) solution of 
compound (132) (0.46g, 1.97mmol), triphenyiphosphine (0.62g, 2.37mmol), and 
imidazole (0.19g, 2.76minol) in anhydrous ether/acetonitrile (3:1) (80m1). 
Temperature was maintained at 0 °C for 2 hours with stirring. The reaction mixture 
was poured into water (60m1) and extracted with ether (3x50m1). The combined 
extracts were washed with saturated aqueous Na 2 S 2 O3 (1 OOml) and water (1 OOml) 
and dried (Na2 SO4), filtered and reduced in vacuo. The residue was purified by wet 
flash chromatography (DCM) to give the title compound as an oil (0.51 g, 76%). tic 
R (DCM) 0.59; v,. 2939 (CH, aromatic), 2225 (carbon-carbon alkyne), 1661 (C=O 
stretch); 8H (200MHz, CDCI 3 ) 1.85-1.93 (m, 2H, C112 ), 2.31-2.39 (in. 2H, alkyne-
C112), 3.15 (t, 2H, CH2-thiobenzoate, J = 7.1Hz), 3.66 (t, 2H, I-CH 2 , J = 2.411z), 
7.25-7.98 (m, 5H, aromatic) ppm; SC (63MHz, CDC1 3) - 17.38 (CH2), 18.23 (alkyne-
CH2), 27.80 (CH2), 28.14 (CH2), 77.93 (alkyne), 84.92 (alkyne), 127.08, 128.47, 
133.24, 136.91 (aromatic), 191.56 (C=O) ppm; m/z (FAB) 345 (M1I-V); HRMS 
(FAB) Found 344.98232, C 13H 14OS1 Requires 344.98 101. 
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Mixture of 2 1 -0 and 3'-O-(Hex-4-ynyl thiobenzoate) uridine (134). 
Compound (133) (2.95g, 8.57mmol) was added with vigorous stirring to a suspension 
of uridine (1.50g. 6.12mmol), dibutyltin oxide (1.83g. 7.35mmol) and tetrabutyl 
ammonium bromide (2.16g, 6.70mmoI) in anhydrous DMF (lOmi) under an 
atmosphere of nitrogen at 60 °C. After 20 hours the reaction was filtered, washed with 
DMF (30m1) and the filtrate reduced in vacuo. The residue was purified by wet flash 
chromatography (1-5% MeOH!DCM) to give the title compound as a sticky foam 
(2.07g, 74%). tic R (10% MeOHJDCM) 0.28; m/z (FAB) 461 (MW); HRMS 
(FAB) Found 46 1.13672, C 22H2407N2 S Requires 461.13825. 
2 1 -0 and 3'-0-(Hex-4-ynyl th iobenzoate)-5'-O-(dimethoxytrityl) uridine (136 
and 135). 
Compound (134) (1.91g, 4.16mmol) was coevaporated with anhydrous pyridine 
(2x5m1) then dissolved in anhydrous pyridine (3m1) and cooled to 0 °C under an 
atmosphere of argon. 4,4'-Dimethoxytrityl chloride (1.69g, 4.99mo1) was added over 
a 1 hour period portionwise. The reaction was allowed to warm to room temperature 
and left to stir overnight. MeOH (2m1) was added and the solvent removed in vacuo. 
The residue was taken up in DCM (40m1) and washed with 5% NaHCO3 solution, 
dried (Na2 SO4), filtered and reduced in vacuo to give a foam. The residue was 
purified by wet flash chromatography (1-5% MeOH in DCM containing 1% pyridine, 
v/v/v) to give the title compounds as foams. 
3'-0-(Hex-4-ynyl thiobenzoate)-5'-O-(dimethoxytrityl) u ridine (135) 
(0.62g. 20%). tic R (10% MeOHJ'DCM) 0.44; C.H.N. Found C: 67.05%, H: 5.67%, 
N: 3.89%, C431142N209 S Requires C: 67.70%, H: 5.55%, N: 3.67%; 8H (200MHz, 
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CDCI3) 1.73-1.84 (m, 2H, CH 2), 2.23-2.29 (m. 2H, CH2), 3.07 (t, 2H, CH2 ). 3.43-
3.54 (m, 2H, 5'-H) 3.76 (s, 6H, OMe), 3.99-4.46 (m, 5H, CH2 , 2',3',4'-H), 5.34-5.38 
(d, 1H, 5-H, J = 8.1Hz), 5.93 (d, 1H, i'-H, J = 2.1Hz), 6.81-7.92 (ni 19H. H-6, 
aromatic), 9.80 (br, 1H, N-3) ppm; öC (63M1-Iz, CDC1 3) 17.80 (CH2), 27.66 (CH 2 ), 
28.14 (CH2), 55.05 (OMe), 58.20 (CH2), 61.62 (C-5'), 73.64 (C-2'), 75.30 (C-3'), 
81.26 (C-4'), 86.79 (CAr 3), 89.94 (C-l'), 102.22 (C-5), 113.12-136.74 (aromatic), 
139.97 (C-6), 150.57 (C-2), 163.30 (C-4), 191.40 (thiobenzoate C=O) ppm; m/z 
(FAB) 762 (M); HRMS (FAB) Found 746.25758, C4314 42N209 S Requires 
762.26011. 
2' -O-(Hex-4-ynyl thiobenzoate)-5'-O-(dimethoxytrityl) u ridine (136) 
(0.96g, 30%). tIc Rf (10% MeOHIDCM) 0.59; C.H.N. Found C: 67.54%, H: 5.64%, 
N: 4.19%, C431L2N209S Requires C: 67.70%, H: 5.55%, N: 3.67%; 6H (200MIHz, 
CDC13 ) 1.83-1.91 (m, 2H, CH2), 2.31-2.37 (m, 2H, CH 2), 3.15 (t, 2H, CH2), 3.52-
3.53 (m, 2H, 5'-H), 3.77 (s, 6H, OMe), 4.03-4.07 and 4.19-4.22 (m, 2H, 3',4'-H), 
4.39-4.55 (m, 3H, CH2, 2'-H), 5.33 (d, 1H, 5-H, J = 8.1Hz), 5.96 (d, 111, 1'-H, J 
2.1Hz), 6.79-8.00 (m., 19H, H-6, aromatic), 9.31 (br, 1H, N-3) ppm; IC (63MHz, 
CDC13) 17.87 (CH2), 27.66 (CH2), 28.19 (CH2), 55.10 (OMe), 58.69 (CH 2), 61.32 
(C-5'), 68.47 (C-3'), 76.01 (alkyne), 81.08 (C-2'), 83.21 (C-4'), 86.64 and 86.86 
(CAr3 , alkyne), 87.27 (C-P), 101.94 (C-5), 113.15-136.82 (aromatic), 139.90 (C-6), 
149.99 (C-2), 163.16 (C-4), 191.66 (thiobenzoate C=O) ppm; mlz (FAB) 762 (M); 
HRMS (FAB) Found 762.26427, C 43H42N209 S Requires 762.264011. 
2'-O-(Hex-4-ynyl thiobenzoate) u ridine (137). 
Compound (136) (150mg, 0.20mmol) was dissolved in DCM (lOmi) to which 
triflouroacetic acid (1 40i1, 0.1 4m1) was added. After stirring at room temperature for 
30 minutes the reaction was diluted with DCM (25m1) and washed with saturated 
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aqueous NaHCO 3 then water. The extracts were dried (Na 2 SO4), filtered and reduced 
in vacuo. The residue was purified by wet flash chromatography (1-5% MeOH in 
DCM) to give the title compound as a foam (69mg, 76%). Analysis by HPLC (Vydac 
reverse phase C18, 250 x 2.6mm, 5ji, A = CH3 CN, B = H20, 0.1% TFA; imI/min. 0-
2mm. 0%A, 2-32mm. 0-90%; R = 22.4 minutes; tic R1 (10% MeOHJDCM) 0.24; 8H 
(200MHz, CDC13) 1.79-1.90 (m, 2H, CH2), 2.29-2.36 (m, 211, CH 2), 3.10-3.16 (m, 
2H, CH2 ), 3.78-4.09 (m., 3H, 2',3',4'-H), 4.27-4.46 (m, 4H, CH 2 , 5'-H), 5.71 (d, 1H, 
5-H, J = 8.1Hz), 5.81 (d, 1H, l'-H, J = 3.6Hz), 7.25-7.95 (m, 6H, H-6, aromatic), 
9.51 (br, 1H, N-3) ppm; SC (63MIHz, CDC1 3) 17.88 (CH2), 27.75 (CH 2), 28.07 
(CH2), 58.80 (CH2), 61.39 (C-5'), 68.99 (C-3'), 76.03 (alkyne), 80.21 (C-2'), 85.08 
(C-4'), 86.91 (alkyne), 89.38 (C-l'), 102.30 (C-5), 127.08-136.76 (aromatic), 141.50 
(C-6), 150.29 (C-2), 163.42 (C-4), 192.17 (tbiobenzoate C0) ppm; m/z (FAB) 461 
(Miff); FIRMS (FAB) Found 461.13972, C22H2 5N207S Requires 461.13825. 
2'-O-(Hex-4-yn-1-thiol) uridine (138). 
Compound (137) (24mg, 0.052mmol) was suspended in ammonia/ethanol (3 : 1) 
solution (1 8m1) and sealed in a vial. Adler 72 hours no starting material remained. The 
reaction mixture was cooled to -20 °C and the solvent removed in vacuo. The residue 
was washed with DCM to give the title compound as a solid. Analysis by HPLC 
(Vydac reverse phase C 1 8, 250 x 2.6mm, 5p., A = CH3CN, B = H20, 0.1% TFA; 
imi/min. 0-2mm. 0%A, 2-32mm. 0-90%; R = 18.0 minutes; tic R1 (15% 
MeOI-I/DCM) 0.37; oH (200MHz, CDC13) 1.95-2.05 (m, 2H, CH2), 2.56-2.60 (m, 
211, C112), 3.02-3.07 (m, 2H, CH2 ), 3.78-3.84 (m, 2H, CH2), 3.94- 4.34 (m, 611, 
2',3',4', 5'-H), 5.53 (d, 1H, 5-H, J = 8.3Hz), 5.71 (d, 1H, 1'-H, J = 4.2Hz), 7.59-
7.63 (m, 1H, H-6, J = 8.211z), 8.53 (br, 111, N-3)ppm; OC (63MHz, CDC13) 29.10 
(CH2), 34.21 (CH2), 37.52 (CH2 ), 61.69 (C-5'), 69.16 (C-3'), 69.58 (CH2), 77.10 
(aIkyne), 79.68 (C-2'), 85.12 (C-4'), 90.83 (C-I'), 102.34 (C-5), 141.87 (C-6), 
150.12 (C-2), 162.68 (C-4); m/z (FAB) 357 (MW); HRMS (FAB) Found 
357.11280, C15H2 1 N206 S Requires 357.11065. 
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6-(Tetrahydropyranyloxy)-hex-4-yne cyanide (147). 
NaCN (0.47g. 9.6mmol) was added to a suspension of 101 (1.04g, 4.8mmol) taken in 
DMSO (15m1) and the reaction stirred for 3.5 hours at 55°C under an atmosphere of 
nitrogen. Water (40m1) was added and the extracted with ether (200m1). The 
combined extracts were dried (Na2 SO4), filtered and reduced in vacuo. The residue 
was purified by wet flash chromatography (DCM) to give the title compound as a 
clear oil (0.95g. 96%). tic R1 (5% MeOHIDCM) 0.73; v,. 2942 (CH), 2245 (CN); 
SH (200MHz, CDC13) 1.51-1.89 (m, 8H, CH2), 2.37-2.52 (n 411, CH 2), 3.45-3.57 
and 3.76-3.89 (m, 2H, CH 2-0), 4.12-4.34 (m, 2H, O-CH2-alkyne), 4.78-4.80 (m. 1H, 
CH) ppm; SC (63MHz, CDC13) 15.47 (alkyne-CH2), 18.38 (CH2), 23.77 (CH2), 24.63 
(CH2), 29.57 (CH2), 31.01 (CH2), 53.78 (0-CH2-alkyne), 61.39 (CH 2-0), 77.34 
(alkyne), 82.82 (alkyne), 96.45 (CH), 118.54 (CN) ppm; mlz (FAB) 208 (MI-V); 
HRMS (FAB) Found 208.13393, C 12H 802N Requires 208.13375. 
7-(Tetrahydropyranyloxy)-hept-5-ynoic acid (148). 
Compound (147) (33.72g, 0.163mo1) in 25% NaOH solution (200m1) and MeOH 
(350m1) were heated at reflux for 6 hours. The reaction mixture was cooled to 0 °C 
and acidified to pH 4-5 with 2M aq. HC1 before being extracted with ethyl acetate. 
The combined organic extracts were dried (Na 2 SO4), filtered and reduced in vacuo. 
The residue was purified by wet flash chromatography (0-3% MeOHIDCM) to give 
the title compound as a clear oil (25.56g, 69%). tic R (5% MeOHJDCM) 0.38; vma . 
3400-3 100 (OH), 2942 (CH), 1708 (C0); 511 (200MiHz, CDC1 3) 1.50-1.82 (m, 8H, 
CH2 ), 2.23-2.47 (m, 4H, CH2), 3.39-3.58 and 3.76-3.90 (m,, 2H, CH 2-0), 4.12-4.34 
(nit, 2H, O-CH2-alkyne), 4.75-4.77 (m, 111, CH) ppm; SC (63MHz, CDC1 3) 16.75 
(alkyne-CH2 ), 17.59 (CH2), 22.06 (CH2), 23.90 (CH2), 28.81 (CH2), 31.30 (CH2 ), 
53.14 (O-CH2-alkyne), 60.56 (CH2-0), 75.51 (alkyne), 83.72 (alkyne), 95.34 (CH), 
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177.73 (C=O) ppm; m/z (FAB) 227 (MW); HRMS (FAB) Found 227.12819, 
C 12H 1904 Requires 227.12833. 
M ethyl-7-(tetra hyd ropy ranyloxy)- h ept-5-yn oate (149). 
Compound (148) (0.68g. 3.0mmol) was dissolved in anhydrous THF (25m1) and 
cooled to 0°C before being treated with an ethereal solution of diazomethane. The 
solvent was removed in vacuo to give the title compound in quantitative yield (0.72g, 
100%). tic Rf (5% MeOHJDCM) 0.69; vm 2945 (CH), 1738 (C0); 8H (200MHz, 
CDC13 ) 1.50-1.86 (m, 8H, CU2), 2.26-2.33 (m,, 2H, alkyne-CH 2), 2.43 (t, 2H, CH2, J 
= 7.4Hz), 3.46-3.58 and 3.74-3.88 (mt, 2H, CH2-0), 3.67 (s, 3H, CH3), 4.12-4.34 (m, 
2H, O-CH2-alkyne), 4.77-4.80 (mt, 1H, CH) ppm; SC (63MHz, CDC13) 17.58 
(alkyne-CH2), 18.41 (CH2), 23.03 (CU2), 24.67 (CH2), 29.57 (CH2), 32.12 (CH2), 
50.88 (CH3), 53.87 (0-CH2 -alkyne), 61.33 (CH2-0), 84.57 (alkyne), 96.07 (CU), 
173.02 (C=O) ppm; m/z (FAB) 241 (MH); HRMS (FAB) Found 241.14364, 
C 13H21 04 Requires 241.14398. 
Methyl-7-hydroxy-hept-5-ynoate (150). 
Compound (149) (14.43g, 0.060mol) was dissolved in MeOH (350m1). 15% Oxalic 
acid (300m1) was added and the reaction allowed to stir for 48 hours. The MeOH was 
removed in vacuo, water (200m1) was added and then extracted with EtOAc 
(3x15 Oml).  The combined organic extracts were dried (Na 2 SO4), filtered and reduced 
in vacuo. The residue was purified by wet flash chromatography (0-5% MeOH!DCM) 
to give the title compound as a clear oil (8.27g. 88%). tic R1 (5% MeOH!DCM) 0.51; 
v,. 3435 (OH), 2950 (CH), 1735 (CO); 5H (200MHz, CDC13) 1.74-1.84 (m, 2H, 
CH2), 2.20-2.42 (m, 511, alkyne-CH 2 , CH2 , OH), 3.62 (s, 3II, CU 3), 4.16-4.19 (ni, 
2H, O-CH2-alkyne) ppm; öC (63MHz, CDC13) 16.73 (alkyne-CH2), 22.24 (CH2), 
31.39 (CR2), 49.78 (CH2), 50.21 (CU3 ), 77.98 (alkyne), 83.57 (alkyne), 172.43 
95 
E\Derim%n1a! 
(C0) ppm; m/z (FAB) 157 (MW); HRMS (FAB) Found 157.08675, C 8H, 303 
Requires 157.08498. 
Methyl-7-iodo-hept-5-ynoate (151). 
Iodine (12.34g, 48.2mmol) was added in one portion to a cooled (0 °C) solution of 
compound (150) (5.92g, 37.9mmol), triphenyiphosphine (11.93g. 45.5mmol), and 
iniidazole (3.35g, 49.3mmol) in anhydrous ether/acetonitrile (3:1) (250m1). 
Temperature was maintained at 0 °C for 1.5 hours with stirring. The reaction mixture 
was poured into water (200m1) and extracted with ether (3x1 OOml). The combined 
organic extracts were washed with saturated aqueous Na 2 S203 (200m1) and water 
(lOOmi) and then dried (Na 2 SO4), filtered and reduced in vacuo. The residue was 
purified by wet flash chromatography (DCM) to give the title compound as a clear oil 
(4.65g, 46%). tic R (DCM) 0.51; 2953 (CH), 1743 (C0); oH (200MHz. 
CDC13 ) 1.72-1.90 (m,, 2H, C112), 2.21-2.30 (m, 2H, alkyne-CH2), 2.42 (t, 211, J = 
7.411z), 3.67 (s, 3H, CH 3), 3.89-3.91 (m, 211, I-CH 2) ppm; OC (63MIHz, CDC13) 
16.75 (alkyne-CH2), 21.94 (CH2), 31.30 (CH2), 50.21 (CH3), 77.66 (alkyne), 82.46 
(alkyne), 172.23 (C=O) ppm; m/z (FAB) 267 (MIT); HRMS (FAB) Found 
266.98906, C91-1 12021 Requires 266.98821. 
Ethyl-7-(tetrahydropyranyloxy)-hept-5-ynoate (152). 
Ethyl chioroformate (4.18g, 38.5mmol) was added to a suspension of (148) (8.71g, 
38.5mmol), DMAP (1.88g, 15.4mmol), and triethylamine (5.90m1, 42.4mmol) in 
anhydrous DCM (SOml) cooled to 0 °C. The reaction was stirred at 0 °C for 40 
minutes. The reaction mixture was diluted with DCM (50m1) and washed with 
saturated aqueous NH4CL before being extracted with DCM (2x50m1), dried 
(Na2SO4), filtered and reduced in vacuo to give an oil. The residue was purified by 
wet flash chromatography (20-0%Hexane/DCM) to give the title compound as a clear 
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oil (8.52g, 85%). tic Rr (5% MeOHIDCM) 0.64; v. 2942 (CH), 1734 (C=O); 8H 
(200M11z, CDC13 ) 1.20 (t, 311, CH3 , J = 7.2Hz), 1.45-1.83 (m, 811, Cl2), 2.20-2.28 
(m, 2H, alkyne-C}i2), 2.36 (t, 2H, CH2 , J = 7.4Hz), 3.43-3.51 and 3.73-3.83 (ni, 2H, 
C112 -0), 4.19 (q, 2H, O-CH 2 , J = 7.1Hz), 4.14-4.27 (m t, 211, O-CH2-alkyne), 4.72-
4.75 (m, 1H, CH) ppm; SC (63MHz, CDC1 3) 12.65 (Cl3), 18.06 (alkyne-CH 2), 18.90 
(CH2), 23.57 (Cl2), 25.16 (CH2), 30.07 (CH2), 32.87 (Cl2), 50.88 (Cl3), 54.30 (0-
CH2-alkyne), 60.08 (0- CH 2 ), 61.75 (CH2), 76.50 (alkyne), 85.03 (alkyne), 96.47 
(CH), 172.85 (C0) ppm; m/z (FAB) 255 (MIFfl; HRMS (FAB) Found 255.15942 
C 1 4H2304 Requires 255.15963. 
Ethyl-7-hydroxy-hept-5ynoate (153). 
Compound (152) (7.47, 29.3nmol) was dissolved in MeOH (210m1). 10% Oxalic 
acid (1 50m1) was added and the reaction allowed to stir for 48 hours. The MeOH was 
removed in vacuo then water (1 50m1) was added and extracted with EtOAc 
(3xlOOml). The combined extracts were dried (Na 2 SO4), filtered and reduced in 
vacuo. The residue was purified by wet flash chromatography (0-5% MeOHJDCM) to 
give the title compound as a clear oil (4.18g, 84%). tic R (5% MeOHIDCM) 0.42; 
3437 (OH), 2951 (CH), 1736 (C0); oH (200MIHz, CDC13) 1.21 (t, 3H, CH3 , J 
= 7.2Hz), 1.69-1.84 (mt, 2H, CH2), 2.19-2.27 (m, 2H, alkyne- CH2), 2.38 (t, 2H, Cl 2 , 
J = 7.3Hz), 2.43 (br, OH), 4.09 (q, 211, CH2, J = 7.2Hz), 4.18 (t, 211, O-CH 2-alkyne, 
J = 2.2Hz) ppm; OC (63MiHz, CDCI3) 13.99 (CH3), 17.99 (alkyne-CH2), 23.55 (CH2), 
32.91 (CH2), 50.92 (HO-CH2), 51.43 (CH2), 79.18 (alkyne), 84.67 (alkyne), 173.13 
(C=O) ppm; mlz (FAB) 171 (MIfl; HRMS (FAB) Found 171.10268, C 9H 1503 
Requires 171.10212. 
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Ethyl-7-iodo-hept-5-ynoate (154). 
Iodine (7.89, 31.1mmol) was added in one portion to a cooled (0 °C) solution of 
compound (153) (4.07g, 23.9mmol), triphenylphosphine (7.52g, 28.7mmol), and 
imidazole (2.28g, 33.5mmol) in anhydrous ether/acetonitrile (3:1) (1 66m1). 
Temperature was maintained at 0 °C for 1.5 hours with stirring. The reaction mixture 
was poured into water (200mJ) and extracted with ether (3x1 50m1). The combined 
extracts were washed with saturated aqueous Na 2 S203 (200m1) and water (100m!) 
and dried (Na2 804), filtered and reduced in vacuo. The residue was purified by wet 
flash chromatography (DCM) to give the title compound as a clear oil (5.81g, 87%). 
tic R 1 (DCM) 0.51; 2978 (CH), 2227 (alkyne), 1731 (CO); 8H (200MiHz, 
CDCI3) 1.24 (t, 311, CH3 , J = 7.2Hz), 1.75-1.86 (m, 2H, CH2), 2.21-2.30 (m, 2H, 
alkyne-CH2), 2.38 (t, 211, CH2 , J = 7.41-1z), 3.66-3.68 (m, 2H, I-CH 2), 4.10 (q, 211, 
CH2 , J = 6.9Hz) ppm; öC (63MHz, CDCI3) 12.80 (CH3), 17.07 (alkyne-CH 2), 22.12 
(CH2 ), 31.56 (CH2), 58.96 (CH2), 76.52 (alkyne), 83.86 (alkyne), 171.68 (C=O) ppm; 
m/z (APCI) 267 (M-W); HRMS (FAB) Found 281.00498, C 9H 1402 1 Requires 
281.003857. 
Mixture of 2'-0 and 3'-O-(Methyl-hept-5-ynoate) u ridine (155). 
Uridine (1.09g. 4.4mmo!), dibutyltin oxide (1.33g, 5.3mmol) and tetrabutyl 
ammonium bromide (1.58g, 4..9mmol) were suspended in anhydrous DMF (lOmi) 
under an atmosphere of nitrogen. Compound (151) (1.46g, 5.5mmol) was added with 
vigorous stirring and the reaction mixture heated to 60 °C. After 24 hours the reaction 
was filtered, washed with DMF (20m1) and the filtrate reduced in vacuo. The residue 
was purified by wet flash chromatography (1-5% MeOHIDCM) to give the title 
compound as a off white sticky foam (0.82g, 81%). tic R (15% MeOH/DCM) 0.41; 
m/z (FAB) 383 (MH). 
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2'-0 and 3'-O-(Methyl-hept-5-ynoate)-5 1 -0-(dimethoxytrityf) uridine (157 and 
156). 
Compound (155) (0.81g, 2.1 immol) was coevaporated with anhydrous pyridine 
(2x5ml) then dissolved in anhydrous pyridine (2m1) and cooled in an ice bath to 0 °C 
under an atmosphere of argon. 4,4'-dimethoxytrityl chloride (0.93g, 2.74mmol) was 
added over a 1 hour period portionwise. The reaction was allowed to warm to room 
temperature and left to stir overnight. MeOH (imi) was added and the solvent 
removed in vacuo. The residue was taken up in DCM (40m1) and washed with 5% 
NaHCO3 solution, dried (Na2 SO4), filtered and reduced in vacuo to give a foam. The 
residue was purified by wet flash chromatography (1-5% MeOH in DCM containing 
1% pyridine, v/v/v) to give the title compounds as foams. 
3'-O-(Methyl-hept-5-ynoate)-5'-O-(dimethoxytrityl) uridine (156). 
(0.43g, 30%). tIc Rf (10%MeOH/DCM) 0.41; C.H.N. Found C: 66.98%, H: 6.00%, 
N: 4.66%, C38H40N2010 Requires C: 66.66%, H: 5.89%, N: 4.09%; SH (200MHz, 
CDC13) 1.75-1.83 (m, 211, CH2), 2.21-2.25 (m, 2H, CH2), 2.36-2.44 (m, 2H, CH2), 
3.51 (s, br, 2H, 5'-H), 3.64 (s, 311, OMe), 3.77 (s, 6H, 2xOMe), 4.05-4.46 (m, 5H, 
CH2, 2',3',4',), 5.29 (d, 111, 5-H, 'J = 8.1Hz), 5.97 (d, III, 1'-H, J = 2.2Hz), 6.80-
7.39 (m, 13H, aromatic), 7.98 (d, 111, 6-H, J = MHz), 9.63 (s, br, N-3) ppm; 8C 
(63MIHz, CDC13) 16.79 (CH2), 22.18 (Cl-I2), 31.33 (CH2), 50.24 (OMe), 53.85 
(2xOMe), 57.44 (CH), 60.11 (C-5'), 67.25 (C-2'), 74.65 (C-3'), 82.05 (C-4'), 85.70 
(CAr3), 85.98 (C-l'), 100.79 (C-5), 111.95-134.01 (aromatic), 138.71 (C-6), 148.90 
(C-2),162.16 (C-4),172.23 (C=O) ppm; mlz (FAB) 684 (M 4 ); HRMS (FAB) Found 
684.26683, C38H400 10N2 Requires 684.26830. 
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2'-O-(Methyl-hept-5-ynoate)-5'-O-(dimethoxytrityl) uridine (157). 
(0.33g, 23%). tic Rf (10%MeOH!DCM) 0.62; C.H.N. Found C: 66.30%, H: 6.18%, 
N: 4.58%, C381440N20 10 Requires C: 66.66%, H: 5.89%, N: 4.09%; oH (200MiHz, 
CDC13) 1.66-1.77 (m, 2H, CH2), 2.09-2.20 (in., 2H, CH 2), 2.28-2.36 (m, 2H, CH2), 
3.46-3.58 (in, 2H, 5'-J{), 3.65 (s, 3H, OMe), 3.78 (s, 611, 2xOMe), 3.82-4.42 (m, 511, 
CH2, 2',3',4',), 5.21 (d, 1H, 5-H, J = 8.1Hz), 6.16 (d, 1H, 1'-H, J = 7.6Hz), 6.69-
7.51 (m, 1311, aromatic), 7.71-7.79 (m, 1H, 6-H)ppm; OC (63MHz, CDCI 3 ) 15.45 
(CH2), 27.22 (CH2), 55.13 (OMe), 58.72 (CH2), 61.64 (C-5'), 63.42 (CH2), 69.28 
80.07 (C-2'), 85.24 (C-4'), 86.86 (CAr 3 ), 89.36 (C-l'), 102.39 (C-5), 113.44-
136.25 (aromatic), 140.18 (C-6), 150.08 (C-2), 162.75 (C-4), 166.77 (C0); m/z 
(FAB) 683 (M-H'); HRMS (FAB) Found 683.25912, C38H390 10N2 Requires 
683.26047. 
2 1 -0-(Methyi-hept-5-ynoate) uridine (158). 
Trifluoroacetic acid (14p.l) was added to (157) (22mg, 0.03mmol) in DCM (2m1). 
After stirring at room temperature for 25 minutes the reaction was diluted with DCM 
(1 5m1) and washed with saturated aqueous NaHCO 3 then water. The extracts were 
dried (Na2 SO4), filtered and reduced in vacuo to give a foam. The residue was 
purified by wet flash chromatography (1-5% MeOH in DCM) to give the title 
compound as a foam (7mg, 64%). Analysis by HPLC (Vydac reverse phase C 18 , 250 x 
2.6mm, 5.t, A = CH3CN, B = H20, 0.1% TFA; imi/min. 0-2mm. 0%A, 2-32mm. 0-
90%; R1 = 18.1 minutes; tic Rf(10% MeOHIDCM) 0.14; OH (200MHz, CDC13 ) 1.67-
1.80 (m, 2H, Cl2), 2.13-2.21 (m, 2H, CH2), 2.28-2.40 (m, 2H, CH2), 3.34-4.41 (m, 
711, CH2 , 2',3',4',5'-H), 3.66 (s, 3H, OMe), 5.61-5.78 (m., 2H, 5-H, 1'-H), 7.72 (d, 
111, 6-H, J = 8.2Hz) ppm; OC (63MHz, CDCI3) 15.77 (CH2), 28.02 (CH2), 55.21 
(OMe), 58.75 (CH2), 59.92 (C-5'), 63.70 (CH2), 68.02 (C-3'), 81.54 (C-2'), 85.10 
89.37 (C- V), 102.29 (C-5), 140.23 (C-6),149.88 (C-2), 162.51 (C-4), 166.29 
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(C=O) ppm; mlz (FAB) 383 (MW); HRMS (FAB) Found 382.13976, C 17H22N208 
Requires 382.13762. 
Mixture of 2'-0 and 3'-O-(Ethyl-hept-5-ynoate) uridine (159). 
Uridine (2.74g, 11 .2mmol), dibutyltin oxide (3.36, 13.5mmol) and tetrabutyl 
ammonium bromide (3.99g, 12.4mmol) were suspended in anhydrous DMF (24m1) 
under an atmosphere of nitrogen. Compound (154) (4.72g, 17.Ommol) was added 
with vigorous stirring and the reaction mixture heated to 60 °C. After 24 hours the 
reaction was filtered, washed with DMF (20m1) and the filtrate reduced in vacuo. The 
residue was purified by wet flash chromatography (1-5% MeOHIDCM) to give the 
title compound as a sticky foam (3.59g. 80%). He Rf (15% MeOHIDCM) 0.40; mlz 
(FAB) (M); HRMS (FAB) Found 396.155 10, C 1 8H2408N2 Requires 396.15327. 
2'-0 and 3'-O-(Ethyl-hept-5-ynoate)-5'-O-(dimethoxytritYl) uridine (161 and 
160). 
Compound (159) (1.87g, 4.7mmol) was coevaporated with anhydrous pyridine 
(2x5m1) then dissolved in anhydrous pyridine (2m1) and cooled in an ice bath to 0 °C 
under an atmosphere of argon. 4,4'-dimethoxytrityl chloride (1.92, 5.7mmol) was 
added over a 1 hour period portionwise. The reaction was allowed to warm to room 
temperature and left to stir overnight. MeOH (lml) was added and the solvent 
removed in vacuo. The residue was taken up in DCM (40m1) and washed with 5% 
NaHCO3 solution, dried (Na2SO4), filtered and reduced in vacuo to give a foam. The 
residue was purified by wet flash chromatography (1-5% MeOH in DCM containing 
1% pyridine, v/v/v) to give the title compounds as foams. 
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3' -O-(Ethyl-Hept-5-ynoate)-5' -O-(dimethoxytrityf) uridine (160). 
(0.27g, 8%). tic Rf (10%MeOHIDCM) 0.40; C.H.N. Found C: 67.16%, H: 6.19%, 
N: 4.29%, C391- 40N20 1 0 Requires C: 67.04%, H: 6.06%, N: 4.01%; SH (200MHz, 
CDC13) 1.22 (t, 3H, CH3, J = 7.2Hz), 1.66-1.77 (m, 2H, CH2), 2.09-2.14 (m, 2H, 
CH2), 2.27-2.37 (m, 2H, CH2), 3.51-3.52 (m, 2H, 5'-H), 3.76 (s, 6H, OMe), 4.05-
4.46 (m, 7H, O-CH2, CH2, 2',3',4',), 5.28 (d, 1H, 5-H, J = 8.0Hz), 5.95 (d, 1H, 1'-H, 
J = 1.9Hz), 6.80-7.36 (m, 13H, aromatic), 7.97 (d, 1H, 6-H, J = 8.0Hz), 9.78 (br, 1H, 
N-3) ppm 8C (63MHz, CDC13) 12.80 (CH3), 16.81 (CH2), 22.34 (CH2), 31.65 
53.85 (OMe), 57.46 (CH2), 59.07 (CH2), 60.08 (C-5'), 67.22 (C-2'), 74.62 
(C-3'), 82.00 (C-4'), 85.70 (CAr3), 85.99 (C-I'), 100.78 (C-5), 111.95-134.76 
(aromatic), 138.74 (C-6), 148.95 (C-2), 162.30 (C-4), 171.82 (C0) ppm; m/z 
(FAB) 697 (M-W); HRMS (FAB) Found 697.27582, C39H41 0 1 0N2 Requires 
697.27612. 
2' -O-(Ethyl-Hept-5-ynoate)-5'-O-(d imethoxytrityl) u ridine (161). 
(1.20g. 36%). tic Rr (10%MeOHIDCM) 0.64; C.H.N. Found C: 67.00%, H: 6.03%, 
N: 4.17%, C 39H42N20 10 Requires C: 67.04%, H: 6.06%, N: 4.01%; SH (200MHz, 
CDC13) 1.22 (t, 3H, CH 3, J = 7.2Hz), 1.66-1.77 (m, 2H, CH 2), 2.09-2.14 (m, 211, 
CH2), 2.27-2.37 (m, 2H, CH2), 3.53-3.63 (m, 2H, 5'-H), 3.76 (s, 6H, OMe), 3.82-
4.42 (m,, 7H, O-CH2, Cl2, 2',3',4',), 5.16 (d, 1H, 5-H, J = 8.0Hz), 6.15 (d, 1H, i'-H, 
J = 4.3Hz), 6.70-7.76 (m, 14H, 6-H, aromatic) ppm; lC (63MHz, CDC13) 14.02 
17.95 (CH2), 23.48 (CH2) 1  32.85 (CH2), 55.04 (OMe), 57.97 (CH2), 60.16 
(CH2), 63.76 (C-5'), 71.32 (C-3'), 75.58 (C-2'), 82.52 (C-4'), 86.65 (CAr 3), 86.74 
(C-I'), 102.39 (C-5), 112.98-135.80 (aromatic), 140.06 (C-6), 150.48 (C-2), 163.20 
(C-4),172.82 (C=O) ppm; m/z (FAB) 697 (M-H+); HRMS (FAB) Found 697.27497 
C39H41N2010 Requires 697.27612. 
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2'-0-(Ethyi-hept-5-ynoate) uridine (162). 
Trifluoroacetic acid (0.086m1) was added to (161) (132mg, 0.19mmol) in DCM 
(4m1). After stirring at room temperature for 25 minutes the reaction mixture was 
diluted with DCM (25 ml) and washed with saturated aqueous NaHCO 3 then water. 
The extracts were dried (Na2 SO4), filtered and reduced in vacuo to give a foam. The 
residue was purified by wet flash chromatography (1-5% MeOH in DCM) to give the 
title compound as a white foam (62mg, 83%). Analysis by HPLC (Vydac reverse 
phase C18, 250 x 2.6mm, 5j.t, A = CH3CN, B = H20, 0.1% TFA; imi/min. 0-2mm. 
0%A, 2-32mm. 0-90%; R = 18.2 minutes; tic R (10% MeOHIDCM) 0.13; SH 
(200MHz, CDC13) 1.25 (t, 3H, CH3, J = 7.2Hz), 1.76-1.85 (m, 2H, CH2), 2.21-2.32 
(m, 211, CH2), 2.35-2.44 (in, 2H, CH2), 3.21-4.48 (m, 9H, 0-CR 2 , CH2 , 2',3',4',5'-
H), 5.68-5.77 (in, 211, 5-H, 1'-11), 7.66 (d, 1H, 6-H, J = 8.lHz)ppm; SC (63MHz, 
CDC13 ) 12.77 (CH3), 16.76 (CH2), 22.21 (Cl 2), 31.73 (CH2), 57.41 (CR2), 59.25 
(Cl2), 60.31 (C-5'), 67.91 (C-3'), 78.61 (C-2'), 81.68 (C-4'), 85.84 (C-l'), 101.19 
(C-5), 140.61 (C-6), 149.27 (C-2), 162.04 (C-4), 172.02 (C0); mlz (APCI) 397 
(MT{'); HRMS (FAB) Found 396.15439, C 18H24N208 Requires 396.15327. 
(Hex-4-ynyi benzoate)-1-phosphodichloridite (164). 
Compound 103 (916mg, 4.20mmol) was added drop-wise to a cooled (0 °C) 2M 
solution of phosphorous trichioride in DCM (2.1 Omi, 4.20mmol) and allowed to stir 
for 2 hours. Analysis by 31 P NIvliR indicated no presence of PC13. The solution was 
removed in vacuo to give the title compound without any purification. oP (200MHz, 
CDC13 ) 178.7. 
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N,N-Diisopropyl-(hex-4-ynyl benzoate)-1-phosphonamidyl chloride (165). 
N,N-Dlisopropylamine (440mg, 4.3mmol) was added drop-wise to a stirred solution 
of 164 in anhydrous ether cooled to 0°C. After 2 hours the reaction was filtered, 
washed and reduced in vacuo and used without purification in the synthesis of the 
phosphoramidite 167. 
N4-Benzoyl Cytidine.' °5 
Cytidine (0.20g, 0.8mmol) was dissolved in anhydrous pyridine (lOmi) under an 
atmosphere of argon. Trimethylsilyl chloride (0.37m1, 2.9mmol) was added at room 
temperature and allowed to stir for 1 hour. Benzoyl chloride (0.1 5m1, 1 .2mmol) was 
added dropwise at 0 °C and the reaction allowed to stir for 4 hours. MeOH (5m1) and 
water (5m1) were added. The solvents and hydrolysed silyl derivatives were removed 
in vacuo. The residue was then treated with ice cold water. The solid residue 
obtained was washed with hexane-ethyl acetate (1:1) mixture and then dried in vacuo 
giving the title compound (232mg, 80%). m.p. 229-234°C; tIc R1 (10% MeOH/DCM) 
0.07; C.N.N. Found C: 55.17%, H: 5.00%, N: 12.04%, C 16H 17N308 Requires C: 
55.33%, H: 4.93%, N: 12.10%; oH (200MFIz, DMSO) 3.59-4.04 (m, 5H, 2',3',4',5'-
H), 5.06 (d, 1H, 5'-OH, J = 5.6Hz), 5.19 (t, 1H, 3'-011, J = 5.0Hz), 5.51 (t, 1H, 2'-
OH), 5.81 (d, 1H, 1'-H, J = 2.8Hz), 7.34 (d, 111, 5-H, J = 5.0Hz), 7.48-8.01 (m, 5H, 
aromatic), 8.49 (d, 1H, 6-H, J = 7.2Hz), 11.22 (s, 1H, 4-N) ppm; SC (63MHz, 
DMSO) 60.04 (C-5'), 68.78 (C-3'), 74.68 (C-2'), 84.36 (C-4'), 90.36 (C-l'), 96.11 
(C-5), 128.57, 132.86, 133.24 (aromatic), 145.48 (C-6), 154.78 (C-2), 163.18 (C-4), 
167.46 (benzoyl C=O) ppm; m/z (FAB) 348 (MW); HRMS (FAB) Found 
348.11943, C 1 6H 1 8N308 Requires 348.11956. 
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5'-O-DimethoxytrityI- (N 4-Benzoyl) cytidine (166). "'  
N4 -Benzoyl cytidine (0.80g, 2.3mmol) was suspended in anhydrous pyridine (5m1) 
under an atmosphere of nitrogen. 4,4'-Dimethoxytrityl chloride (0.86g. 2.5mmol) was 
added portionwise over a period of 1 hour and then left to stir for 3.75 hours. EtOH 
(5m1) was added to quench the reaction and the solvent reduced in vacuo. The residue 
was taken up in DCM (30m1) and washed with cold saturated NaHCO3 then saturated 
NaCl sol. before being dried (Na 2 SO4), filtered and reduced in vacuo. The residue 
was purified by wet flash chromatography (1-5% MeOH in DCM containing 1% 
pyridine, v/v/v) to give the title compound as a white foam (624mg, 42%). m.p. 77-
78°C; tic Rf (10% MeOH!DCM) 0.34; C.H.N. Found C: 68.03%, H: 5.67%, N: 
7.10%, C37H35N308 Requires C: 68.40%, H: 5.43%, N: 6.47%; 8H (200M11z, 
DMSO) 3.37 (s, 2H, 5'-H), 3.75 (s, 6H, OMe), 4.07-4.24 (m, 3H, 2',3',4'-H), 5.21 
(d, 111, 3'-011, J = 7.0Hz), 5.76 (d, 1H, 5-H, J = 4.7Hz), 5.84 (d, 1H, 1'-H, J = 
1.4Hz), 6.90-7.79 (m, 18H, aromatic), 8.41 (d, 1H, 6-H, J = 7.5Hz), 11.31 (s, 1,4-
N) ppm; 8C (63MHz, DMSO) 55.13 (OMe), 62.05 (C-5'), 68.66 (C-3'), 74.59 (C-
2'), 86.15 (C-4'), 86.15 (CAr3), 91.20 (C- 1'), 96.21 (C-5), 113.44-136.25 (aromatic), 
144.55 (C-6), 154.49 (C-2), 163.18 (C-4), 167.46 (benzoyl C=O) ppm; m/z (FAB) 
650 (MW); HRMS (FAB) Found 650.24954, C3 7H36N308 Requires 650.25062. 
5 1 -0-4,4'-Dimethoxytrityl-(N 4-Benzoyl)-cytidine-3'-O-[N,N-diisopropyi-(hex-4-
ynyl benzoate)-1-phosphoramiditej (167). 
A solution of 166 (321mg, 0.05mmol) in anhydrous DCM was added to a solution of 
165 in the presence of NN-diisopropylethylamine (0.35m1, 1 .6Smmol) and allowed to 
stir overnight under an atmosphere of argon. MeOH (lml) then EtOAc (lOmi) were 
added and then washed with saturated aqueous NaHCO 3 and saturated NaCl solutions 
before being dried (Na 2 SO4), filtered and reduced in vacuo. The residue was purified 
by wet flash chromatography (0-2% MeOHJDCM containing 1% pyridine) and then 
taken up in Imi of dry toluene and precipitated in petroleum ether under vigorous 
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stirring (150m1, cooled to -65°C) to give the title compound as a white foam (0.28g, 
72%). tic R1 (5% MeOH]DCM) 0.72; oH (200MHz, CDCI3 ) 0.98-1.28 (m, 12H, 
CH3 ), 1.93-1.96 (m, 2H, CH2), 2.31-2.42 (m, 211, C11 2), 2.60-2.67 (CH2 CN), 3.38-
3.68 (m,, 6H, OCH2, CH, 5'-H), 3.77 (s, 611, OMe), 3.80-4.42 (m t, 711, 2xCH2, 
2',3',4'), 5.25 (d, 1H, 5-H, J = MHz), 5.98 (d, III, l'-H, J = 2.9Hz), 6.79-8.03 (m, 
19H, H-6, aromatic) ppm; OC (63MHz, CDC1 3 ) 15.57 (CH2), 27.22 (CH2), 55.13 
(OMe), 58.72 (CH2), 61.64 (C-5'), 63.42 (CH2), 69.28 (C-3'), 80.07 (C-2'), 85.24 
(C-4'), 86.82 (CAr 3), 87.32 (C-I'), 101.79 (C-5), 113.04-135.08 (aromatic), 117.50 
(CN), 139.93 (C-6), 149.82 (C-2), 162.65 (C-4), 166.31 (benzoate C0) ppm; OP 
(200MIHz, CDCI 3) 140.51 ppm; mlz (FAB) 982 (MW); HRMS (FAB) Found 
982.4 1590, C56116 1 N40, 0P Requires 982.4 1374. 
Bis-(4-methylphenyl)-4-(1O-(17-tetrabenzo[a,c,g,I] fluorenyl)-decyloxy) 	phenyl 
methanol (173). 
A solution of 4-bromotoluene (0.55g. 3.24mmol) in anhydrous THF (lOmi) was 
slowly added to magnesium turnings (83mg, 3.4mmol) and a crystal of iodine. After 
stirring under an atmosphere of nitrogen for 30 minutes the reaction mixture was 
heated to reflux for 1 hour. The reaction mixture was cooled to room temperature and 
a solution of ethyl-4-( 1 0-( 1 7-tetrabenzo [a,c,g,I] fluorenyl)decyclooxy)benzoate 
(0.20g, 0.23mmol) in THF was added dropwise. After 3 hours heating at reflux the 
mixture was cooled and poured into saturated aqueous ammonium chloride (20m1). 
The product was extracted with DCM, dried (MgSO 4) and reduced in vacuo to give a 
light brown oil. The residue was purified by wet flash chromatography (DCM) and 
crystallised in DCM/J-Iexane, to give the title compound as a beige crystalline solid 
(125mg, 52%). tic R1 (DCM) 0.40; C.H.N. Found C: 89.36%, H: 7.40% C 60H5602 
Requires C: 89.07%, H: 6.98%; 3542 (OH), 2927, 2854 (CH stretch); OH 
(200MHz, CDC13 ) 0.33-1.64 (ni,, 16H, CH2), 2.33 (s, 6H, C11 3), 2.58-2.66 (m, 2H, - 
OCH2f2-), 3.83 (t, 2H, -OCH2-, J = 6.611z), 5.07 (t, 1H, CH, J = 4.311z), 6.75-
6.80 (m, 2H, aromatic), 7.07-7.17 (m,, 1011, aromatic, Tbf, toluene), 7.59-7.74 (in. 
Experimenmi 
811, aromatic, Tbf), 8.25-8.29 (m., 211, aromatic), 8.67-8.83 (m. 6H, aromatic, Tbf) 
ppm; 8C (63MHz, CDC1 3) 20.90 (2xCH3 ), 22.01, 25.72, 28.62, 28.80, 28.94, 28.99, 
29.04, 29.25 (CH2), 47.16 (allylic C), 67.75 (OCH2), 81.33 (quat. -OH), 113.50 
(aromatic), 123.41, 124.37, 124.92, 125.53, 125.78, 126.70, 127.37 (aromatic, Tbf), 
127.61, 127.95, 128.41, 128.69, 129.34, 131.16, 136.56, 136.78, 139.09, 144.27, 
144.29, 158.01 (aromatic) ppm; A., 1/nm (c/ din3moF'cm) 238 (48889), 254 
(54444), 288(26667),301(29444), 365 (12778),381(12222); m/z (FAB) 809 (Md). 
3.3. Deprotection and Stability Studies 
3.3.1. Stage 1: Ammonia Cleavage Conditions 
The conditions used for the first stage of the deprotection of the proposed 2'-
hydroxyl protecting groups, where those required for the removal of the phosphate 
protecting groups and cleavage of the completed chain from the solid support. The 2'-
0-protected uridine monomers were treated with freshly prepared 33% aqueous 
ammonia solution in ethanol (3: 1) at room temperature in a screw -capped vial. 
Base Hydrolysis of 2'-O-(Hex-4-ynyl benzoate) uridine (127) and 2 1 -0-(Hex-4-
ynyl thiobenzoate) uridine (137). 
HPLC data obtained (Vydac reverse phase C 1 8, 250 x 2.6mm,, 5J.L, A = CH3CN, B = 
1120, 0.1% TFA; imi/min., 0-2mm. 0%A, 2-32mm. 0-90%A); 
COMPOUND RETENTION TIME (MINUTES) 
2'-0-(Hex-4-yny1 benzoate) uridine (127). 20.1 
2'-0-(Hex-4-yn-1-oI) uridine (128). 12.7 
2'-0-(Hex-4-yny1 thiobenzoate) uridine (137). 22.4 
2'-O-(Hex-4-yn- 1 -thiol) uridine (138). 18.0 
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Base Hydrolysis of 2'-O-(Methyl-hept-5-ynoate) uridine (158). 
Compound (158) (2mg) was suspended in ammonia/ethanol (3: 1) solution (2m1) and 
sealed in a vial. After 72 hours no starting material remained. The reaction mixture 
was cooled to -20°C and the solvent removed in vacuo. The residue was dissolved in 
2m1 of water and analysed by HPLC. Several peaks were observed on the HPLC trace 
and showed approximately 25% deprotection to the uridine. 
COMPOUND RETENTION TIME (MINUTES) 
3'-0-(Methyl-hept-5-ynoate) uridine (158). 18.1 
2'-O-(Hept-5-ynoic acid) uridine 12.8,13.2,14.6,14.8 
Uridine 4.4 
Base Hydrolysis of 2' -O-(Ethyl-hept-5-ynoate)u rid me (162). 
Compound (162) (24mg, 0.052mmol) was suspended in ammonia/ethanol (3 : I) 
solution (1 8m1) and sealed in a vial. After 72 hours no starting material remained. The 
reaction mixture was cooled to -20 °C and the solvent removed in vacuo. The residue 
was analysed be HPLC. Several peaks were observed on the HPLC trace and showed 
approximately 25% deprotection to the uridine. Mass spec. indicated the presence of 
the carboxylic acid. m/z (FAB) 368 (M'); HRMS (FAB) Found 368.12193, 
C 16H20N208 Requires 368.12197. 
COMPOUND RETENTION TIME (MINUTES) 
2'-0-(Ethyl-hept-5-ynoate) uridine (162). 18.2 




3.3.2. Stage 2: Acid cleavage 
The deprotection of 2'-O-(Hex-4-yn-1-ol) uridine (128) and 2'-O-(hex-4-yn-1-thiol) 
uridine (138) were studied over the pH range 1 to 3 using 0.1dm (pH 1. 1), 0.01dm' 
(pH 2.0) hydrochloric acid, and a buffer solution of 50mM ammonium formate (pH 
3.1). The uridine monomer (I mg) was dissolved in the appropriate aqueous acid or 
buffer solution, and monitored by HPLC. The deprotection studies of 2'-0-(2-
hexynthiol) uridine (138) were carried out under an atmosphere of argon. See 
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5.0. Branched Oligodeoxynucleotides (ODNs) : Automated Synthesis 
and Triple Helical Hybridization Studies 
5.1 .Introduction 
5.1.1. Antisense Oligonucleotides 
In the search for new drugs it is still necessary to synthesise and test, on average, 
10,000 compounds in order to discover a new active substance that is considered to 
be worth developing. Generally the active substance is directed against proteins such 
as enzymes, receptors or ion channels of which the structure and mode of action are 
usually very complex and often incompletely understood. If the active substance could 
be directed at the level of the nucleic acid, a number of advantages would be gained. 
At present there are a number of drugs on the market whose activity is based on direct 
interaction with deoxyribonucleic acid (DNA).' These are mainly used for 
chemotherapy in which the compound interchelates or binds specifically to DNA. 
However, drugs like Cisplatin are unable to use the specificity that is available in the 
sequence information in the nucleic acids of particular genes. Sequence specific 
recognition of nucleic acids can be obtained using synthetic oligonucleotides. These 
small, synthetic oligonucleotides, resembling single stranded DNA are called 
antisense oligonucleotides. These bind through hybridization to coding sequences 
(sense strand) in a specific messenger RNA (mENA) target by Watson-Crick base 
pairing (Figure 1). Adenosine (A) and thymidine (T) or guanosine (G) and cytidine 
(C) interact through hydrogen bonding. These simple base pairing rules govern the 
interaction between the antisense ODNs and the cellular RNA allowing the design of 
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Figure 1. Base Pairs of DNA 
Due to this specificity, antisense ODNs have been classified as a major class of new 
pharmaceuticals, stimulating huge interest and increased activity in this area of 
research. 
Statistically, a small ODN of 15 nucleotides in length has the specificity capable to 
inhibit the expression of a single target gene through complementary hybridisation 
with a cellular messenger ribonucleic acid (mRNA).' It was Zamecnik and Stephenson 
who first reported in 1978 the use of synthetic antisense oligonucleotides for 
therapeutic purposes. 2 They showed the inhibition of Rous sarcoma viral replication 
with the addition of a 13-mer nucleotide that was complementary to its RNA. 
The synthesised antisense single strand ODN can attack the complementary sense 




duplex with 	RNA target molecules or a complex of protein and 
oligodeoxynucleotides. This is represented schematically in figure 2. 
Transcription 	 Translation 
DNA 	- 	 RNA 	 Do 	Protein 
¶ ¶ 
Triplex forming 	 Duplex forming 	 Comp1es 
ODN 	 ODN 
Figure 2. Mechanism of attack 
For the antisense oligonucleotide to be able to inhibit transcription or translation it 
must reach the interior of the cell unaltered. First, the ODN must be able to cross the 
cellular membrane to reach the cytoplasm or nucleus. When the ODN is in the cell it 
must be resistant to degradation and be able to bind specifically, and with high affinity 
to the target sequence in order to inhibit expression of the disease causing gene. 
Figure 3 shows a simple representation of this process. 
Normal 	 Inhibition 
mRNA 	DNA 
Protein 	mRNA 	DWI - 	Cytoplasm-  
No 




Cellular Membrane , • 	 Oligonucleotide 
Figure3. Action of antisense oligonucleotides 
In order to satisfy these requirements to reach the target sequence unaltered, ODNs 
have to be chemically modified. Modifications in the sugar moiety, phosphodiester 
bond and at the phosphorus atom have been extensively studied and reviewed. 1,4,1,6 
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Enhanced resistance towards nucleases has often been achieved, however, a decrease 
in the stability of the resulting duplexes has frequently been observed. 
5.1.2. Triplex Formation 
Oligonucleotides can interact with double-stranded DNA to form triple-stranded 
complexes. RNA and DNA triple-stranded complexes were first recognised by 
Felsenfeld et al in 1957. The formation of a stable 2:1 complex was described 
between two strands of polyuridylic acid and one strand of polyadenylic acid in the 
presence of MgCl2 . Subsequently, triple-stranded complexes containing other 
combinations of polynucleotide strands were described and reviewed. 8 '9 ' 10" 1 
Site specific binding of an oligonucleotide to the major groove of a DNA duplex via 
intermolecular triple helix formation was demonstrated by Moser and Dervan in 
1987.12 This study, along with others," demonstrated a new strategy for recognition 
of specific double-stranded DNA sequences with far reaching implications in the field 
of genetics, biochemistry, and medicine. 
At least two classes of DNA triplexes have been characterised based on specific, 
Hoogsteen' 4 or reversed Hoogsteen type hydrogen bonding interactions, between the 
bases in the homopurine strand of a Watson-Crick duplex and an additional 
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Figure 4. Triple Helix Formation: Watson-Crick and Hoogsteen Base Pairing 
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In the pyriniidine-purine-pyrimidine triplexes, a pyrimidine rich third strand is aligned 
in parallel with the purine strand of the Watson-Crick duplex to form 1-AT and C"- 
GC base triple combinations (Figure 4). In the purine-purine-pyrimidine triplexes, a 
purine rich third strand is aligned anti-parallel to the purine strand, yielding G-GC, A-
AT and T-AT base triple combinations. 
5.1.3. Branched Oligodeoxynucleotides 
The targeting of single stranded nucleic acids by bi-molecular triplex formation has 
previously been addressed by use of back folding linear DNA" and circular 
oligonucleotides.' 6" 7 ' 18 Entropic reasons, increased affinities and selectivities for such 
bimolecular complexes led to an extension of this approach. Branched ODNs were 
synthesised and studied as possible probes for high affinity 
targeting of complementary ODNs with the rationale being that 	Duplex 
full duplex formation (Watson-Crick hydrogen bonds) between 	region 
the branched DNA segment and the target is followed by 
alignment of the branch in the major groove of the duplex, thus 	Triplex - 
region - 
forming a triple helix (Hoogsteen hydrogen bonds).' 9 Figure 5 	- 
shows a schematic representation of the structure formed 
between the branched oligodeoxynucleotide and the target 
complementary strand. The majority of research in the field of 
synthetic branched nucleic acids has been focused on 
synthesising, investigating and mimicking the branching moiety 
- Target 
' 	' strand 
Figure 5. 
of lariat-RNA occurring 	in eukaryotic mRNA 
splicing. 2021 ' 22 ' 23 ' 24 ' 25 Synthesis of branched oligonucleotides has been performed 
largely by use of rather laborious solution phase methods. 2024 However, there have 
been accounts of solid phase synthesis as well . 2 ' The hybridisation results obtained by 
Azhayeva et al . 2' employing 3'-deoxypsicothymidine (structure A, Figure 6) as the 
branching monomer were rather disappointing. It was thought that the unnatural 
structure of the branching point nucleoside and destabilisation caused by the presence 
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of the branch resulted in substantial decreases in melting points compared with linear 
controls. 
o 0 u 
Figure 6. Branching monomers 
Previously Wengel et al27 ' 28 used 1 -(2-methyl--D-aribinofuranosyl)-uracil (structure 
B, Figure 6) as a branching monomer. A fully automated synthetic strategy was 
described for the preparation of novel mono-branched ("Y-shaped") and double 
branched ("H-shaped") ODN analogues with sequences of arbitrary length and base 
composition. Increased thermal stabilities compared to linear references containing 
one modified monomer (structure B, 2'-O-unbranched, Figure 6), due to the 
formation of short triple helical complexes, was reported . 27' 28 However, compared to 
unmodified linear ODNs, the branched analogues, containing the modified monomer, 
exhibited lower melting temperatures (11-14 °C). This was thought to be caused by 
disruption of the normal Watson-Crick duplex structure upon incorporation of the 
modified monomer. 
A more favourable branching point geometry seemed necessary to achieve thermal 
stabilities comparable or even higher than those of unmodified controls. Previously it 
had been shown that the destabilising effect of incorporating one 2'-0-
methylarabinonucleoside into an 11 -mer or a I 7-mer was a decrease in melting points 
of 1-6°C per modification 29 which was lower than the decrease observed for the 1-(2- 
methyl-o-D-aribinofuranosyl)-uraciI  monomer (structure B, Figure 6). It was, thus, 
decided to synthesise and evaluate branched ODNs using arabino-uridine [1 -(-D-
aribinofuranosyl)uradil] as the branching monomer (structure C, Figure 6). This 
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utilises the 2'-hydroxyl group which orientates itself into the major groove as an 
attachment site for the branch. 
5.2. Results and Discussion 
5.2.1. Synthesis of 1-(5',2'-O-(4,4'-Dimethoxytrity1)-3-D-ara bin ofuranosyI) 
U racil 
Initially, 1 -(5' ,2 ' -O-(4,4'-Dimethoxytrityl)--D-arabinofuranosyl) uradil (4) was 
chosen as the branching monomer for the synthesis of the branched ODNs. 
Incorporation of the 4,4'-dimethoxytrityl protecting group at 2'-hydroxyl position, as 
well as at the 5'-hydroxyl, would allow for the same deprotection, activation/coupling 
and capping methodologies employed in ODN synthesis using the established 
phosphoraniidite chemistry. It would, therefore, be unnecessary to deprotect from off 
the solid support before branching. From the branching monomer identical branches 
would, therefore, be synthesised allowing a model study for the possible formation of 
antiparallel triplexes. 
The phosphoramidite of 1 -(5' ,2 ' -O-(4,4' -dirnethoxytrity1)-3-D-arabinofuranosyl) 
uradil was synthesised in 5 steps (Figure 7). Arabino-uridine was initially protected at 
the 5' and 3' hydroxyl positions using Markiewicz reagent" (1,3-dichloro-1,1,3,3-
tetraisopropy1disiloxane) in anhydrous pyridine giving 1 -[5',3'-0-(1, 1,3,3- 
tetraisopropyldisiloxane- 1 ,3-diyl)--D-arabinofuranosyl] uracil (1) in a 93% yield. 
4,4'-Dimethoxytritylation of compound 1 using dimethoxytrityl chloride and DMAP 
in anhydrous triethylamine gave compound 2 in 52%. Desilylation using potassium 
fluoride dihydrate with 18-crown-6-ether in tetrahyrofuran (THF) gave compound 
(3) in 89% yield . 3 ' This was followed by selective protection of the 5'-hydroxyl 
functionality by reaction with 4,4'-dimethoxytrityl chloride (DM1'-Cl) and silver 
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nitrate in anhydrous pyridine affording 1-(5',2'-O-(4,4'-dimethoxytrity1)--D-
arabinofuranosyl) uradil (4) in 65% yield. 
HO U 	 Y, U 
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Figure 7 1-(5',2 '-O-(4,4 '-Dimethoxylrilyl)-/J-D-arabinofuranosyl) uracil 
Phosphitylation of (4) was carried out in anhydrous dichloromethane (DCM) with 
N,N-diisopropylethylamine and 2-cyanoethyl-N,N-diisopropylethylaminochloro-
phosphoramidite. The phosphoramidite (5) was purified by wet flash chromatography 
and precipitation from anhydrous toluene in petroleum ether cooled to -65°C giving a 
yield of 40%. The branching monomer was then ready to be incorporated into ODNs. 
5.2.2. Synthesis of Branched ODNs 
The synthesis via phosphoramidites according to Caruthers 32 (Section 1.6.4.), 
originally introduced by Letsinger 33 as the phosphite triester method, is currently the 
most efficient method for preparing ODNs. It entails the 5'-hydroxyl group of the 
growing DNA chain being reacted with a nucleoside 3'-3-cyanoethyl N,N-diisopropyl 
phosphoramidite with catalysis by 111-tetrazole. The resulting phosphite triester is 
then immediately oxidised with iodine to the phosphotriester (see Chapter 1). 
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The ODNs were synthesised using standard phosporaniidite chemistry 34 employing the 
usual cycles. The base sequences and lengths of the ODNs corresponded to previous 
research that had been carried out by Wengel et al.28 
Base Sequences of ODNs 
A 	5'-TTTTT-5 X 3 -TTTTTT-3' 
5'-TTTTT' 
B 	5'-TTT-5 X 3 -TTTTTTTT-3' 
2' 
5'-TTT' 
C 	5'-TTTTTTT-5 X 3 -TTTTTT-3' 
2 ' 
D 	5'-CCTCC- 5 X 3 -TTTTTT-3' 
2 ' 
5'-CCTCC' 







A = 2'deoxyadenosine, C = 2'deoxycytidine, T = thymidine, 
X = branching monomer (arabino-uridine). 
Figure 8. Sequences Synthesised 
A fully automated strategy using phophoramidite chemistry for the synthesis of the 
novel branched oligonucleotides A-E and complementary strands F-I was devised. 
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Using a Pharrnacia Gene Assembler Special synthesiser the synthesis was controlled 
by use of different concentrations and coupling times of amidites commencing from 
the incorporated branching monomer. For the initial sequence to the branching 
monomer commercial aniidites were used in 0. 1M concentration with 2 minute 
coupling times. The modified branching monomer (X) was then incorporated using a 
0.3M concentration with a 24 minute coupling time. To circumvent the sterical 
hindrance at the unprotected 2'-hydroxyl position and the need to synthesise two 
strands at the branching step, the concentrations of the amidites were trebled to 0.3M 
and the coupling times increased to 12 minutes. This procedure gave coupling 
efficiencies of amidite (5) (Figure 7) from 60% to 80%, as VJS-spectrometrically 
determined by the release of the DMT-cation during detritylation. The branching step 
gave an increased coupling yield to that of (5) since the release of DMT-cation is 
expected to double due to the two symmetrical branches. The DMT group of the last 
nucleotide incorporated was retained as a purification aid for all the ODNs. 
The DMT protected ODNs were cleaved from the solid support by incubation in 
concentrated aqueous ammonia at room temperature for 3 days. Subsequent 
purification using disposable reverse-phase cartridges afforded the pure oligomers. 
Since all modified ODNs were left with the final DMT group on, they were separated 
from all the truncated sequences which were capped during the syntheses and, 
therefore, lacked the DMT handle. 
The composition of the branched ODNs was confirmed by matrix assisted laser 
desorption mass spectrometry (Figure 9) using internal PNA calibrants. 35 The masses 
of ODNs A and D were experimentally found to be within 0.06% of the calculated 
values. 
Oligodeoxynucleotide Calculated Mass Mass Found 
A 5110.33 5113.44 
D 4990.24 4992.84 
Figure 9. MALDI-mass spectrometry 
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5.2.3. Hybridization Studies 
The thermal stabilities of the novel branched ODNs were compared to their 
corresponding linear analogues in hybridization experiments. The melting point 
samples were run using 2.5.tM of each participating oligonucleotide in a 10 mM Tris-
HC1 pH 7 (at 25°C), 10mM M902, 100mM NaCl buffer solution. The mixtures were 
heated to 80°C for 10 minutes, allowed to cool to room temperature for 30 minutes 
and then kept between 0-5°C for at least 1 hour prior to measurement. The melting 
curves were acquired on a Perkin-Elmer Lambda 2 UV/VIS spectrometer equipped 
with a temperature controlling system (consisting of a Peltier Temperature 
Programmer PTP-6 and a Heto constant temperature cooling cycle). Absorption at 
260nm and 284nm were measured while the temperature was raised from 10 to 80 °C 
with a linear rise of 1 °C min'. The melting points were determined, using the PECSS 
software provided by Perkin-Elmer, as the maximum of the first derivative of the 
melting curve. 
The ODNs were designed to orient the additional branches antiparallel to the 
complementary dA l2 strand which should allow formation of antiparallel triple helices. 
The length of the branches were varied to evaluate the effect of the length. The strand 
dissociation's were detected through hyperchromicities at 260nm and 284nm4 the 
latter being characteristic for triple-helix dissociation. Figure 10 shows the derivative 
of a UV melting curve at 260nm, of branched oligomer A with the complementary 
strand I (dA l2). The measured melting point (T m) was 32°C, which is a drop of 4 °C 
compared with unmodified controls (dT 12 with dAl2). At 284nm no transition was 
detected, therefore, no triple-helix formation had been achieved. Similar Tm results 
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Figure 10. Derivative of a UVMelting Curve at 260nm 
The length of the additional branches were thought to be too short to allow the 
correct orientation to generate triplex formation. The decrease in Tm compared to the 
corresponding linear reference was attributed to disruption of the Watson-Crick 
duplex structure caused by the incorporation of the branching monomer as well as 
unfavourable steric interactions in the branching point. For example between the 
nucleobase and the 2'-phosphate group. It was, therefore, decided to synthesise and 
further evaluate, branched ODNs using arabino-uridine but with non-identical and 
extended branched strands. Incorporation of non-identical strands would allow the 
possibility of further triplexes being formed. This could be achieved by replacement of 
either of the dimethoxytrityl groups, of (5',2'-O-(4,4 1 -Dimethoxytrityl)-3-D-











Figure 11. Branching Monomers 
The levulinyl protecting group is removed by treating the support with 0.5M 
hydrazine hydrate in pyridine-acetic acid (4:1, v/v) for 90 minutes, thereby, freeing a 
5' or 2'-hydroxyl for the preparation of branching. 16 
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5.2.4. Future Work 
5.2.4.1. Synthesis of Modified Branching Monomers 
Synthesis of 1 [2' -O-(4,4'-dimethoxytrityl)-5 '-0- 1evulinyl-3-D-arabinofuranosy1] 
uradil (6) was achieved by selective levulination of the primary hydroxyl group of 
nucleoside 3 using the enzyme Novozym 435® in anhydrous dioxan in a yield of 64%. 
Similarly, nucleoside (1) was levulinated using levulinic anhydride and DMAP and 
anhydrous pyridine to give 1 [2-O-levulinyl-3 ,5 -O-( 1,1,3 ,3-tetraisopropyldisioxane-
1,3-diyl)--D-arabinofuranosy1] uracil (8) in 65% yield. 
Due to time constraints, the synthesis of the branching monomers were not continued 
by myself. However, work by Meldgaard et a136 discussed the synthesis of the 5' and 
2'-levullnyl monomers. Desilylation using tetrabutylammonium fluoride, followed by 
dimethoxytritylation of the 5'-hydroxyl using standard procedures gave 1 [5-0-(4,4'-  
dimethoxytrityl)-2-0-  levuliny1--D-arabinof1iranosy1] uradil (7) (Figure 12). 










OHO 	 OHO 
7 9 




5.2.4.2. Synthesis of Branched Oligoribonucleotides 
Meldgaard et a!36 incorporated the branching monomers 6 and 7 in the synthesis of 
looped and branched ODNs using similar protocols that have been described in this 
chapter. The synthetic strategy allowed the synthesis of branched ODNs with 
sequences of arbitrary length and base composition. The melting results for the looped 
and branched ODNs showed that eight nucleotides in the additional branch were 
sufficient to achieve a stable triplex structure. However, compared with the 
corresponding unmodified linear reference, no significant increase in Tm could 
achieved. It was suggested that the use of arabinonucleosides containing short, non-
phosphorus 2'-O-linkers would relieve the disruption to the Watson-Crick duplex 
structure by steric interactions at the branching point. 
5.3. Experimental 
5.3.1. Notes 
NMR spectra were obtained on a Brucker AC250 spectrometer at 250 MHz for 'H 
NMR, 63 MFIz for ' 3C NMR and 101 MHz for 31 P NMIR spectroscopy. 6-Values are 
reported in ppm relative to internal SiMe 4 for 'H and ' 3C and relative to external 85% 
H3PO4 for 31 P spectra. Fast-atom bombardment mass spectrometry (FAB-MS) was 
performed on a Kratos MS 50 RF spectrometer. The enzyme Novozym 435 ® is 
commercially available from Novo Nordisk A/S, Bagsvaerd, Denmark. Unmodified 
amidites were purchased from Cruachem. Matrix-assisted laser desorption mass 
spectrometry was performed using Micromass TofSpec E mass spectrometer. 
129 
Chanter 
5.3.2. Synthetic Procedures 
1-(5' ,3'-1,1,3,3-Tetraisopropyldisiloxane-f3-D-arabinofuranosyl) uracil (1). 
1 -(-D-Arabinofuranosyl)uraci1 (2.0g. 8.1 9mmol) was dissolved in anhydrous pyridine 
(1 5ml) under an atmosphere of nitrogen. This was cooled on an ice bath while 
1,1,3,3-tetraisopropyldisioxane (3.00ml, 8.8mmol) was added over a 5mm. period. 
After 3 hours no starting material remained and the reaction was quenched with 
methanol (1 Omi) and the solvent then removed in vacuo. The residue was taken up in 
DCM (50m1) and washed with 5% NaHCO3 solution (50m1). The organic phase was 
dried (Na2 SO4), filtered and evaporated in vacuo. The residue was then purified by 
wet flash chromatography (1-5% MeOH in CH202 , v/v) to give the title compound as 
a white foam (3.72g, 93%). m.p. 187-8°C; tic Rf (10% MeOH!DCM) 0.47; C.H.N. 
Found C: 51.92%, H: 8.10%, N: 5.41%, C21 H38N207Si2 Requires C: 51.57%, H: 
7.78%, N: 5.73%; 6H (250M1Hz, DMSO) 0.96 - 1.07 (m, 28H, CH(CH 3)2), 3.69 - 
3.72 (m,, 2H, 5'-H), 3.90 - 4.13 (m, 2H, 3'-H, 4'-H), 4.27 - 4.35 (m, 1H, 2'-H), 5.85 
(d, 1H, 1'-H, J 1 ' 2 ' = 5.79Hz), 6.02 (d, 1H, 5-H, J5 = 6.37Hz), 7.46 (d, 1H, 6-11, J65 
= 8.1Hz), 11.28 (s, 1H, 3-H) ppm; 8C (63MHz, DMSO) 11.87 - 17.16 (12C, 
TIPDS), 60.77 (C-5'), 74.39 (C-2'), 75.07 (C-3'), 79.23 (C-l'), 82.46 (C-4'), 100.32 
(C-5), 141.19 (C-6), 150.32 (C-2), 162.91 (C-4) ppm; m/z (El) 443 (M - 'Pr). 
1-[2 '-O-(4,4'-Dimethoxytrityl)-5' ,3'-O-1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-
3-D-arabinofuranosyI1 uracil (2). 
Method A: 
Compound (1) (1.8g,3.68mmol) was dissolved in triethylamine (15m1) under an 
atmosphere of argon. Dimethylaminopyridine (0.022g. 0.1 84mmol) and 5equivalents 
of 4,4 1 -dimethoxytrityl chloride (6.234g. 1 8.4mmol,) were then added. This was 
allowed to stir under an atmosphere of argon for 24 hours at room temperature. The 
reaction was quenched with methanol (5mi) and reduced in vacuo. The residue was 
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taken up in DCM and washed with 5% NaHCO3 solution (50m1). The extracts were 
dried (Na2 SO4), filtered and evaporated in vacuo. The residue was purified by wet 
flash chromatography (1-5% MeOH in CH 2 C12 containing 1% pyridine, v/v/v) to give 
the title compound as a white foam (1 .52g, 52%). 
Method B: 
Compound (1) (0.72g, 1.47mmol) was dissolved in anhydrous pyridine (5m1) under an 
atmosphere of argon. Silver nitrate (1 .25g, 7.35mmol, 5 equivalents) then 4.4'-
dimethoxytrityl chloride (2.49g, 7.35mmol, Sequivalents) were then added. After 36 
hours the reaction was quenched with methanol (5m1) and filtered. This was then 
washed with 5% NaHCO3 solution (50m1) and then extracted with DCM. The 
extracts were dried (Na 2 SO4), filtered and evaporated in vacuo. The residue was the 
purified by wet flash chromatography (1-5% MeOH in CH 202 containing 1% 
pyridine, v/v/v) to give the title compound as a white foam (1 .52g, 1 .9mmol, 52%). 
m.p. 94-7°C; tic Rf (10% MeOHIDCM) 0.71; C.H.N. Found C: 63.55%, H: 7.35%, 
N: 3.52%, C42H56N209 Si2 Requires C: 63.72%, H: 7.08%, N: 3.54%; 8H (250MHz, 
DMSO) 0.96 - 1.07 (m, 28H, CH(CH3)), 3.65 (m, 5'-H), 3.70-3.75 (s, 6H, OCH3), 
3.83-4.14 (m, 2H, 3'-H, 4'-H), 4.63-4.71 (m, 1H, 2'-H), 5.31 (d, 1H, 1'-H), 5.50 (d, 
111, 5-H, J5 6 = 8.111z), 6.76-7.40 (m, aromatic, 6-H), 11.04 (s, 1H, 3-H) ppm; 5C 
(63MHz, DMSO) 12.14-17.09 (12C, TIPDS), 54.87 (OCH3), 60.77 (C-5'), 75.73 (C-
2'), 76.98 (C-3'), 78.74 (C-l'), 87.30 (C-4'), 100.42 (C-5), 113.04-135.95 
(aromatic), 144.42 (C-6), 149.74 (C-2), 162.60 (C-4) ppm; m/z (FAB) 811 (M' + 
Na) 
1- 12'-O-(4,4'-DimethoxytrityO-13-D-arabinofuranosytl u racil (3). 
Compound (2) (1.52g. 1.90mmol) was dissolved in THF (30m1). Potassium fluoride 
dihydrate (1.07g. 11 .4mmol)) and 18-crown-6-ether (0.207g, 0.57mmol) were added 
to a vigorously stirred solution at room temperature. After 48 hours the reaction was 
filtered and the solids washed with THE The filtrate was reduced in vacuo and the 
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residue purified wet flash chromatography (1-5% MeOH in CH 2Cl2 containing 1% 
pyridine, v/v/v) to give the title compound as a white foam (0.927g. 1 .7Ommol, 
89%). m.p. 69-70°C; tic R f (10% MeOH/DCM) 0.35; C.H.N. Found C: 66.16%, H: 
5.74%, N: 4.98%, C3 0H30N208 Requires C: 65.87%, H: 5.49%, N: 5.12%; 8H 
(250MIHz, DMSO) 3.22 (s, 111, 4'-H);3.41-3.46 (m. 1H, 3'-H); 3.58-3.60 (m, 211, 5'-
H); 3.73 (s, 6H, OCH 3); 3.84-3.91 (m, 1H, 2'-ll), 5.69 (d, 1H, 5-H, J5 = MHz), 
6.03 (d, 1H, 1'-H), 6.85-7.42 (m, 13H, aromatic), 11.52 (s, 1H, 3-H) ppm; öC 
(63M1Hz, DMSO) 54.90 (OCH3), 66.44 (C-5'), 74.71 (C-3'), 76.03 (C-2'), 83.59 
(CAr3), 84.57 (C-I'), 87.04 (C-4'), 100.34 (C-5), 113.02-135.95 (aromatic), 144.63 
(C-6), 149.48 (C-2), 162.60 (C-4) ppm; m/z (FAB) 547 (MW). 
1-[5',2'-O-Di(4,4'-dimethoxytrityJ)-3-D-arabjnofuranosytJ uracil (4). 
Compound (3) (0.29g, 0.53mmol) was dissolved in anhydrous pyridine (0.5m1). 
AgNO3  (0.09g, 0.53mmol) and 4,4'-dimethoxytrityl chloride (0.18g,0.53mmoI) were 
added under an atmosphere of argon. After 24 hours the reaction mixture was filtered 
and washed with 5% NaHCO3 solution (25m1) then extracted with DCM. The 
extracts were dried (Na 2 SO4), filtered and evaporated in vacuo. The residue was the 
purified by wet flash chromatography (1-5% MeOH in CH202 containing 1% 
pyridine, v/v/v) to give the title compound as a white foam ( 0.291g, 0.34mmoI, 
65%). m.p. 104-5°C; tic Rf (I0% MeOH/DCM) 0.69; C.H.N. Found C: 72.63%, H: 
6.20%, N: 3.85%, C51 1148N20 10 Requires C: 72.09%, H: 5.65%, N: 3.30%; SH 
(250MHz, CDC1 3) 3.19-3.23 (m, 211, 5'-H), 3.36-3.43 (m. 1H, 4'-H), 3.55(m, 111, 3'-
H), 3.74 (m, 12H, OCH 3), 4.22-4.24 (m, 1H, 2'-H), 5.65 (d, 1H, 5-H, J5 -6 = 8.1Hz), 
6.19 (d, 1H, 1'-H, J= 2.5Hz), 6.73-7.32 (m, 27H, 6-H, aromatic) ppm; 3C (63MHz, 
CDC13) 55.22 (OCH3), 63.17 (C-5'), 78.55 (C-2'), 81.96 (C-3'), 84.27 (CAr 3), 86.34 
(C-I'), 88.28 (C-4'), 101.28 (C-5), 113.16-135.98 (aromatic), 144.63 (C-6), 149.72 




dimethoxytrityl)-13-D-arabinofu ranosyI u racil (5). 
Compound (4) (0.200g. 0.236mmo1) was coevaporated with anhydrous CH 3 CN and 
dissolved in anhydrous CH202 (2m1) under an atmosphere of argon. N,N -
diisopropylethylamine (0.9m1) was added dropwise followed by 2-cyanoethyl-N,N-
diisopropylaminochlorophosphoramidite (0. 136m1, 0.779mmo1). After 60 minutes 0.5 
equivalents of reagents were then added and left for a further 30 minutes. Methanol 
(1 ml) was added to quench the reaction. EtOAc (6m1) was added and the reaction 
mixture was washed with saturated NaHCO 3 (3x25ml) and NaCl (3 x 25 ml). The 
organic phase was dried (Na2 SO4), filtered and reduced in vacuo. The residue was 
purified by wet flash chromatography (30-50% ethyl acetate-cyclohexane, 1% 
pyridine) which was taken up in lml of dry toluene and precipitated in petroleum 
ether with vigorous stirring (150m1, cooled to -65 °C) to give the title compound as a 
white foam (100mg, 0.095mmol, 40%). tic R f (5% MeOHIDCM) 0.49; 6P (250 
MHz, CDC13) 151.2 and 151.3 ppm. 
1-[5'-O -Levu linyl-2 '-O-(4,4'-dimethoxytrityl)-3-D-arabinofuranosyIJ u racit (6). 
Compound (3) (100mg, 0.1 83mmol) was dissolved in anhydrous dioxane (2m1) under 
an atmosphere of argon. The Novazym 435 (ig) and freshly prepared levulmic 
anhydride (1 .76m1,2mmol) were added and the reaction left to stir overnight. After 
24hours the enzyme was filtered off and the reaction washed with 5% NaHCO 3 and 
extracted with EtOAc. The extracts were dried ( NaSO 4), filtered and reduced in 
vacuo. The residue was then purified by wet flash chomatography (1-5% MeOH in 
CH2 C12 containing 1% pyridine, v/v/v) to give the title compound as a foam (0.075g. 
64%). tic Rf (10% MeOWDCM) 0.68; 8H (250MHz, DMSO) 2.12 (s, 3H, CH 3 ), 
2.46-2.74 (m, 414, CH2CH2), 3.12 (s, 1H, 3'-OH), 3.75 (s, 6H, OCH3 ), 4.00-4.11 (m, 
2H, 3'-H and 4'-H), 4.29-4.36 (m, 1H, 2'H), 5.29 (d, III, ), 5.69 (d, 1H, 5-H, J = 
7.6), 5.90 (s, 1H, 1'-H), 6.83-6.91 (m., 414, ArH), 7.12-7.40 (m,9H, ArH), 7.86 (s. 
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111, 6-11), 8.58 (s, 1H, 3-H) ppm; 8C (63MHz, DMSO) 27.45 and 29.42 (CH2CH2), 
37.27 (CH3 ), 54.97 (OCH3), 63.13 (C-5'), 74.27 and 76.78 (C-2' and C-3'), 80.84, 
83.83 and 87.46 (C-l' and C-4', Car 3), 100.58 (C-5), 113.21-136.00 (aryl), 142.78 
(C-6), 150.08 (C-2), 158.31 (aryl), 162.89 (C-4), 172.08 (C0) and 206.62 (C0) 
ppm; m/z (FAB) 644 (M). 
1-(2 ' -0- levu linyl-5' ,3 '-1, 1,3,3-tetraisopropyfdisiIoxane-3-D-arabinofuranosy1) 
uracil (8). 
Compound (1) (0.7g, 1 .43mmol) was dissolved in anhydrous pyridine (5m1). 
DMAP(5%) and 3 equivalents of freshly prepared levulinic anhydride in dioxane were 
added and was left to stir under an atmosphere of argon overnight. Methanol (5m1) 
was added and the reaction reduced in vacuo. The residue was taken up in EtOAc and 
washed with 5% NaHCO3 The extracts were dried ( NaSO 4), filtered and reduced in 
vacuo. The residue was then purified by wet flash chomatography (1-5% MeOH in 
CH202) to give the title compound as a foam (0.504g, 65%). tic R f (10% 
MeOHIDCM) 0.72; SH (250 MHz, CDC13) 0.99-1.19 (m, 28H, CH(CH 3)2), 2.17 (s, 
311 CH3), 2.36-2.78 (m, 4H, CH2CH2), 3.82 (m. 11-1, 4'-H), 3.98-4.19 (m, 211, 5'-H), 
4.44 (t, 1H, 3'-H, J = 8.2), 5.55 (dd, 111, 2'-H, J = 6.3 and 7.9), 5.7 (d, 1H, 5-H, J = 
8.1), 6.2 (d, 1H, 1'-H, J = 6.2), 7.6 (d, 1H, 6-H, J = 8.2), 9.1 (s, 1H, 3-H) ppm; öC 
(63MHz, CDC13 ) 12.23-17.30 (TIPDS), 27.30 (CH3), 29.54 (CR 2), 37.44 (CH), 
60.22 (C-5'), 71.18 (C-3'), 75.83 (C-2'), 80.56 and 81.64 (C-l', C-4'), 101.75 (C-5), 
140.15 (C-6), 149.87 (C-2), 163.07 (C-4), 171.18 (C=O), 205.60 (C=O) ppm; m/z 
(FAB) 585 (MW). 
1- I5'-O-(4,4'-Dimethoxytrityl)-E-D-ara bin ofuranosytJ uraciL 
1 -(3-D-Arabinothranosy1)uradil) (0.5g, 2.05mmol) was dissolved in anhydrous 
pyridine (2m1) under an atmosphere of argon. AgNO3 (0.382g, 2.26mmol) then 4,4'- 
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dimethoxytrityl chloride (0.76g. 2.26mmol) were added and the reaction left to stir 
overnight. The reaction was quenched with methanol (5m1) and then filtered. The 
filtrate was washed with 5% NaHCO3 and extracted with DCM (2 x 30m1). The 
extracts were dried (Na 2 SO4), filtered and reduced in vacuo. The residue was then 
purified by wet flash chomatography (1-5% MeOH in CH 2 C12 containing 1% pyridine, 
v/v/v) to give the title compound as a white foam (0.567g, 1.04mmol, 5 1%). m.p. °C; 
tic Rf (10% MeOH/DCM) 0.35; C.H.N. Found C: 66.22%, H: 5.81%, N: 5.07%, 
C30H30N208 Requires C: 65.87%, H: 5.49%, N: 5.12%; 8H (250 MHz, DMSO) 3.21- 
3.29 (m,, 2H, 5'-H), 3.74 (s, 6H, 0C143), 3.87-3.91 (m. 2H, 3'-H, 4'-H), 4.01 (m.. 1H, 
2'-H), 5.39 (d, 114, 5-H, J5 .6 8.1Hz), 6.04 (d, 1H, 1'-H, J = 4.5Hz), 6.88-7.47 (mt, 
13H, aromatic), 8.56 (d, 2H, 6-H, J = 7.6), 11.27 (s, 1H, 3-H); SC (250 
MiHz,DMSO) 54.94 (OCH3), 63.06 (C-5'), 74.98 (C-2'), 76.03 (C-3'), 82.58 (CAr 3 ), 
84.72 (C-l'), 85.46 (C-4'), 99.86 (C-5), 113.13-135.48 (aromatic), 144.63 (C-6), 
149.49 (C-2), 163.09 (C-4); m/z (FAB) 547 (MW). 
1-{3 1 -0-[2-Cyanoethoxy(diisopropyiamino)phosphino]-5'-O-(4,4'-
DimethoxytrityI)-3-D-arabinofuranosyi} uracil. 
Compound (4) (0.160g, 0.293mmo1) was coevaporated with anhydrous CH 3CN and 
dissolved in anhydrous CH2C12 (2ml) under an atmosphere of argon. N,N-
Diisopropylethylamine (0.3m1) was added dropwise followed by 2-cyanoethyl-N,N-
diisopropylaminochlorophophoramidite (0.056m1, 0.3 i7mmol, 1. iequivalents). After 
60 minutes methanol (imi) was added to quench the reaction. EtOAc (6ml) was 
added and the reaction mixture washed with saturated NaHCO 3 (3 x 25m1) and NaCl 
(3 x 25m1). The organic phase was dried (Na2SO4), filtered and reduced in vacuo. The 
residue was purified by wet flash chromatography (30-50% ethyl acetate-cyclohexane, 
1% pyridine) which was taken up in iml of dry toluene and precipitated in petroleum 
ether under vigorous stirring (1 50m1, cooled to -65°C) to give the title compound as a 
white foam (160mg, 0.214mmol, 73%). He Rf (10% MeOHIDCM) 0.27; SH (250 
MHz, CDC13) 0.99-1.29 (m, 12H, (CH3 )2), 2.76 (t, 2H, CH2CN, J = 6.3Hz), 3.30- 
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3.67 (m, 5H, 5'-H, OCH2 , CH(N)), 3.79 (s, 6H, OCH3), 4.10-4.41 (m, 3H, 2'-H, 3'-
H,4'-H), 5.49 (d, 1H, 5-H, J5 = 1.88Hz), 6.79-7.45(rn, 14H, aromatic, 6-H); 6C 
(250 MHz, CDC13) 22.75 (CH2CN), 24.43 (CH(CH3)2), 43.06 (CHN), 55.11 
(OCH3), 58.08 (OCH2), 1 13.02-130.02(aromatic); SP (250 MHz, CDC13) 149.6 and 
149.8. 
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Automated synthesis of branched oligodeoxynucleotide analogues 
using arabino-uridine as branching nucleotide 
Michael Meldgaard, 3 Nanna K. Nielsen, 3 Murray Bremner,t'3 
Ole S. Pedersen,3 Carl Erik Olsen" and Jesper Wengel *C 
' Department of Chemistry, Odense University, DK-5230 Odense M, Denmark 
'Department of Chemistry, Royal Veterinary and Agricultural University, 
DK-1871 Frederiksberg C, Denmark 
Department of Chemistry, University of Copenhagen, Universitetsparken 5, 
DK-2100 Copenhagen, Denmark 
Fully automated synthesis of branched oligodeoxynucleotides (branched ODNs) has been accomplished 
using 2'-O-levulinyl- or 5'-O-levulinyl-protected arabino-uridine derivatives as branching monomers. 
Selective removal of the levulinyl groups is accomplished using 0.5 M hydrazine hydrate in a pyridine—
acetic acid—water (4:3:0.35, v/v/v) buffer. The affinity of the branched ODNs towards complementary 
DNA has been evaluated at 260 nm and 284 nm during thermal denaturing experiments. Enhanced affinity 
of a branched ODN compared with the corresponding linear reference is attributed to bimolecular triple 
helix formation. 
Introduction 
Recently, development of Y-shaped branched oligodeoxynu-
cleotides (branched ODNs) as possible probes for high-affinity 
targeting of complementary ODNs has been attempted using 
the strategies outlined in Fig. lA, the rationale being that 
full-length duplex formation (Watson—Crick hydrogen bonds) 
between the branched DNA segment and the target is followed 
by alignment of the branch in the major groove of the duplex 
thus forming a triple helix (Hoogsteen hydrogen bonds). For 
entropic reasons, increased affinities and selectivities for such 
bimolecular complexes are envisaged in analogy with results 
reported for circular oligonuc1eotides." 
The hybridisation results obtained by Azhayeva et al.2 
employing 3'-deoxypsicothymidine (structure A, Fig. 2) as 
branching monomer were rather disappointing. Thus, two-
phasic transitions and appreciable decreases in melting points 
(mps) compared with linear controls were obtained. These 
results were explained by the unnatural structure of the branch-
ing point nucleoside and destabilisation caused by the presence 
of the branch. We have used I -(2-methyl--D-arabinofuranosyl)-
uracil (structure B, Fig. 2) as branching monomer 3 '4 to give 
branched ODN analogues capable of hybridising to target 
ODNs as depicted in Fig. IA. Increased thermal stabilities 
compared with the corresponding linear reference containing 
one modified monomer (structure B, 2'-0-unbranched, Fig. 2) 
were obtained in monophasic transitions. 
However, to achieve thermal stabilities comparable to or even 
higher than those of unmodified controls, a more favourable 
branching-point geometry seems necessary. Earlier, we have 
shown an only moderately destabilising effect of incorporating 
one 2'-O-methylarabinonucleoside into 1 1-mer or 17-mer 
ODNs. 7 Decreases in mps of 1-6°C per modification, com-
pared with observed decreases of 11-14 °C for one unbranched 
I -(2-methyl-3-o-arabinofuranosyl)uracil monomer B,3 ' 4 were 
achieved. Therefore, we decided to synthesize and evaluate the 
novel branched ODNs B—M (Tables 1-3) using arabino-uridine 
[1-(3-o-arabinofuranosyl)uracil] as branching monomer utilis-
ing the 2'-hydroxy group oriented into the major groove as 
attachment site for the branch. Besides the potential entropic 
t Present address: Department of Chemistry, University of Edinburgh, 
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Fig. I Schematic representation of the structures of complexes 
formed between branched ODNs and complementary oligonucleotides 
o-vi-o- - 
Fig. 2 Structures around branching nucleotides in previously 
described branched ODNs used in oligonucleotide targeting as depicted 
in Fig. IA. T= thymin-1-yl, U = uracil-l-yl. 
advantages, the C-type branched ODNs (Fig. I) might be 
capable of forming it-interactions at the ends of the two triplex-
forming strands thereby inducing cooperativity between the 
two strands which has been reported to increase the stability of 
a related complex.' 
Results and discussion 
Nucleoside i was levulinated using levulinic anhydride and 4- 
(dimethylamino)pyridine (DMAP) in anhydrous diethyl ether 
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Table 1 Sequences of synthesized branched ODNs (plus non-
branched reference strand A) and measured mps (Tm ) from hybridis-
ation with complementary dA l2 
Sequence" 	 Tm / 0Cb 	Triple helix 
A 	3'-i ill_1TF'F-3.X 5.-TTT-5' 30 
B 3'-I 111111 I- 3 .X.-TTT-5' 27 	 + 
5 1 -1 111111CC-2 ' 
C 	3-I 111111 I- 3 .X 5.-TVT-5 27 	 + 
5 1 -I 11111 ICCC-2 ' 
D 	3'-TTT 11111 -3 .X.-T1T-5' 27 	 + 
5 1 -IIIIIIICCCC- 2 ' 
E 	3'-I 111111 I- 3 .X 5.-TTT-5' 24 
5 1 -TTTGTTTCC-2 ' 
F 	3'-I 111111 l-3 .X,.-TTT-5 23 
5'-TGTGTGTCC- 2 ' 
C = 2'-Deoxycytidine; G = 2'-deoxyquanosine: T = thymidine X= 
modified ara-U nucleotide. b  Mps were determined as the maximum of 
the first derivative of the absorption vs. temperature curve at 260 nm. 
+ Denotes confirmation of transition at 284 nm. 
Table 2 Sequences of synthesized branched ODNs of the B-type and 
measured mps (Tm ) from hybridisation with complementary dA, 2 
Sequence" 	 Tm / OC b 	Triple helix 
C 	3'-CATTTTTTTTTrT-3 .X 37.6 
5'TTfl'TT 2 ' 
H 	3-CATTI 1111_ITTT-3 .X 41.2 	+ 
5'-TTTTI III 1T- 
I 	3'-CATTTTTTTTTTT-3 X 35.8 	+ 
5 '-TrTrTTCCCCC-2 ' 
J 	3'-CATTTTTTTTTTT-3 .X 41.0 	+ 
5'-TTTTTTTTTTCCCCC-2 ' 
K 	3'-CATTTTTTTTTTT-3 .X 29.8 
5'-TTTTTGTfTT-2 '. 
"C = 2'-Deoxycytidine; A = 2'-deoxyadenosine; G = 2'-deoxyguano-
sine: T = thymidine; X = modified ara-U nucleotide. "Mps were deter-
mined as the maximum of the first derivative of the absorption vs. 
temperature curve at 260 nm. + Denotes confirmation of transition at 
284 nm. 
Table 3 Sequences of synthesized branched ODNs of the C-type and 
measured mps (Tm ) from hybridisation with complementary dA l2 
Type" 	0 a.b 	 o.b 	Tm I °C ° 	Triple helix" 
L 	C 	T4-3' 	T 4-5' 	29.6 
M C T8-3' T 8-5' 34.0 	+ 
"Refers to Fig. I. T = Thymidine. Mps were determined as the max-
imum of the first derivative of the absorption vs. temperature curve at 
260 nm. d  + Denotes confirmation of transition at 284 nm. 
and anhydrous pyridine to give I -[2-O-levulinyl-3,5-O-( 1,1,3,3-
tetraisopropyldisiloxane- I ,3-diyl)-3-D-arabinofuranosyl]uracil 
2a in 87% yield. Desilylation using tetrabutylammonium fluor-
ide (TBAF) in tetrahydrofuran (THF) to give compound 3a in 
76% yield followed by selective protection of the 5'-hydroxy 
functionality by reaction with 4,4'-dimethoxytrityl chloride 
(DMTCI) and silver nitrate in anhydrous pyridine afforded 
I -[5-O-(4,4'-dimethoxytrityl)-2-O-levulinyl--D-arabinofurano-
syl]uracil 4a in 96% yield. Subsequent phosphitylation of the 
3'-hydroxy group using 2-cyanoethyl N.N-diisopropylphos-
phoramidochloridite and N,N-diisopropylamine in dichioro-
methane gave the desired amidite 5a in 67% yield after precipi-
tation from light petroleum (Scheme I). 4.4'-Dimethoxy-
tritylation of compound I using silver nitrate in anhydrous 
THF afforded. nucleoside 2b in quantitative yield. Subsequent 
desilylation to give compound 3b was achieved in 97% yield 
using KF2H 20 in THE Selective levulination of the primary 
hydroxy group using the enzyme Novozym 435® under condi-
tions described earlier '° afforded derivative 4b in 93% yield. 
The corresponding acylation with pyridine as base afforded the 
undesired diacylated by-product in addition to compound 4b. 
0 
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Sa R = Lev. R' = DM1 	4a R = Lev. R'= DMT 	3a R = Lev 
Sb R = DMT. R'= Lev 0 R = DM1. R' = Lev 3b R = DMT 
Scheme I Reagents: (a) Levulinic anhydride. DMAP, pyridine; (b) 
DMTCI. AgNO3. THF, pyridine; (c) THAF. THF; (d) KF21­1 20. 18-
crown-6, THF; (e) levulinic anhydride, Novozym 435, 1.4-dioxane; 
(f) 2-cyanoethyl N.N-diisopropylphosphoramidochloridite, N,N-
diisopropylethylamine, CH 2Cl2. DMT = 4.4'-dimethoxytrityl: Lev = 
levulinyl; U = uracil- l -yl. 
Nucleoside 4b was phosphitylated as described above for syn-
thesis of compound 5a to give phosphoramidite 5b in 64% 
yield. 
All ODNs were synthesized using standard phosphoramidite 
chemistry" with cycles including detritylation, coupling, cap-
ping and oxidation. Synthesis of the type A branched ODNs 
(Fig. 1) was initiated by constructing the linear strand using 
standard amidite concentration (0.1 M) and coupling time (2 
mm). However, when incorporating the modified nucleotide X, 
a 0.15 M solution of amidite 5a and a coupling time of 12 mm 
were applied. A separate end-capping cycle (consisting of 
detritylation and acetylation) was used to block further linear 
elongation at the 5'-end, thus preparing for branching. The 
support was treated with 0.5 M hydrazine hydrate in pyridine–
acetic acid (4:1, v/v) for 90 min to remove the 2'-O-levulinyl 
protecting group. The first nucleotide in the branch was - sub-
sequently attached at the 2'-hydroxy group of nucleotide X by 
12 min couplings at standard amidite concentration whereupon 
the remaining part of the branch was synthesized usinj stand-
ard conditions. The ODNs of the B- and C-type (Fig. I) were 
synthesized by using compound 5b at standard concentration 
and a coupling time of 2 x  12 mm (coupling, washing, coup-
ling with a fresh solution of amidite, apping, oxidation and 
detritylation). This procedure increased the coupling efficiency 
of amidite 5b from —65% (single coupling) to —95%. As the next 
step, the first nucleotide in the branch originating from the 2'-
hydroxy group was attached using a coupling time of 2 x  12 
mm. After finishing this branch, the looped B-type ODNs were 
subjected to standard ammonolytic deprotection which, besides 
nucleobase and phosphate deprotection and cleavage from the 
support, effected delevulination, thus liberating the 5'-hydroxy 
group of monomer X. Synthesis of the C-type branched and 
looped ODNs was accomplished using commercially available 
'reversed' (5 '-O-phosphitylated and 3'-0-4,4'-dimethoxy-
tritylated) phosphoramidites in branch 0 (Fig. 1C). After 
completion of branch CD, end-capping at the 3'-end was per-
formed as described above. Subsequently, the support was 
treated with a freshly prepared 0.5 M solution of hydrazine 
hydrate in a buffer consisting of pyridine—acetic acid—water 
(4:3:0.35, v/v/v) for 5 min in order selectively to 5'-0-
delevulinate at the branching point V. The remaining part of 
the type-C ODNs were synthesized using amidite 5b (to 
incorporate monomer X 2) and standard phosphoramidites. The 
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DMT group of the last nucleotide incorporated was in all syn-
theses left on for the purpose of purification. The coupling 
yields determined by a VIS spectrophotometer as the amount 
of the DMT carbenium ion released during each detritylation 
step was >99% for commercial amidites and —60% for the 
modified amidite 5a. The branched ODNs were cleaved from 
the solid support and deprotected by treatment with 32% aq. 
ammonia for 72 h at room temperature. The crude ODNs were 
desalted, purified and detritylated on disposable reversed-phase 
cartridges, taking advantage of the hydrophobicity of the DMT 
group. The composition of ODNs C, F, H, J and M, chosen as 
representative probes, was confirmed by matrix-assisted laser 
desorption mass spectrometry (C: Found, 6589 Da. CaIc., 6587 
Da F: Found, 6374 Da. CaIc., 6373 Da; H: Found, 7237 
Da. CaIc., 7235 Da; J: Found, 8678 Da. CaIc., 8681 Da; M: 
Found, 9060 Da. CaIc., 9062 Da. The purity was confirmed for 
all ODNs using capillary gel electrophoresis. 
The ODNs were designed to orient the additional branches 
parallel to the complementary dA, 2 strand which should allow 
the formation of stable triple helices.' 2 The sequence of branch-
ing in the A-type oligodeoxynucleotides was varied to evaluate 
the effect of the length of the cytidine linker. Furthermore, 
thymidines in the branch were replaced with guanosines to test 
the effect of mismatches on triple-helix formation and thermal 
stability. Mp (Tm ) determinations were carried out in medium 
salt buffer as described earlier." The strand dissociations (Tables 
1-3) were detected through hyperchromicities at 260 nm and 
284 nm, the latter being characteristic for triple-helix dissoci-
ations.' 3 ' 4 The insertion of the modified nucleotide X without 
attaching an additional branch (ODN A) causes a drop in T. of 
6'C compared with unmodified controls (T, 2 and 3'-T8dUT3-
5'). As expected, no transition was detected at 284 nm with the 
linear ODN A. For the branched ODNs B—D, triple-helix dis-
sociations were confirmed, and, as expected, ODNs E and F 
having mismatches in the branch showed no sign of dissoci-
ation when measured at 284 nm. It may therefore be concluded 
that the T8-branches in ODNs B—D are involved in complexes 
with dA,2 as depicted in Fig. IA. The mp of mismatched 
ODNs E and F reveal that a non-binding branch has a signifi-
cant destabilising effect on the duplex (decrease in T. compared 
with that of A: —7 °C). This could, at least in part, be due to 
unfavourable steric interactions at the branching point. This 
effect is partly compensated for by the stabilising effect of 
triple-helix formation as seen for ODNs B—D, but the mps are 
still lower than for the linear reference A. The results for the 
different linkers indicate that the length of the cytidine linker 
(C2—C4 ) is of no importance. 
The looped ODNs G—K (Fig. 1B, Table 2) show, in contrast 
to earlier results for unmodified triplex-forming back-looped 
ODNs,' 5 that there seems to be no preference for the sequence 
with a five-nucleotide loop versus the corresponding sequence 
without a connecting loop (ODN J versus ODN H). This sup-
ports our original idea that direct entropically favoured back-
folding should be possible having an attachment site oriented 
into the major groove. However, incorporation of the modifi-
cation causes a decrease in the mp of 4 °C (3'-CAT 12-5': 
28.2 °C, 3'-CAT, 1 X-5': 24.0 °C), a decrease that can be over-
come by bimolecular triplex formation (Table 2, ONDs H and 
J). The looped ODNs form triplexes of comparable stability to 
complexes formed between a target strand and unmodified 
ODNs with a loop consisting of five nucleotides (3'-
CAT 12C5T6-5': 36.0 °C, 3'-CAT, 2C5T,0-5': 40.4'C). Incorpor-
ation of one or two mismatches in the triplex-forming strand 
causes a decrease in the mp and no detectable transition at 284 
nm, indicating the expected selectivity in the binding of the 
third strand, and also showing that binding involving the third 
strand causes stabilisation of the complex. 
The looped and branched ODNs Land M (Fig. IC, Table 3) 
show that eight nucleotides in the third strand are sufficient for 
triplex formation, whereas four are not. Triplex formation for 
ODN M causes an increase in the T. to 34°C compared with 
28.5 °C for the corresponding linear ODN (3'-CAXT, 0X-5'). 
The results indicate that the two branches do not interact 
cooperatively and do not stabilise the triplexes by it-
interactions. In contrast to the A-type ODNs, there seems to be 
no destabilising effect in the B- and C-type ODNs due to 
branches not involved in Hoogsteen hydrogen bonding. This 
may originate from the difference in incorporating X in the 
middle (in A-type ODNs) or in the ends, the latter generally 
known to be less detrimental to duplex formation. In all cases 
where triplex structures were found, concomitant dissociation 
of the triplex and duplex complexes was observed (monophasic 
bimolecular transitions), indicating a cooperativity between the 
Watson—Crick bonds and the Hoogsteen bonds. 
To summarise, synthesis of branched ODNs using arabino-
uridine as branching point X has been accomplished. The syn-
thetic strategy allows synthesis of branched ODNs with 
sequences of arbitrary length and base composition. The ther-
mal stability of branched ODNs is increased compared with the 
branched mismatched references. The melting results for the 
looped and branched ODNs showed that eight nucleotides in 
the additional branch are sufficient to achieve a stable triplex 
structure. However, compared with the corresponding unmodi-
fied linear reference, no significant increase in T. could be 
obtained. This is probably due to disruption of the Watson—
Crick duplex structure caused by the modification X as well as 
unfavourable steric interactions in the branching point, e.g 
between the nucleobase and the 2'-phosphate group. This 
suggests that arabinonucleosides containing short, non-
phosphorus 2'-0-linkers should be examined as the next class 
of arabino-configurated branched ODNs. 
Experimental 
NMR spectra were obtained on a Bruker AC250 spectrometer 
at 250 MHz for 'H NMR, 63 MHz for ' 3C NMR and 101 MHz 
for 31 P NMR spectroscopy. c5-Values are reported in ppm rela-
tive to internal SiMe 4 for 'H and ' 3C and relative to external 
85% H 3PO4 for ' 3P spectra. All coupling constants are in Hz. 
Fast-atom bombardment mass spectrometry (FAB-MS) was 
performed on a Kratos MS 50 RF spectrometer. The enzyme 
Novozym 435 ® is commercially available from Novo Nordisk 
A/S, Bagsvaerd, Denmark. Unmodified and reversed (5'-0-
phosphitylated and 3 '-O-4,4'-dimethoxytritylated) amidites 
were purchased from Cruachem. Matrix-assisted laser desorp-
tion mass spectrometry was performed using a Micromass 
TofSpec E mass spectrometer using a matrix of diammonium 
hydrogen citrate and 2,6-dihydroxyacetophenone. Capillary gel 
electrophoresis was performed using a Beckman P/ACE System 
5000 (ss DNA 100 Gel Column). Light petroleum refers to the 
fraction with distillation range 60-80 °C. 
1-[2 '-O-Levulinyl-3 ',5 ' -O-(1 , 1  ,3,3-tetraisopropyldisiloxane-I,3-
diyl)-p-n-arabinofuranosylluracil 2a 
Compound i (497 mg, 1.02 mmol) was dissolved in anhydrous 
pyridine (10 cm 3) and DMAP (6 mg, 0.05 mmol) was added. 
The mixture was kept under N 2 and cooled to 0°C. An ethereal 
solution of levulinic anhydride (3.1 cm 3, 3.1 mmol) was added 
dropwise. After being stirred for 1.5 h, the reaction was 
quenched with saturated aq. NaHCO 3 (45 cm 3). The mixture 
was extracted with ethyl acetate (2 x  100 cm') and the organic 
phase was dried (Na 2SO4), filtered, and evaporated in vacuo. 
The residue was purified by column chromatography (5% 
MeOH in CH2Cl2, v/v) to give compound 2a as a foam (522 mg, 
87%), 6H(CDCI3) 0.9-1.2 (m, 28 H, 4 X  Pr'), 2.2 (s, 3 H, CH 3), 
2.4-2.8 (m, 4 H, CH2CH2), 3.8 (m, 1 H, 4'-H), 4.0-4.2 (m, 2 H, 
5'-H 2), 4.4 (t, J 8.3, 1 H, 3'-H), 5.6 (dd, J 6.3 and 7.9, I H, 
2'-H), 5.7 (d, J 8.2, 1 H, 5-H), 6.2 (d, J 6.2, 1 H, I'-H), 7.6 (d, 
J 8.2, 1 H, 6-H) and 8.8 (br, 1 H, NH); 6(CDC1 3) 12.3-17.4 
(TIPDS), 27.4 (CH 3), 29.7 (CH,), 37.5 (CH 2), 60.3 (C-5'), 71.1 
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(C-3'). 75.9(C-2'),80.6 and 81.7(C- I', C-4'), 101.9 (C-5), 140.3 
(C-6). 149.9 (C-2), 163.0(C-4), 171.3 (C=O) and 205:7 (C=O). 
142'-O-LevuIinyl--D-arabinofuranosyl)uraci1 3a 
Compound 2a (495 mg. 0.85 mmol) was dissolved in anhydrous 
THF (25 cm') under N 2 and a solution of TBAF in THF (2.5 
cm', 2.5 mmol) was added. After being stirred for 15 mm, the 
reaction was complete, and the mixture was loaded directly 
onto a silica gel column where it was eluted with 10% MeOH 
in CH2Cl2 (vlv) to give compound 3a as a pale yellow foam 
(221 mg, 76%). ÔH(CD30D) 2.3 (s, 3 H, CH 3), 2.5-2.9 (m, 4 H, 
CH 2CH 2 ). 3.8-4.3 (m, 6 H, 3'- and 4'-H, 5'-1-1 2, 3'- and 5'-OH), 
5.4 (dd, J 3.9 and 5.0, 1 H, 2'-H), 5.8 (d, J8.l, 1 H, 5-H), 6.4(d, 
J 5.0, I H, I'-H) and 7.9 (d, J 8. 1, 1 H, 6-H); öC(CD30D) 28.6 
(CH 3 ). 29.5 (CH 2 ), 38.4 (CH 2). 61.8 (C-5'), 74.5 (C-3'), 79.1 
(C-2'). 84.9 and 85.3 (C-I' and -4'), 102.0 (C-5), 143.2 (C-6), 
152.0 (C-2), 166.26(C-4), 172.9 (C=O) and 208.7 (C=O). 
1-[5'-O-(4,4'-Dimethoxytrityl)-2'-O-levulinyl--D-arabino-
furanosyl]uracil 4a 
Compound 3a (162.5 mg, 0.47 mmol) was dissolved in 
anhydrous THF (IS cm') under argon and anhydrous pyridine 
(1 cm 3 ) was added. Silver nitrate (89 mg, 0.52 mmol) and 
DMTCI (177 mg, 0.52 mmol) were added and the mixture was 
stirred at room temperature for 24 h. The mixture was filtered, 
poured into 5% aq. NaHCO 3 (10 cm 3 ) and was extracted with 
ethyl acetate (2 X  50 cm 3 ). The organic phase was dried 
(Na2SO4 ), filtered, and evaporated in vacuo. The residue was 
purified by column chromatography (5% MeOH in CH2CI21  v/v) 
to give compound 4a as a pale yellow foam (287 mg, 96%), 
H(CDCl 3) 2.1 (s, 3 H, CH 3 ), 2.4-2.8 (m, 4 H, CH 2CH2), 3.5 (m, 
2 H, 5'-H2 ), 3.6 (br, I H, 3'-01-1), 3.8 (s, 6 H, OCH 3 ), 4.0 (m, 1 
H, 4'-H), 4.4-4.5 (m, I H, 3'-H), 5.3 (dd, J 4.7 and 5.6, 1 H, 
2'-H), 5.5 (d, J8.1, I H, 5-H), 6.3 (d, J 5.7, 1 H, 1'-H), 7.1-7.5 
(m, 13 H, ArH). 7.7 (d, J8.2, I H, 6-H) and 9.0 (br, 1 H, NH); 
( H(CDCl 3 ) 27.7 (CH,), 29.6 (CH 2), 37.7 (CH,), 55.1 (OCH 3), 
55.2 (OCH 3 ), 61.7 (C-5'), 74.2 (C-3'), 79.0 (C-2'), 81.9, 83.2 and 
86.7 (C-I' and 4', CAr 3 ), 101.6 (C-5), 113.2, 113.3, 127.0, 
127.9, 128.1, 130.1, 130.1, 135.4 and 135.5 (aryl), 141.0 (C-6), 
144.4 (aryl), 150.0 (C-2), 158.6 (aryl), 163.1 (C-4), 172.4 (C=O) 




Nucleoside 4a (192 mg, 0.298 mmol) was coevaporated with 
anhydrous acetonitrile (3 X  2.5 cm') and dried overnight in 
1'acuo. After dissolution of compound 4a in anhydrous CH 2Cl2 
(1.5 cm 3 ) under argon, NN-diisopropylethylamine (0.20 cm', 
1.2 mmol) and 2-cyanoethyl N,N-diisopropylphosphoramido-
chloridite (0.13 cm', 0.48 mmol) was added under stirring at 
room temperature. After I h, the reaction was quenched with 
MeOH (I cm 3 ), dissolved in ethyl acetate (6 cm') and washed 
successively with saturated aq. NaHCO 3 (3 x  5 cm3 ) and sat-
urated aq. NaCl (3 X  5 cm 3 ). The organic phase was dried 
(Na 2SO4 ), filtered, and evaporated in vacuo. The residue was 
dissolved in toluene (1 cm 3 ) and the product was precipitated 
from light petroleum (70 cm 3 ; cooled to —65 °C) under vigorous 
stirring. The precipitate was collected by filtration, re-dissolved 
and coevaporated with anhydrous acetonitrile (3 x  2.5 cm 3) to 
give compound 5a as a foam (168 mg, 67%), ô(CDC1 3) 151.8 
and 151.9. 
1-[2'-O-(4,4'-Dimethoxyhityl)-3',5'-O-(1 ,1,3,3-tetraisopropyl-
disiloxane-1 ,3-diyl)--D-arabinofuranosylJuracil 2b 
Compound i (1.62 g, 3.33 mmol) was coevaporated with 
anhydrous pyridine (2 X  5 cm 3 ) and dissolved in a mixture of 
anhydrous THF (30 cm') and anhydrous pyridine (3 cm') under 
argon. Silver nitrate (2.64 g, 15.5 mmol) was added followed by 
DMTCI (5.33 g, 15.7 mniol) and the mixture was stirred over- 
night. The reaction mixture was subsequently filtered through a 
layer of silica gel, and evaporated in 'acuo. The residue was 
taken up in ethyl acetate and washed successively with saturated 
aq. NaHCO 3 (3 x  20 cm') and saturated aq. NaCl (2 x  20 cm'), 
and the organic phase was dried (Na 2504), filtered, and evapor-
ated in 'acuo. The residue was purified by column chroma-
tography (20-40% ethyl acetate—light petroleum, 1% pyridine) 
to give compound 2b as a yellow foam (2.62 g, 100%), 
c5H(CDCI 3) 1.0-1.1 (m, 28 H, Pr'), 3.7 (m, I H, 4'-H), 3.8 
(s, 6 H, OCH 3 ), 3.9-4.6 (m, 4 H, 2'- and 3'-H, 5'-1-1 2 ), 5.5 (d, J 
5.0, 1 H, l'-H), 5.6 (d, J 8.2, 1 H, 5-H), 6.8 (m, 4 H, AM), 
7.1-7.4 (m, 9 H, ArH), 7.5 (d, J8.2, I H, 6-H) and 8.4 (s, I H, 
NH);ö(CDC1 3) 12.8-17.3 (Pr'), 55.1 (OCH 3 ), 61.8 (C-5'), 75.1 
(C-2'), 77.4 (C-3'), 80.7, 81.8 and 88.4 (C-I' and 4', CAr 3 ), 
101.0 (C-5), 113.2, 127.2-135.1, 142.8 and 144.2 (aryl), 149.6 
(C-2), 158.9 (aryl) and 162.7 (C-4); FAB-MS: ml: 811 
(M + 23). 
1-[2'-O-(4,4'-Dimethoxytrityl)4-n-arabinofuranosyl]uracil 3b 
Compound 2b (1.97 g, 2.50 mmol) was dissolved in THF (36 
cm'). KF2H 20 (1.42 g, 15 mmol) and 18-crown-6 (233 mg. 
0.88 mmol) was added to the vigorously stirred solution at 
room temperature. After 48 h, the reaction mixture was filtered, 
evaporated in vacuo and the residue was purified by column 
chromatography (2-5% MeOH in CH 2Cl2 containing 1% pyri-
dine, v/v/v) to give compound 3b as a foam (1.33 g, 97%); öH 
(CD 30D) 3.4-3.5 (m, I H, 4'-H), 3.7-3.9 (m, 3 H, 3'-H and 
5'-H2)), 3.9(s, 6 H, OCH 3), 4.4(dd, J3. I and 4.6, 1 H, 2'-H), 5.8 
(d, J8.1, I H, 5-H), 6.1 (d, J4.4, I H, l'-H), 6.9-7.5 (m, 13 H, 
AM) and 8.1 (d, J 7.0, 1 H, 6-H); ö(CD30D) 56.0 (OCH 3 ), 
63.1 (C-5'), 76.8 (C-2'), 79.3 (C-3'), 85.9, 86.0 and 89.9 (C-I' 
and 4', CAr 3 )
1 
 101.8 (C-5), 114.6, 128.5-132.0 and 136.9 (aryl), 
145.7 (C-6), 146.5 (aryl), 152.1 (C-2), 160.8 (aryl) and 166.5 
(C-4); FAB-MS: ml: 569 (M + 23). 
1-[2'-O-(4,4'-Dimethoxytriyl)-5'-O-levulinyl-B-D-arabino-
furanosylluracil 4b 
Compound 3b (306 mg, 0.56 mmol) was dissolved in anhydrous 
dioxane (3 cm') under argon. Novozym 435®  (200 mg) was 
added followed by a freshly prepared solution of levulinic 
anhydride in 1,4-dioxane (10 cm', 3.68 mmol), and the mixture 
was stirred overnight at room temperature. The mixture was 
filtered, washed with saturated aq. NaHCO 3 (3 x  5 cm'), and 
the organic phase was dried (Na 2504), filtered, and evaporated 
in vacuo. The residue was purified by column chromatography 
(1-5% MeOH in CH2Cl2 containing 1% pyridine, .vlv/v) to give 
compound 0 as a pale yellow foam (332 mg, 93%), 6 H(CDCI 3 ) 
2.2 (s, 3 H, CH 3), 2.6-2.8 (m, 4 H, CH 2CH2), 3.5 (br, 1 H, 
3'-OH), 3.8 (s, 6 H, OCH 3 ), 3.8-4.4 (m, 5 H, 2'-, 3'- and 4'-H 
and 5'-H 2), 5.8 (d, J8.l, 1 H, 5-H), 6.1 (br. 1 H, l'-H). 6.8-6.9 
(m, 4 H, AM), 7.2-7.3 (m, 9 H, ArH), 7.8 (br, 1 H, 6-H) and 9.1 
(s, 1 H, NH); 3(CDC1 3) 27.8 and 29.7 (CH 2CH 2), 37.8 (CH 3), 
55.1 (OCH 3), 63.1 (C-5'), 76.0 and 78.0 (C-2' and -3'), 80.2, 
84.0 and 88.3 (C-l' and 4', CAr 3), 101.4 (C-5), 113.3 and 
127.3-135.3 (aryl), 143.0 (C-6), 144.2 (aryl), 150.0 (C-2), 158.8 
(aryl), 163.0 (C-4),172.6 (C=O) and 206.7 (C=O); FAB-MS: ml: 




Nucleoside 4b (291 mg, 0.45 mmol) was coevaporated with 
anhydrous acetonitrile (3 x  2 cm') and re-dissolved in 
anhydrous CH 2Cl2 (3.6 cm') under argon. N,N-Diisopropyl-
ethylamine (1.7 cm', 9.9 mmol) and 2-cyanoethyl N,N-
diisopropylphosphoramidochloridite (0.18 cm', 0.67 mmol) 
were added to the stirred mixture at room temperature. After 
1 h, the reaction was quenched with anhydrous methanol 
(1 cm'), diluted with ethyl acetate and washed successively 
with saturated aq. NaHCO 3 (3 X 5 cm3) and NaCl (3 x  5 cm 3 ). 
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The organic phase was dried (Na 2SO4 ), filtered, and evaporated 
in vacua. The residue was purified by column chromatography 
[a I: I (vlv) mixture of light petroleum and a mixture of 
Cl-1 2 C1 2 . ethyl acetate and Et,N (9:9:2, vlv/v)], evaporated, 
re-dissolved in toluene (2 cm') and precipitated from light 
petroleum (65 cm 3 ; — 65 °C) under vigorous stirring. The pre-
cipitate was collected by filtration as a solid, re-dissolved, and 
coevaporated with anhydrous acetonitrile (3 x  5 cm') to give 
compound 5b as a pale yellow foam (243 mg, 64%), o(CDCl,) 
149.5 and 150.6. 
Oligonucleotide synthesis 
All oligonucleotides were synthesized on a Pharmacia Gene 
Assembler Special" synthesizer. Solid supports on a 0.2 iimol 
scale were obtained from Pharmacia or Cruachem. The amidite 
solution volume applied for all couplings was 75 pl. The com-
mercial amidites were used in 0.1 M concentration with 2 mm 
coupling time. The modified arabino-uridine building block was 
used in 0.1-0.2 M concentrations and the coupling time was 
extended to 12 min or 2 x  12 min as described in the Results 
and discussion section. The levulinyl protection group was 
removed by treatment of the solid support either with a 0.5 M 
solution of hydrazine hydrate in pyridine—acetic acid (4: 1, v/v) 
for 90 min or with a 0.5 M solution of hydrazine hydrate 
in a buffer consisting of pyridine—acetic acid—water (4:3 :0.35, 
v/v/v). The branching step was performed with a 0.1 M amidite 
solution using 12 min or 2 X 12 min coupling time. For all 
modified oligonucleotides the DMT group of the latest 
incorporated nucleotide was left on for purification, but for the 
unmodified references it was removed as the last step on the 
synthesizer. The oligonucleotides were deprotected and cleaved 
from solid support by incubation in 32% aq. ammonia at room 
temperature for 72 h. All oligonucleotides were desalted 
through size-exclusion chromatography (NAPTM  10-columns, 
Sephadex® G-25 medium, Pharmacia). Purification of the 
modified oligonucleotides was achieved by use of disposable 
reversed-phase columns (COPTMcolumns,  Cruachem; the pro-
cedure includes detritylation). The procedures were carried out 
according to manufacturer's protocols. 
Determination of T. 
Mps (Tm ) were determined as described earlier." 
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